( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
High B-ADR B-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
: O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
prescribe O-ADR O-ADR
Natazia O-ADR O-ADR
for O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
uncontrolled O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
hypertension O-ADR O-ADR
with O-ADR O-ADR
vascular O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
fFatal O-ADR O-ADR
bleed B-ADR B-ADR
: O-ADR O-ADR
Adjudicated O-ADR O-ADR
major O-ADR O-ADR
bleed B-ADR B-ADR
as O-ADR O-ADR
defined O-ADR O-ADR
above O-ADR O-ADR
with O-ADR O-ADR
investigator O-ADR O-ADR
reported O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
and O-ADR O-ADR
adjudicated O-ADR O-ADR
death B-ADR B-ADR
with O-ADR O-ADR
primary O-ADR O-ADR
cause O-ADR O-ADR
from O-ADR O-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
XIAFLEX O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
shortening B-ADR B-ADR
of I-ADR I-ADR
penile I-ADR I-ADR
length I-ADR I-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Myocardial B-ADR B-ADR
ischemia I-ADR I-ADR
or O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
led O-ADR O-ADR
to O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arms O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
Increased B-ADR B-ADR
levels I-ADR I-ADR
of I-ADR I-ADR
thyroid I-ADR I-ADR
stimulating I-ADR I-ADR
hormone I-ADR I-ADR
( O-ADR O-ADR
TSH O-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
57 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
COMETRIQ O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
19 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
baseline O-ADR O-ADR
value O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
potassium I-ADR I-ADR
is O-ADR O-ADR
usually O-ADR O-ADR
transient O-ADR O-ADR
, O-ADR O-ADR
not O-ADR O-ADR
requiring O-ADR O-ADR
supplementation O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
adjusted O-ADR O-ADR
change O-ADR O-ADR
at O-ADR I-ADR
the O-ADR I-ADR
distal O-ADR I-ADR
forearm O-ADR I-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Skin B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Discontinue O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
skin O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Allopurinol O-ADR O-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
beginning O-ADR O-ADR
of O-ADR O-ADR
TREANDA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
87 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
; O-ADR O-ADR
58 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
GI B-ADR B-ADR
events I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
month O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
usually O-ADR O-ADR
decreased O-ADR O-ADR
over O-ADR O-ADR
time O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
58 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
is O-ADR O-ADR
considered O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
. O-ADR O-ADR
Transient O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
pain I-ADR I-ADR
were O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Qutenza O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
mild O-ADR O-ADR
( O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR B-ADR
> O-ADR I-ADR
1 O-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
to O-ADR I-ADR
< O-ADR I-ADR
= O-ADR I-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR I-ADR
and O-ADR O-ADR
any O-ADR O-ADR
AST O-ADR B-ADR
) O-ADR I-ADR
hepatic O-ADR I-ADR
impairment O-ADR I-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
tolerability O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
despite O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatic B-ADR B-ADR
Toxicity I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
monthly O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
and O-ADR O-ADR
abatacept O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monotherapy O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Bipolar O-ADR O-ADR
Mania O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
findings O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
trials O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
sublingual O-ADR O-ADR
SAPHRIS O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
those O-ADR O-ADR
17 O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
subjects O-ADR O-ADR
developed O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
Adjust O-ADR O-ADR
total O-ADR O-ADR
fluid O-ADR O-ADR
intake O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
baseline O-ADR O-ADR
cardiac O-ADR O-ADR
failure O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
cardiac O-ADR O-ADR
failure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
breathing B-ADR B-ADR
difficulties I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
respiratory B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
using O-ADR O-ADR
OTEZLA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
prescribers O-ADR O-ADR
should O-ADR O-ADR
carefully O-ADR O-ADR
weigh O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
in O-ADR O-ADR
such O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
relevance O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
belimumab O-ADR O-ADR
antibodies O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
impairment I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
terms O-ADR O-ADR
renal B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
acute I-ADR I-ADR
) O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
1015 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
ZERBAXA O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
comparator O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
Immediate O-ADR O-ADR
gentle O-ADR O-ADR
pressure O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
site O-ADR O-ADR
can O-ADR O-ADR
limit O-ADR O-ADR
that O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
the O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
transaminases I-ADR I-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
or O-ADR O-ADR
hepatitis B-ADR B-ADR
B I-ADR I-ADR
reactivation I-ADR I-ADR
particularly O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
where O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hepatitis O-ADR O-ADR
therapy O-ADR O-ADR
was O-ADR O-ADR
withdrawn O-ADR O-ADR
. O-ADR O-ADR
Fifty O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
72 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
or O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
POST B-ADR B-ADR
- O-ADR O-ADR
TRANSPLANT O-ADR O-ADR
LYMPHOPROLIFERATIVE I-ADR I-ADR
DISORDER I-ADR I-ADR
, O-ADR O-ADR
OTHER O-ADR O-ADR
MALIGNANCIES B-ADR B-ADR
, O-ADR O-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
INFECTIONS B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
included O-ADR O-ADR
chest B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
pharyngeal B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rhinorrhea B-ADR B-ADR
, O-ADR O-ADR
sneezing B-ADR B-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
wheezing B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypotension B-ADR B-ADR
. O-ADR O-ADR
Apprise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
harm O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
Primary O-ADR O-ADR
prophylaxis O-ADR O-ADR
with O-ADR O-ADR
G O-ADR O-ADR
- O-ADR O-ADR
CSF O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
clinical O-ADR O-ADR
features O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
abnormalities O-ADR O-ADR
were O-ADR O-ADR
considered O-ADR O-ADR
potentially O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hematocrits O-ADR O-ADR
initially O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
reference O-ADR O-ADR
range O-ADR O-ADR
had O-ADR O-ADR
values O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reference O-ADR O-ADR
range O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
insufficient O-ADR O-ADR
information O-ADR O-ADR
to O-ADR O-ADR
characterize O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
resumption O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
severe O-ADR O-ADR
visual O-ADR O-ADR
loss O-ADR O-ADR
; O-ADR O-ADR
a O-ADR O-ADR
decision O-ADR O-ADR
to O-ADR O-ADR
resume O-ADR O-ADR
XALKORI O-ADR O-ADR
should O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
benefits O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pulmonary O-ADR O-ADR
toxicity O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
MULTAQ O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Gadavist O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Nephrogenic O-ADR O-ADR
Systemic O-ADR O-ADR
Fibrosis O-ADR O-ADR
Gadolinium O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
contrast O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
GBCAs O-ADR O-ADR
) O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
nephrogenic B-ADR B-ADR
systemic I-ADR I-ADR
fibrosis I-ADR I-ADR
( O-ADR O-ADR
NSF B-ADR B-ADR
) O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reported O-ADR O-ADR
thromboembolic B-ADR B-ADR
events I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
six O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
RVO O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Follow O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
adjustment O-ADR O-ADR
guidelines O-ADR O-ADR
to O-ADR O-ADR
achieve O-ADR O-ADR
and O-ADR O-ADR
maintain O-ADR O-ADR
target O-ADR O-ADR
platelet O-ADR O-ADR
counts O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Neither O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
nor O-ADR O-ADR
epidemiologic O-ADR O-ADR
studies O-ADR O-ADR
conducted O-ADR O-ADR
to O-ADR O-ADR
date O-ADR O-ADR
have O-ADR O-ADR
shown O-ADR O-ADR
an O-ADR O-ADR
association O-ADR O-ADR
between O-ADR O-ADR
chronic O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
class O-ADR O-ADR
of O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
tumorigenesis B-ADR O-ADR
in O-ADR O-ADR
humans O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
available O-ADR O-ADR
evidence O-ADR O-ADR
is O-ADR O-ADR
too O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
conclusive O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
trial O-ADR O-ADR
medication O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ESAs O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thromboembolic O-ADR B-ADR
events O-ADR I-ADR
including O-ADR O-ADR
pulmonary O-ADR B-ADR
embolism O-ADR I-ADR
, O-ADR O-ADR
acute O-ADR B-ADR
myocardial O-ADR I-ADR
infarction O-ADR I-ADR
, O-ADR O-ADR
cerebrovascular O-ADR B-ADR
accident O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
deep O-ADR B-ADR
vein O-ADR I-ADR
thrombosis O-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
Decreases O-ADR O-ADR
in O-ADR O-ADR
neutrophil O-ADR O-ADR
counts O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
comparator O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
which O-ADR O-ADR
could O-ADR O-ADR
affect O-ADR O-ADR
liver O-ADR O-ADR
enzymes O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
chronic O-ADR O-ADR
viral O-ADR O-ADR
hepatitis O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
alcohol O-ADR O-ADR
abuse O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
current O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
please O-ADR O-ADR
visit O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
pfizer O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
these O-ADR O-ADR
doses O-ADR O-ADR
, O-ADR O-ADR
SAPHRIS O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
QTc I-ADR I-ADR
interval I-ADR I-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
msec O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
or O-ADR O-ADR
recurrent O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
andClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
active O-ADR O-ADR
TB O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
if O-ADR O-ADR
initial O-ADR O-ADR
latent O-ADR O-ADR
TB O-ADR O-ADR
test O-ADR O-ADR
is O-ADR O-ADR
negative O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
: O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
infusion O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
interrupt O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2757 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
hyperuricemia O-ADR O-ADR
and O-ADR O-ADR
gout O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ULORIC O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
80 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Risk O-ADR O-ADR
Factors O-ADR O-ADR
Other O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
PTLD O-ADR O-ADR
include O-ADR O-ADR
cytomegalovirus O-ADR O-ADR
( O-ADR O-ADR
CMV O-ADR O-ADR
) O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
T O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
- O-ADR O-ADR
depleting O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
Pneumonitis O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
is O-ADR O-ADR
a O-ADR O-ADR
class O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
rapamycin O-ADR O-ADR
derivatives O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
when O-ADR O-ADR
JARDIANCE O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sulfonylurea O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
JEVTANA O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
neutrophils O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
500 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
Neuraceq O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
978 O-ADR O-ADR
administrations O-ADR O-ADR
of O-ADR O-ADR
Neuraceq O-ADR O-ADR
to O-ADR O-ADR
872 O-ADR O-ADR
subjects O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
vehicle O-ADR O-ADR
only O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
8 O-ADR O-ADR
compares O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
occurring O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
with O-ADR O-ADR
AFINITOR O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1C O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
established O-ADR O-ADR
microvascular O-ADR O-ADR
complications O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
. O-ADR O-ADR
c O-ADR O-ADR
Includes O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
lung B-ADR B-ADR
infiltration I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
alveolar I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
pulmonary B-ADR B-ADR
toxicity I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
alveolitis B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Monitored O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
- O-ADR O-ADR
Pruritus B-ADR B-ADR
, O-ADR O-ADR
Erythema B-ADR B-ADR
, O-ADR O-ADR
Pyoderma B-ADR B-ADR
and O-ADR O-ADR
Ocular B-ADR B-ADR
Irritation I-ADR I-ADR
with O-ADR O-ADR
Onset O-ADR O-ADR
After O-ADR O-ADR
Treatment O-ADR O-ADR
Signs O-ADR O-ADR
/ O-ADR O-ADR
Symptoms O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
Vehicle O-ADR O-ADR
Pruritus B-ADR B-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
/ O-ADR O-ADR
116 O-ADR O-ADR
) O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
67 O-ADR O-ADR
) O-ADR O-ADR
Erythema B-ADR B-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
32 O-ADR O-ADR
/ O-ADR O-ADR
309 O-ADR O-ADR
) O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
/ O-ADR O-ADR
217 O-ADR O-ADR
) O-ADR O-ADR
Pyoderma B-ADR B-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
22 O-ADR O-ADR
/ O-ADR O-ADR
308 O-ADR O-ADR
) O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
/ O-ADR O-ADR
230 O-ADR O-ADR
) O-ADR O-ADR
Ocular B-ADR B-ADR
irritation I-ADR I-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
/ O-ADR O-ADR
428 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
313 O-ADR O-ADR
) O-ADR O-ADR
Other O-ADR O-ADR
less O-ADR O-ADR
common O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
but O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
decreasing O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
incidence O-ADR O-ADR
: O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
dryness I-ADR I-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
excoriation I-ADR I-ADR
, O-ADR O-ADR
paraesthesia B-ADR B-ADR
, O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
excoriation B-ADR B-ADR
, O-ADR O-ADR
thermal B-ADR B-ADR
burn I-ADR I-ADR
, O-ADR O-ADR
dandruff B-ADR B-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
skin B-ADR B-ADR
exfoliation I-ADR I-ADR
. O-ADR O-ADR
Elevating O-ADR O-ADR
the O-ADR O-ADR
head O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
bed O-ADR O-ADR
lessens O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
supine O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
measured O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
position O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
prescribers O-ADR O-ADR
should O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
considering O-ADR O-ADR
resumption O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
situation O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
) O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
additional O-ADR O-ADR
51 O-ADR O-ADR
subjects O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
separate O-ADR O-ADR
repeat O-ADR O-ADR
dose O-ADR O-ADR
study O-ADR O-ADR
were O-ADR O-ADR
tested O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
only O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
risk O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
reduced O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
( O-ADR O-ADR
calculated O-ADR O-ADR
using O-ADR O-ADR
Cockcroft O-ADR O-ADR
and O-ADR O-ADR
Gault O-ADR O-ADR
equation O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
population O-ADR O-ADR
included O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
27 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Hispanic O-ADR O-ADR
or O-ADR O-ADR
Latino O-ADR O-ADR
, O-ADR O-ADR
83 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Black O-ADR O-ADR
/ O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
other O-ADR O-ADR
( O-ADR O-ADR
American O-ADR O-ADR
Indian O-ADR O-ADR
, O-ADR O-ADR
Alaska O-ADR O-ADR
Native O-ADR O-ADR
or O-ADR O-ADR
Indian O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
15 O-ADR O-ADR
13 O-ADR O-ADR
13 O-ADR O-ADR
Psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
Insomnia B-ADR B-ADR
13 O-ADR O-ADR
16 O-ADR O-ADR
15 O-ADR O-ADR
15 O-ADR O-ADR
Vascular O-ADR O-ADR
disorders O-ADR O-ADR
Hypertension B-ADR B-ADR
2 O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
term O-ADR O-ADR
schizophrenia O-ADR O-ADR
trials O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
akathisia B-ADR B-ADR
appeared O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
( O-ADR O-ADR
seeTable O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
nadir O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
calcium O-ADR O-ADR
level O-ADR O-ADR
occurs O-ADR O-ADR
at O-ADR O-ADR
approximately O-ADR O-ADR
day O-ADR O-ADR
10 O-ADR O-ADR
after O-ADR O-ADR
Prolia O-ADR O-ADR
dosing O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Females O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
becoming O-ADR O-ADR
pregnant O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
JEVTANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
percent O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
gastrointestinal B-ADR B-ADR
events I-ADR I-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Local B-ADR B-ADR
skin I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
assessed O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
selected O-ADR O-ADR
treatment O-ADR O-ADR
area O-ADR O-ADR
and O-ADR O-ADR
graded O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
scale O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
INVOKANA O-ADR O-ADR
can O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
when O-ADR O-ADR
combined O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
insulin O-ADR O-ADR
secretagogue O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
total B-ADR B-ADR
cholesterol I-ADR I-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
240 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
versus O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
intolerable O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
following O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
resuming O-ADR O-ADR
the O-ADR O-ADR
previously O-ADR O-ADR
prescribed O-ADR O-ADR
dose O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
reflect O-ADR O-ADR
serious O-ADR O-ADR
injury O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
injected O-ADR O-ADR
finger O-ADR O-ADR
/ O-ADR O-ADR
hand O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
promptly O-ADR O-ADR
evaluated O-ADR O-ADR
because O-ADR O-ADR
surgical O-ADR O-ADR
intervention O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Skin O-ADR O-ADR
Discoloration O-ADR O-ADR
POTIGA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
skin B-ADR B-ADR
discoloration I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Body O-ADR O-ADR
Weight O-ADR O-ADR
FANAPT O-ADR O-ADR
FANAPT O-ADR O-ADR
Placebo O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
20 O-ADR O-ADR
- O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
576 O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
481 O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
391 O-ADR O-ADR
Weight O-ADR O-ADR
( O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
Change O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Weight O-ADR O-ADR
Gain O-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
increase O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Seizures O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
seizures B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1344 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
587 O-ADR O-ADR
) O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Controlled O-ADR O-ADR
Study O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Tables O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
229 O-ADR O-ADR
EGFR O-ADR O-ADR
- O-ADR O-ADR
TKI O-ADR O-ADR
naive O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
EGFR O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
, O-ADR O-ADR
metastatic O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
squamous O-ADR O-ADR
, O-ADR O-ADR
NSCLC O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Interstitial O-ADR O-ADR
Lung O-ADR O-ADR
Disease O-ADR O-ADR
and O-ADR O-ADR
Eosinophilic O-ADR O-ADR
Pneumonia O-ADR O-ADR
Interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
and O-ADR O-ADR
eosinophilic B-ADR B-ADR
pneumonia I-ADR I-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
venlafaxine O-ADR O-ADR
( O-ADR O-ADR
the O-ADR O-ADR
parent O-ADR O-ADR
drug O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
) O-ADR O-ADR
therapy O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
rarely O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
these O-ADR O-ADR
considerations O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prescribed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
manner O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
most O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
tardive O-ADR O-ADR
dyskinesia O-ADR O-ADR
. O-ADR O-ADR
Percentage O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patientsa O-ADR O-ADR
YERVOY3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kgn O-ADR O-ADR
= O-ADR O-ADR
131 O-ADR O-ADR
YERVOY3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
+ O-ADR O-ADR
gp100n O-ADR O-ADR
= O-ADR O-ADR
380 O-ADR O-ADR
gp100n O-ADR O-ADR
= O-ADR O-ADR
132 O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
/ O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
AnyGrade O-ADR O-ADR
Grade3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
AnyGrade O-ADR O-ADR
Grade3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
AnyGrade O-ADR O-ADR
Grade3 O-ADR O-ADR
- O-ADR O-ADR
5 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
Diarrhea B-ADR B-ADR
32 O-ADR O-ADR
5 O-ADR O-ADR
37 O-ADR O-ADR
4 O-ADR O-ADR
20 O-ADR O-ADR
1 O-ADR O-ADR
Colitis B-ADR B-ADR
8 O-ADR O-ADR
5 O-ADR O-ADR
5 O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
0 O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
Pruritus B-ADR B-ADR
31 O-ADR O-ADR
0 O-ADR O-ADR
21 O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
11 O-ADR O-ADR
0 O-ADR O-ADR
Rash B-ADR B-ADR
29 O-ADR O-ADR
2 O-ADR O-ADR
25 O-ADR O-ADR
2 O-ADR O-ADR
8 O-ADR O-ADR
0 O-ADR O-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
Fatigue B-ADR B-ADR
41 O-ADR O-ADR
7 O-ADR O-ADR
34 O-ADR O-ADR
5 O-ADR O-ADR
31 O-ADR O-ADR
3 O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
per O-ADR O-ADR
- O-ADR O-ADR
patient O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
from O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
a O-ADR O-ADR
mass O-ADR B-ADR
in O-ADR I-ADR
the O-ADR I-ADR
neck O-ADR I-ADR
, O-ADR O-ADR
dysphagia O-ADR B-ADR
, O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
hoarseness O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZYTIGA O-ADR O-ADR
Arm O-ADR O-ADR
of O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
Abiraterone O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
542 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
540 O-ADR O-ADR
) O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormality O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Hematology O-ADR O-ADR
Lymphopenia B-ADR B-ADR
38 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
31 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Chemistry O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
56 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
50 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
High B-ADR B-ADR
ALT I-ADR I-ADR
41 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
29 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
High B-ADR B-ADR
AST I-ADR I-ADR
37 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
28 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypernatremia B-ADR B-ADR
32 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypokalemia B-ADR B-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
combined O-ADR O-ADR
data O-ADR O-ADR
for O-ADR O-ADR
studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
COCs O-ADR O-ADR
also O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
arterial B-ADR B-ADR
thromboses I-ADR I-ADR
such O-ADR O-ADR
as O-ADR O-ADR
strokes B-ADR B-ADR
and O-ADR O-ADR
myocardial B-ADR B-ADR
infarctions I-ADR I-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
more O-ADR O-ADR
extensive O-ADR O-ADR
systemic O-ADR O-ADR
involvement O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Neutropenia B-ADR B-ADR
may O-ADR O-ADR
precede O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
agranulocytosis B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
fatal B-ADR B-ADR
pneumonia B-ADR B-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
vilanterol O-ADR O-ADR
or O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
50 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
GlaxoSmithKline O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
825 O-ADR O-ADR
- O-ADR O-ADR
5249 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
the O-ADR O-ADR
fourth O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patient O-ADR O-ADR
developed O-ADR O-ADR
high O-ADR O-ADR
titers O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
both O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
and O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
. O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
: O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
peripheral I-ADR I-ADR
, O-ADR O-ADR
multi B-ADR B-ADR
- O-ADR O-ADR
organ O-ADR O-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
118 O-ADR O-ADR
days O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
HALAVEN O-ADR O-ADR
and O-ADR O-ADR
63 O-ADR O-ADR
days O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
control O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
do O-ADR O-ADR
require O-ADR O-ADR
chronic O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
smallest O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
shortest O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
producing O-ADR O-ADR
a O-ADR O-ADR
satisfactory O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
sought O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
485 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Parkinson O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
multiple O-ADR O-ADR
system O-ADR O-ADR
atrophy O-ADR O-ADR
, O-ADR O-ADR
pure O-ADR O-ADR
autonomic O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
dopamine O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
hydroxylase O-ADR O-ADR
deficiency O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
diabetic O-ADR O-ADR
autonomic O-ADR O-ADR
neuropathy O-ADR B-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
, O-ADR O-ADR
245 O-ADR O-ADR
with O-ADR O-ADR
NORTHERA O-ADR O-ADR
and O-ADR O-ADR
240 O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Persistence B-ADR B-ADR
of I-ADR I-ADR
sinus I-ADR B-ADR
tachycardia I-ADR I-ADR
( O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
visits O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Severe O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disease O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
severe O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
week O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
developed O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibodies O-ADR O-ADR
by O-ADR O-ADR
Week O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
MS O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
mean O-ADR O-ADR
lymphocyte B-ADR B-ADR
counts I-ADR I-ADR
decreased I-ADR I-ADR
by O-ADR O-ADR
approximately O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
remained O-ADR O-ADR
stable O-ADR O-ADR
. O-ADR O-ADR
Closely O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
Vimizim O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
be O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
manage O-ADR O-ADR
anaphylaxis O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
individual O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
when O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
or O-ADR O-ADR
sulfonylureas O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
A O-ADR O-ADR
28 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
US O-ADR O-ADR
study O-ADR O-ADR
comparing O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonist O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
each O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
usual O-ADR O-ADR
asthma O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
/ O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
176 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
179 O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
; O-ADR O-ADR
RR O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
37 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
SJS B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
TEN B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
when O-ADR O-ADR
TREANDA O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
allopurinol O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
these O-ADR O-ADR
syndromes O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
352 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
180 O-ADR O-ADR
days O-ADR O-ADR
and O-ADR O-ADR
58 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
had O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1212 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsing O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
multiple O-ADR O-ADR
sclerosis O-ADR O-ADR
received O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
partial O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
seizures O-ADR O-ADR
, O-ADR O-ADR
1195 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
586 O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
462 O-ADR O-ADR
for O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
In O-ADR O-ADR
an O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
QTc O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
or O-ADR O-ADR
schizoaffective O-ADR O-ADR
disorder O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
160 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
QTc B-ADR B-ADR
prolongation I-ADR I-ADR
of O-ADR O-ADR
9 O-ADR O-ADR
msec O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
iloperidone O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
ADRs O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
Metabolic B-ADR O-ADR
Changes I-ADR O-ADR
: O-ADR O-ADR
Atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
metabolic O-ADR B-ADR
changes O-ADR I-ADR
that O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR B-ADR
cerebrovascular B-ADR I-ADR
risk I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
taking O-ADR O-ADR
HORIZANT O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
drive O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
gained O-ADR O-ADR
sufficient O-ADR O-ADR
experience O-ADR O-ADR
to O-ADR O-ADR
assess O-ADR O-ADR
whether O-ADR O-ADR
HORIZANT O-ADR O-ADR
impairs O-ADR O-ADR
their O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
drive O-ADR O-ADR
. O-ADR O-ADR
Kyprolis O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
increased B-ADR B-ADR
serum I-ADR I-ADR
transaminases I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
Least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
RCC O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
Higher O-ADR O-ADR
Rate O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
Arm O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Placebo O-ADR O-ADR
Arm O-ADR O-ADR
Grading O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
CTCAE O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Stomatitis B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
aphthous B-ADR B-ADR
stomatitis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tongue B-ADR B-ADR
ulceration I-ADR I-ADR
. O-ADR O-ADR
Subjects O-ADR O-ADR
received O-ADR O-ADR
1 O-ADR O-ADR
inhalation O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
/ O-ADR O-ADR
vilanterol O-ADR O-ADR
50 O-ADR O-ADR
mcg O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
, O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
, O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
200 O-ADR O-ADR
mcg O-ADR O-ADR
, O-ADR O-ADR
vilanterol O-ADR O-ADR
25 O-ADR O-ADR
mcg O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
asthma B-ADR B-ADR
exacerbation I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
indacaterol O-ADR O-ADR
300 O-ADR O-ADR
mcg O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
indacaterol O-ADR O-ADR
600 O-ADR O-ADR
mcg O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
salmeterol O-ADR O-ADR
active O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
IgG O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
retrospectively O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
inhibitory O-ADR O-ADR
antibodies O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
enzyme O-ADR O-ADR
activity O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
uptake O-ADR O-ADR
in O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
assays O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
INCREASED O-ADR B-ADR
MORTALITY B-ADR I-ADR
IN O-ADR O-ADR
ELDERLY O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
DEMENTIA O-ADR O-ADR
- O-ADR O-ADR
RELATED O-ADR O-ADR
PSYCHOSIS O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
the O-ADR O-ADR
subgroup O-ADR O-ADR
of O-ADR O-ADR
187 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
subcutaneous O-ADR O-ADR
KALBITOR O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
anaphylaxis B-ADR B-ADR
. O-ADR O-ADR
KALBITOR O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
clinical O-ADR O-ADR
hypersensitivity O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Eye B-ADR B-ADR
irritation I-ADR I-ADR
: O-ADR O-ADR
Avoid O-ADR O-ADR
eye O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Lipids O-ADR O-ADR
Elevations B-ADR B-ADR
in I-ADR I-ADR
fasting I-ADR I-ADR
serum I-ADR I-ADR
total I-ADR I-ADR
cholesterol I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
periodically O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infusion O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Reactions O-ADR O-ADR
DALVANCE O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
via O-ADR O-ADR
intravenous O-ADR O-ADR
infusion O-ADR O-ADR
, O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
infusion O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
immune O-ADR O-ADR
system O-ADR O-ADR
responds O-ADR O-ADR
may O-ADR O-ADR
develop O-ADR O-ADR
an O-ADR O-ADR
inflammatory O-ADR B-ADR
response O-ADR I-ADR
to O-ADR O-ADR
indolent O-ADR O-ADR
or O-ADR O-ADR
residual B-ADR B-ADR
opportunistic I-ADR B-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
Mycobacterium B-ADR B-ADR
avium I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
cytomegalovirus B-ADR B-ADR
, O-ADR O-ADR
Pneumocystis B-ADR B-ADR
jirovecii I-ADR I-ADR
pneumonia I-ADR I-ADR
( O-ADR O-ADR
PCP B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
tuberculosis B-ADR B-ADR
] O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
necessitate O-ADR O-ADR
further O-ADR O-ADR
evaluation O-ADR O-ADR
and O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Invasive O-ADR O-ADR
Fungal O-ADR O-ADR
Infections O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reside O-ADR O-ADR
or O-ADR O-ADR
travel O-ADR O-ADR
in O-ADR O-ADR
regions O-ADR O-ADR
where O-ADR O-ADR
mycoses O-ADR O-ADR
are O-ADR O-ADR
endemic O-ADR O-ADR
, O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infection O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
suspected O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Discontinue O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
infection O-ADR O-ADR
or O-ADR O-ADR
sepsis O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Hypokalemia O-ADR O-ADR
and O-ADR O-ADR
Hypomagnesemia O-ADR O-ADR
with O-ADR O-ADR
Potassium O-ADR O-ADR
- O-ADR O-ADR
Depleting O-ADR O-ADR
Diuretics O-ADR O-ADR
Hypokalemia B-ADR B-ADR
or O-ADR O-ADR
hypomagnesemia B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
potassium O-ADR O-ADR
- O-ADR O-ADR
depleting O-ADR O-ADR
diuretics O-ADR O-ADR
. O-ADR O-ADR
Antigen O-ADR O-ADR
and O-ADR O-ADR
antibody O-ADR O-ADR
testing O-ADR O-ADR
for O-ADR O-ADR
histoplasmosis O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
negative O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
give O-ADR O-ADR
DUAVEE O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
people O-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
symptoms O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
important O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
include O-ADR O-ADR
PML B-ADR B-ADR
, O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
104 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
101 O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
MALIGNANCY O-ADR O-ADR
Lymphoma B-ADR B-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescent O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
What O-ADR O-ADR
can O-ADR O-ADR
I O-ADR O-ADR
do O-ADR O-ADR
to O-ADR O-ADR
lower O-ADR O-ADR
my O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
serious O-ADR O-ADR
side O-ADR O-ADR
effect O-ADR O-ADR
with O-ADR O-ADR
DUAVEE O-ADR O-ADR
? O-ADR O-ADR
Prescribers O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
prostatic O-ADR O-ADR
hyperplasia O-ADR O-ADR
or O-ADR O-ADR
bladder O-ADR O-ADR
- O-ADR O-ADR
neck O-ADR O-ADR
obstruction O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
difficulty O-ADR O-ADR
passing O-ADR O-ADR
urine O-ADR O-ADR
, O-ADR O-ADR
painful O-ADR O-ADR
urination O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Treat O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
rehydration O-ADR O-ADR
, O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheal O-ADR O-ADR
or O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
emetic O-ADR O-ADR
medications O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
transfusion O-ADR O-ADR
rate O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
ribavirin O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
ESA O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
are O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
VICTRELIS O-ADR O-ADR
must O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Empiric O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
fungal O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
invasive O-ADR O-ADR
fungal O-ADR O-ADR
infections O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
severe O-ADR O-ADR
systemic O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
if O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
symptoms O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
and O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis O-ADR B-ADR
and O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reactions O-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
Systemic I-ADR I-ADR
Fibrosis I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
STRIBILD O-ADR O-ADR
therapy O-ADR O-ADR
; O-ADR O-ADR
review O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
during O-ADR O-ADR
STRIBILD O-ADR O-ADR
therapy O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Immune O-ADR O-ADR
Reconstitution O-ADR O-ADR
Syndrome O-ADR O-ADR
Immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
, O-ADR O-ADR
insufficient O-ADR O-ADR
information O-ADR O-ADR
was O-ADR O-ADR
obtained O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
or O-ADR O-ADR
refute O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
causality O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
A O-ADR O-ADR
) O-ADR O-ADR
PREMATURE O-ADR O-ADR
DISCONTINUATION O-ADR O-ADR
OF O-ADR O-ADR
ELIQUIS O-ADR O-ADR
INCREASES O-ADR O-ADR
THE O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THROMBOTIC B-ADR O-ADR
EVENTS I-ADR O-ADR
: O-ADR O-ADR
Premature O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ELIQUIS O-ADR O-ADR
, O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic B-ADR B-ADR
events I-ADR I-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
require O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
JEVTANA O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Peripheral O-ADR O-ADR
Neuropathy O-ADR O-ADR
ADCETRIS O-ADR O-ADR
treatment O-ADR O-ADR
causes O-ADR O-ADR
a O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
treatment O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CAPS O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
Cytomegalovirus O-ADR O-ADR
and O-ADR O-ADR
pneumocystis O-ADR O-ADR
prophylaxis O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
additional O-ADR O-ADR
postmarketing O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
specific O-ADR O-ADR
for O-ADR O-ADR
emtricitabine O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
lists O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ZERBAXA O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
positivity O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
assay O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
, O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
or O-ADR O-ADR
caregivers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
if O-ADR O-ADR
swallowing O-ADR O-ADR
, O-ADR O-ADR
speech O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
disorders O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
manifestations O-ADR O-ADR
include O-ADR O-ADR
hyperpyrexia B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
rigidity I-ADR I-ADR
, O-ADR O-ADR
altered B-ADR B-ADR
mental I-ADR I-ADR
status I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
catatonic B-ADR B-ADR
signs I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
autonomic B-ADR B-ADR
instability I-ADR I-ADR
( O-ADR O-ADR
irregular B-ADR B-ADR
pulse I-ADR I-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
diaphoresis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cardiac B-ADR B-ADR
dysrhythmia I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
rates O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
anxiety B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XALKORI O-ADR O-ADR
arm O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
172 O-ADR O-ADR
) O-ADR O-ADR
received O-ADR O-ADR
XALKORI O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
documented O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
, O-ADR O-ADR
intolerance O-ADR O-ADR
to O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
investigator O-ADR O-ADR
determined O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
was O-ADR O-ADR
no O-ADR O-ADR
longer O-ADR O-ADR
experiencing O-ADR O-ADR
clinical O-ADR O-ADR
benefit O-ADR O-ADR
. O-ADR O-ADR
Mean O-ADR O-ADR
changes B-ADR B-ADR
( I-ADR I-ADR
percent I-ADR I-ADR
changes I-ADR I-ADR
) I-ADR I-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
relative O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
were O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
TREANDA O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
340 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
; O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
older O-ADR O-ADR
than O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
KALBITOR O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
drug O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
were O-ADR O-ADR
sustained O-ADR O-ADR
or O-ADR O-ADR
increased O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
Vimizim O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Cytopenias B-ADR B-ADR
: O-ADR O-ADR
Check O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
monthly O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
grade O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
represented O-ADR O-ADR
no O-ADR O-ADR
reaction O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treated O-ADR O-ADR
area O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
grade O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
indicated O-ADR O-ADR
a O-ADR O-ADR
marked O-ADR O-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
skin O-ADR B-ADR
reaction O-ADR I-ADR
that O-ADR O-ADR
extended O-ADR O-ADR
beyond O-ADR O-ADR
the O-ADR O-ADR
treated O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
was O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
generally O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
limiting O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
discontinuation O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
skin B-ADR B-ADR
laceration I-ADR I-ADR
requiring O-ADR O-ADR
skin O-ADR O-ADR
graft O-ADR O-ADR
after O-ADR O-ADR
finger O-ADR O-ADR
extension O-ADR O-ADR
procedures O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Selected O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
a O-ADR O-ADR
Incidences O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
table O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
underreported O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
lack O-ADR O-ADR
of O-ADR O-ADR
assay O-ADR O-ADR
sensitivity O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
48 O-ADR O-ADR
% O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
African O-ADR O-ADR
/ O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
Hispanic O-ADR O-ADR
/ O-ADR O-ADR
Latino O-ADR O-ADR
. O-ADR O-ADR
b O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
terms O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
haemorrhage I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
As O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
administer O-ADR O-ADR
prophylactic O-ADR O-ADR
antibiotics O-ADR O-ADR
and O-ADR O-ADR
employ O-ADR O-ADR
surveillance O-ADR O-ADR
testing O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
those O-ADR O-ADR
diseases O-ADR O-ADR
causing O-ADR O-ADR
thinning O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
cornea O-ADR O-ADR
or O-ADR O-ADR
sclera O-ADR O-ADR
, O-ADR O-ADR
perforations B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
topical O-ADR O-ADR
steroids O-ADR O-ADR
. O-ADR O-ADR
TRULICITY O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
reports O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
adverse B-ADR O-ADR
reactions I-ADR O-ADR
were I-ADR O-ADR
local I-ADR B-ADR
events I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
penis I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
of O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
severity O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
( O-ADR O-ADR
79 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
resolved O-ADR O-ADR
within O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
post O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
detected O-ADR O-ADR
and O-ADR O-ADR
86 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
detected O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
correlation O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
histopathological O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
suspected O-ADR O-ADR
recurrence O-ADR O-ADR
site O-ADR O-ADR
, O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
to O-ADR O-ADR
proper O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
PET O-ADR O-ADR
imaging O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
fasting O-ADR O-ADR
glucose O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
Serum O-ADR O-ADR
chemistry O-ADR O-ADR
abnormalities O-ADR O-ADR
ALT B-ADR B-ADR
increased I-ADR I-ADR
73 O-ADR O-ADR
( O-ADR O-ADR
50 O-ADR O-ADR
) O-ADR O-ADR
20 O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
7 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
AST B-ADR B-ADR
increased I-ADR I-ADR
60 O-ADR O-ADR
( O-ADR O-ADR
41 O-ADR O-ADR
) O-ADR O-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
Hematology O-ADR O-ADR
abnormalities O-ADR O-ADR
neutrophils B-ADR B-ADR
decreased I-ADR I-ADR
78 O-ADR O-ADR
( O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
20 O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
16 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
hemoglobin B-ADR B-ADR
decreased I-ADR I-ADR
41 O-ADR O-ADR
( O-ADR O-ADR
28 O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
platelets B-ADR B-ADR
decreased I-ADR I-ADR
38 O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
) O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FATAL B-ADR B-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
TOXICITIES B-ADR B-ADR
, O-ADR O-ADR
SEVERE O-ADR O-ADR
DIARRHEA B-ADR B-ADR
, O-ADR O-ADR
COLITIS B-ADR B-ADR
, O-ADR O-ADR
PNEUMONITIS B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INTESTINAL B-ADR B-ADR
PERFORATION I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
FATAL B-ADR B-ADR
AND O-ADR O-ADR
SERIOUS O-ADR O-ADR
TOXICITIES B-ADR B-ADR
, O-ADR O-ADR
SEVERE O-ADR O-ADR
DIARRHEA B-ADR B-ADR
, O-ADR O-ADR
COLITIS B-ADR B-ADR
, O-ADR O-ADR
PNEUMONITIS B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
INTESTINAL B-ADR B-ADR
PERFORATION I-ADR I-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
adjudicated O-ADR O-ADR
events O-ADR O-ADR
revealed O-ADR O-ADR
5 O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
confirmed O-ADR O-ADR
pancreatitis B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
TRULICITY O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
patient O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
in O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
incretin O-ADR O-ADR
comparators O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
88 O-ADR O-ADR
cases O-ADR O-ADR
per O-ADR O-ADR
1000 O-ADR O-ADR
patient O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Delayed O-ADR O-ADR
AdreView O-ADR O-ADR
clearance O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
target O-ADR O-ADR
to O-ADR O-ADR
background O-ADR O-ADR
ratios O-ADR O-ADR
and O-ADR O-ADR
decrease O-ADR O-ADR
the O-ADR O-ADR
quality O-ADR O-ADR
of O-ADR O-ADR
scintigraphic O-ADR O-ADR
images O-ADR O-ADR
. O-ADR O-ADR
Brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
caused O-ADR O-ADR
embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicities I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
significantly O-ADR O-ADR
decreased B-ADR B-ADR
embryo I-ADR I-ADR
viability I-ADR I-ADR
and O-ADR O-ADR
fetal B-ADR B-ADR
malformations I-ADR I-ADR
, O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
at O-ADR O-ADR
maternal O-ADR O-ADR
exposures O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
human O-ADR O-ADR
exposures O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
classical O-ADR O-ADR
HL O-ADR O-ADR
and O-ADR O-ADR
sALCL O-ADR O-ADR
. O-ADR O-ADR
Delay O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
HALAVEN O-ADR O-ADR
and O-ADR O-ADR
reduce O-ADR O-ADR
subsequent O-ADR O-ADR
doses O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
febrile O-ADR O-ADR
neutropenia O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
neutropenia O-ADR O-ADR
lasting O-ADR O-ADR
longer O-ADR O-ADR
than O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
How O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
route O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
corticosteroid O-ADR O-ADR
administration O-ADR O-ADR
affect O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
a O-ADR O-ADR
disseminated O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
an O-ADR O-ADR
alternate O-ADR O-ADR
contraceptive O-ADR O-ADR
method O-ADR O-ADR
for O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
uncontrolled O-ADR O-ADR
dyslipidemia O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
XIAFLEX O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
injected O-ADR O-ADR
only O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
collagen O-ADR O-ADR
cord O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
MP O-ADR O-ADR
or O-ADR O-ADR
PIP O-ADR O-ADR
joint O-ADR O-ADR
contracture O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
injecting O-ADR O-ADR
into O-ADR O-ADR
tendons O-ADR O-ADR
, O-ADR O-ADR
nerves O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
vessels O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
collagen O-ADR O-ADR
- O-ADR O-ADR
containing O-ADR O-ADR
structures O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
hand O-ADR O-ADR
. O-ADR O-ADR
Subsequently O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
physician O-ADR O-ADR
may O-ADR O-ADR
continue O-ADR O-ADR
decreasing O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
more O-ADR O-ADR
gradual O-ADR O-ADR
rate O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
hypertensive O-ADR O-ADR
crisis O-ADR O-ADR
. O-ADR O-ADR
On O-ADR O-ADR
electrocardiograms O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
PR B-ADR B-ADR
interval I-ADR I-ADR
increase I-ADR I-ADR
to O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
220 O-ADR O-ADR
milliseconds O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
TRULICITY O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
assay O-ADR O-ADR
has O-ADR O-ADR
substantial O-ADR O-ADR
limitations O-ADR O-ADR
in O-ADR O-ADR
detecting O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
ipilimumab O-ADR O-ADR
antibodies O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
ipilimumab O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
FULYZAQ O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
indicated O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
infectious O-ADR O-ADR
diarrhea O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
belatacept O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
received O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
have O-ADR O-ADR
included O-ADR O-ADR
difficulty B-ADR B-ADR
breathing I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
throat I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Change O-ADR O-ADR
in O-ADR O-ADR
Body O-ADR O-ADR
Weight O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
from O-ADR O-ADR
Baseline O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
= O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
assessments O-ADR O-ADR
at O-ADR O-ADR
both O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
Endpoint O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
phimosis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
uncircumcised O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
required O-ADR O-ADR
circumcision O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
the O-ADR O-ADR
phimosis B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Female B-ADR B-ADR
patients I-ADR I-ADR
who I-ADR I-ADR
developed I-ADR I-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
recurrence O-ADR O-ADR
and O-ADR O-ADR
require O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
oral O-ADR O-ADR
or O-ADR O-ADR
topical O-ADR O-ADR
antifungal O-ADR O-ADR
agents O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
microbial O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIRTURO O-ADR O-ADR
if O-ADR O-ADR
significant O-ADR O-ADR
ventricular O-ADR O-ADR
arrhythmia O-ADR O-ADR
or O-ADR O-ADR
QTcF O-ADR O-ADR
interval O-ADR O-ADR
> O-ADR O-ADR
500 O-ADR O-ADR
ms O-ADR O-ADR
develops O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
Creutzfeldt B-ADR B-ADR
- O-ADR O-ADR
Jakob O-ADR O-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
CJD B-ADR B-ADR
) O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
viral B-ADR B-ADR
diseases I-ADR I-ADR
or O-ADR O-ADR
CJD B-ADR B-ADR
have O-ADR O-ADR
ever O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
for O-ADR O-ADR
albumin O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Lack O-ADR O-ADR
of O-ADR O-ADR
Interchangeability O-ADR O-ADR
between O-ADR O-ADR
Botulinum O-ADR O-ADR
Toxin O-ADR O-ADR
Products O-ADR O-ADR
The O-ADR O-ADR
potency O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
specific O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
preparation O-ADR O-ADR
and O-ADR O-ADR
assay O-ADR O-ADR
method O-ADR O-ADR
utilized O-ADR O-ADR
. O-ADR O-ADR
and O-ADR O-ADR
untreated O-ADR O-ADR
or O-ADR O-ADR
inadequately O-ADR O-ADR
treated O-ADR O-ADR
extrapyramidal O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
EPS O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
other O-ADR O-ADR
patient O-ADR O-ADR
developed O-ADR O-ADR
probable O-ADR O-ADR
PML B-ADR B-ADR
after O-ADR O-ADR
taking O-ADR O-ADR
GILENYA O-ADR O-ADR
for O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
early O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
this O-ADR O-ADR
condition O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
appropriate O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
anaphylactic O-ADR O-ADR
reaction O-ADR O-ADR
to O-ADR O-ADR
ZERBAXA O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Delayed O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusion O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
more O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
included O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
causes O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
varied O-ADR O-ADR
and O-ADR O-ADR
included O-ADR O-ADR
complications B-ADR O-ADR
of I-ADR O-ADR
infection I-ADR B-ADR
, O-ADR O-ADR
surgery O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
average O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
53 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
from O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
97 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Hypokalemia O-ADR B-ADR
( O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR B-ADR
) O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
QT O-ADR B-ADR
prolongation O-ADR I-ADR
and O-ADR O-ADR
arrhythmia O-ADR B-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
trametinib O-ADR O-ADR
if O-ADR O-ADR
RPED O-ADR O-ADR
is O-ADR O-ADR
diagnosed O-ADR O-ADR
. O-ADR O-ADR
Mortality B-ADR B-ADR
related O-ADR O-ADR
to O-ADR O-ADR
diarrhea B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
prescribing O-ADR O-ADR
DIFICID O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
macrolide O-ADR O-ADR
allergy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
aware O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
: O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
should O-ADR O-ADR
only O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
on O-ADR O-ADR
children O-ADR O-ADR
under O-ADR O-ADR
the O-ADR O-ADR
direct O-ADR O-ADR
supervision O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
adult O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hematologic B-ADR B-ADR
toxicities I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Rebound O-ADR O-ADR
Hypertension O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
receive O-ADR O-ADR
prolonged O-ADR O-ADR
Cleviprex O-ADR O-ADR
infusions O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
transitioned O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
antihypertensive O-ADR O-ADR
therapies O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
rebound O-ADR O-ADR
hypertension O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
8 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
is O-ADR O-ADR
stopped O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
cardiomyopathy B-ADR B-ADR
resolved O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
following O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
dose O-ADR O-ADR
interruption O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SAPHRIS O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
neutropenia O-ADR O-ADR
( O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
< O-ADR O-ADR
1000 O-ADR O-ADR
/ O-ADR O-ADR
mm O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
follow O-ADR O-ADR
their O-ADR O-ADR
WBC O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
for O-ADR O-ADR
example O-ADR O-ADR
, O-ADR O-ADR
age O-ADR O-ADR
> O-ADR O-ADR
60 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
hypertension O-ADR O-ADR
or O-ADR O-ADR
diabetes O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
estimate O-ADR O-ADR
the O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
) O-ADR O-ADR
through O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
ribavirin O-ADR O-ADR
and O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
for O-ADR O-ADR
guidelines O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
parameters O-ADR O-ADR
. O-ADR O-ADR
Abdominal O-ADR O-ADR
pain O-ADR O-ADR
and O-ADR O-ADR
tenderness O-ADR O-ADR
, O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
constipation O-ADR O-ADR
, O-ADR O-ADR
diarrhea O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
neutropenia O-ADR O-ADR
, O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
early O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
gastrointestinal O-ADR O-ADR
toxicity O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
evaluated O-ADR O-ADR
and O-ADR O-ADR
treated O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
by O-ADR O-ADR
Greater O-ADR O-ADR
Than O-ADR O-ADR
or O-ADR O-ADR
Equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
With O-ADR O-ADR
STENDRA O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
Open O-ADR O-ADR
- O-ADR O-ADR
Label O-ADR O-ADR
Extension O-ADR O-ADR
Trial O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
STENDRA O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
711 O-ADR O-ADR
) O-ADR O-ADR
Headache B-ADR B-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Flushing B-ADR B-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Nasopharyngitis B-ADR B-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
Nasal B-ADR B-ADR
congestion I-ADR I-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
study O-ADR O-ADR
included O-ADR O-ADR
: O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
URI B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
PROMACTA O-ADR O-ADR
if O-ADR O-ADR
antiviral O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
31 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
any O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
endophthalmitis O-ADR O-ADR
or O-ADR O-ADR
retinal O-ADR O-ADR
detachment O-ADR O-ADR
without O-ADR O-ADR
delay O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
managed O-ADR O-ADR
appropriately O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
andPatient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
XALKORI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
new O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
visual O-ADR O-ADR
loss O-ADR O-ADR
( O-ADR O-ADR
best O-ADR O-ADR
corrected O-ADR O-ADR
vision O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
20 O-ADR O-ADR
/ O-ADR O-ADR
200 O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
both O-ADR O-ADR
eyes O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
manifesting O-ADR O-ADR
as O-ADR O-ADR
bullous B-ADR B-ADR
rash I-ADR I-ADR
. O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
BMD O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
for O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
infected O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pathologic O-ADR O-ADR
bone O-ADR O-ADR
fracture O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
osteoporosis O-ADR O-ADR
or O-ADR O-ADR
bone O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
medical O-ADR O-ADR
history O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
because O-ADR O-ADR
CDAD O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
established O-ADR O-ADR
way O-ADR O-ADR
to O-ADR O-ADR
reverse O-ADR O-ADR
the O-ADR O-ADR
anticoagulant O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
apixaban O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
persist O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
about O-ADR O-ADR
two O-ADR O-ADR
drug O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
lives O-ADR O-ADR
. O-ADR O-ADR
ATEs O-ADR O-ADR
are O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
nonfatal O-ADR O-ADR
stroke O-ADR B-ADR
, O-ADR O-ADR
nonfatal O-ADR O-ADR
myocardial O-ADR B-ADR
infarction O-ADR I-ADR
, O-ADR O-ADR
or O-ADR O-ADR
vascular O-ADR B-ADR
death O-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
deaths O-ADR B-ADR
of O-ADR O-ADR
unknown O-ADR O-ADR
cause O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Electrocardiogram O-ADR O-ADR
( O-ADR O-ADR
ECG O-ADR O-ADR
) O-ADR O-ADR
measurements O-ADR O-ADR
were O-ADR O-ADR
taken O-ADR O-ADR
at O-ADR O-ADR
various O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
SAPHRIS O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
program O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
doses O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Proper O-ADR O-ADR
aseptic O-ADR O-ADR
injection O-ADR O-ADR
technique O-ADR O-ADR
must O-ADR O-ADR
always O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
EYLEA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
presents O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
from O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
multicenter O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
162 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
BRAF O-ADR O-ADR
V600E O-ADR O-ADR
or O-ADR O-ADR
V600K O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
melanoma O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
TAFINLAR O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
1 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
54 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
high O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
high O-ADR O-ADR
cholesterol O-ADR O-ADR
( O-ADR O-ADR
fat O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
blood O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
overweight O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
use O-ADR O-ADR
tobacco O-ADR O-ADR
, O-ADR O-ADR
you O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
higher O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
PROMACTA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
liver B-ADR B-ADR
enzyme I-ADR I-ADR
elevations I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
total O-ADR O-ADR
, O-ADR O-ADR
536 O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
75 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
increased O-ADR O-ADR
their O-ADR O-ADR
dose O-ADR O-ADR
to O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
reduced O-ADR O-ADR
their O-ADR O-ADR
dose O-ADR O-ADR
to O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
when O-ADR O-ADR
STENDRA O-ADR O-ADR
was O-ADR O-ADR
taken O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
( O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
as O-ADR O-ADR
- O-ADR O-ADR
needed O-ADR O-ADR
basis O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
neutropenia O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
EOVIST O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
body O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Increased B-ADR B-ADR
susceptibility I-ADR I-ADR
to I-ADR I-ADR
infection I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
from O-ADR O-ADR
immunosuppression O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
cardiomyopathy B-ADR B-ADR
( O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
LVEF I-ADR I-ADR
below O-ADR O-ADR
institutional O-ADR O-ADR
lower O-ADR O-ADR
limits O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
absolute B-ADR O-ADR
decrease I-ADR O-ADR
in I-ADR O-ADR
LVEF I-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
below O-ADR O-ADR
baseline O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
ELIQUIS O-ADR O-ADR
was O-ADR O-ADR
statistically O-ADR O-ADR
superior O-ADR O-ADR
to O-ADR O-ADR
enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
warfarin O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
primary O-ADR O-ADR
safety O-ADR O-ADR
endpoint O-ADR O-ADR
of O-ADR O-ADR
major O-ADR O-ADR
bleeding B-ADR B-ADR
( O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
31 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
[ O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
55 O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
value O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0001 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Piramal O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
855 O-ADR O-ADR
- O-ADR O-ADR
545 O-ADR O-ADR
- O-ADR O-ADR
5245 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
122 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
18 O-ADR O-ADR
) O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
were O-ADR O-ADR
administered O-ADR O-ADR
intravenously O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
doses O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
specified O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
Closely O-ADR O-ADR
monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
. O-ADR O-ADR
Keep O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
reach O-ADR O-ADR
of O-ADR O-ADR
children O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
allergic B-ADR B-ADR
contact I-ADR I-ADR
dermatitis I-ADR I-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
histories O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular O-ADR O-ADR
illness O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
QT O-ADR O-ADR
prolongation O-ADR O-ADR
, O-ADR O-ADR
recent O-ADR O-ADR
acute O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
uncompensated O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
cardiac O-ADR O-ADR
arrhythmia O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
findings O-ADR O-ADR
were O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
an O-ADR O-ADR
earlier O-ADR O-ADR
144 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
+ O-ADR O-ADR
lamivudine O-ADR O-ADR
+ O-ADR O-ADR
efavirenz O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Mortality B-ADR B-ADR
: O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
deaths B-ADR B-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUPINE B-ADR B-ADR
HYPERTENSION I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
expanded O-ADR O-ADR
access O-ADR O-ADR
programs O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
included O-ADR O-ADR
livedo B-ADR B-ADR
reticularis I-ADR I-ADR
, O-ADR O-ADR
irritability B-ADR B-ADR
, O-ADR O-ADR
retching B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
lacrimation I-ADR I-ADR
, O-ADR O-ADR
ventricular B-ADR B-ADR
extrasystoles I-ADR I-ADR
, O-ADR O-ADR
nodal B-ADR B-ADR
rhythm I-ADR I-ADR
, O-ADR O-ADR
rales B-ADR B-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
irritation I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cold B-ADR B-ADR
sweat I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Clostridium O-ADR O-ADR
difficile O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
Diarrhea O-ADR O-ADR
Clostridium B-ADR B-ADR
difficile I-ADR I-ADR
- I-ADR I-ADR
associated O-ADR O-ADR
diarrhea I-ADR I-ADR
( O-ADR O-ADR
CDAD B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
nearly O-ADR O-ADR
all O-ADR O-ADR
systemic O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ZERBAXA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
range O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
diarrhea B-ADR B-ADR
to O-ADR O-ADR
fatal B-ADR B-ADR
colitis B-ADR B-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
delayed O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
included O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
glucose O-ADR O-ADR
regularly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
diabetes O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
indications O-ADR O-ADR
, O-ADR O-ADR
about O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
uric O-ADR O-ADR
acid O-ADR O-ADR
lowering O-ADR O-ADR
drugs O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
TLS O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
additional O-ADR O-ADR
estrogen O-ADR O-ADR
products O-ADR O-ADR
while O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Using O-ADR O-ADR
estrogens O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
your O-ADR O-ADR
chances O-ADR O-ADR
of O-ADR O-ADR
getting O-ADR O-ADR
strokes O-ADR O-ADR
or O-ADR O-ADR
blood O-ADR O-ADR
clots O-ADR O-ADR
. O-ADR O-ADR
Estrogens O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prescribed O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
lowest O-ADR O-ADR
effective O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
shortest O-ADR O-ADR
duration O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
goals O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
individual O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
patients O-ADR O-ADR
died B-ADR B-ADR
of O-ADR O-ADR
herpetic B-ADR B-ADR
infections I-ADR I-ADR
during O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
monitored O-ADR O-ADR
, O-ADR O-ADR
since O-ADR O-ADR
recurrences O-ADR O-ADR
of O-ADR O-ADR
NMS O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
DALVANCE O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
summarizes O-ADR O-ADR
all O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
postherpetic O-ADR O-ADR
neuralgia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Qutenza O-ADR O-ADR
group O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
XALKORI O-ADR O-ADR
was O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Impairment O-ADR O-ADR
in O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
INVOKANA O-ADR O-ADR
increases B-ADR B-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decreases B-ADR B-ADR
eGFR I-ADR I-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
often O-ADR O-ADR
have O-ADR O-ADR
multiple O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
reduced O-ADR O-ADR
BMD O-ADR O-ADR
, O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
BMD O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neuropsychiatric B-ADR B-ADR
symptoms I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
confusional O-ADR O-ADR
state O-ADR O-ADR
, O-ADR O-ADR
psychotic O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hallucinations O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Seizure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
seizure B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
with O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
Contact O-ADR O-ADR
AstraZeneca O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
236 O-ADR O-ADR
- O-ADR O-ADR
9933 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
lipid B-ADR B-ADR
metabolic I-ADR I-ADR
effects I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
prediabetic O-ADR O-ADR
and O-ADR O-ADR
diabetic O-ADR O-ADR
women O-ADR O-ADR
taking O-ADR O-ADR
Natazia O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
; O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
monitoring O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
cytopenias O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
racial O-ADR O-ADR
and O-ADR O-ADR
ethnic O-ADR O-ADR
distribution O-ADR O-ADR
was O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
83 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Black O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Asian O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
diarrhea B-ADR B-ADR
or O-ADR O-ADR
colitis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
Marketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ZYTIGA O-ADR O-ADR
. O-ADR O-ADR
eOn O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
analysis O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
ITT O-ADR O-ADR
analysis O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Section O-ADR O-ADR
14 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Headache B-ADR B-ADR
: O-ADR O-ADR
Evaluate O-ADR O-ADR
significant O-ADR O-ADR
change O-ADR O-ADR
in O-ADR O-ADR
headaches O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
diagnosed O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
Neuropsychiatric B-ADR O-ADR
Symptoms I-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Epilepsy O-ADR O-ADR
Trials O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Number O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
Number O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Discontinuing O-ADR O-ADR
POTIGA O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
813 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
427 O-ADR O-ADR
) O-ADR O-ADR
POTIGA O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
813 O-ADR O-ADR
) O-ADR O-ADR
Placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
427 O-ADR O-ADR
) O-ADR O-ADR
Confusional B-ADR B-ADR
state I-ADR I-ADR
75 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
11 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
32 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Psychosis B-ADR B-ADR
9 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
Hallucinationsa O-ADR B-ADR
14 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Hallucinations B-ADR B-ADR
includes O-ADR O-ADR
mixed B-ADR B-ADR
hallucinations I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
contribution O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
prior O-ADR O-ADR
corticosteroid O-ADR O-ADR
treatment O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
is O-ADR O-ADR
also O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
Discoloration B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
palate I-ADR I-ADR
has O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
However O-ADR O-ADR
, O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
and O-ADR O-ADR
findings O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
, O-ADR O-ADR
ADCETRIS O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
- O-ADR O-ADR
site O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
- O-ADR O-ADR
site O-ADR O-ADR
rash I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Injection O-ADR O-ADR
into O-ADR O-ADR
these O-ADR O-ADR
structures O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
possible O-ADR O-ADR
permanent B-ADR O-ADR
injury I-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
corporal B-ADR O-ADR
rupture I-ADR O-ADR
( O-ADR O-ADR
penile B-ADR O-ADR
fracture I-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Urinary B-ADR B-ADR
retention I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
in O-ADR O-ADR
29 O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
365 O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
epilepsy O-ADR O-ADR
database O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Cardiac O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Angina B-ADR B-ADR
pectoris I-ADR I-ADR
, O-ADR O-ADR
arrhythmias B-ADR B-ADR
, O-ADR O-ADR
atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
, O-ADR O-ADR
cardiac B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
hypertensive B-ADR B-ADR
heart I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
ischemia I-ADR I-ADR
, O-ADR O-ADR
pericardial B-ADR B-ADR
effusion I-ADR I-ADR
, O-ADR O-ADR
pericarditis B-ADR B-ADR
, O-ADR O-ADR
stroke B-ADR B-ADR
and O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attack I-ADR I-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
92 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
moderately O-ADR O-ADR
impaired O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
eGFR O-ADR O-ADR
86 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Proteinuria O-ADR O-ADR
At O-ADR O-ADR
Month O-ADR O-ADR
1 O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
+ O-ADR O-ADR
proteinuria B-ADR B-ADR
on O-ADR O-ADR
urine O-ADR O-ADR
dipstick O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
was O-ADR O-ADR
33 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
130 O-ADR O-ADR
/ O-ADR O-ADR
390 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
28 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
107 O-ADR O-ADR
/ O-ADR O-ADR
384 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Infections O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
such O-ADR O-ADR
as O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
bacteremia B-ADR B-ADR
, O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
catheter B-ADR B-ADR
- O-ADR O-ADR
site O-ADR O-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
transaminases I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
199 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
mono O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
different O-ADR O-ADR
AEDs O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
AEDs O-ADR O-ADR
had O-ADR O-ADR
approximately O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
adjusted O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
[ O-ADR O-ADR
CI O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
TABLE O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Changes O-ADR O-ADR
in O-ADR O-ADR
Lipids O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
= O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
assessments O-ADR O-ADR
at O-ADR O-ADR
both O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
Endpoint O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
cause O-ADR O-ADR
mortality B-ADR B-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
DUAVEE O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Infusion B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
medicate O-ADR O-ADR
with O-ADR O-ADR
dexamethasone O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
general O-ADR O-ADR
agreement O-ADR O-ADR
about O-ADR O-ADR
specific O-ADR O-ADR
pharmacological O-ADR O-ADR
treatment O-ADR O-ADR
regimens O-ADR O-ADR
for O-ADR O-ADR
NMS O-ADR O-ADR
. O-ADR O-ADR
ZERBAXA O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
cIAI O-ADR O-ADR
and O-ADR O-ADR
cUTI O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1015 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZERBAXA O-ADR O-ADR
and O-ADR O-ADR
1032 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
( O-ADR O-ADR
levofloxacin O-ADR O-ADR
750 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
cUTI O-ADR O-ADR
or O-ADR O-ADR
meropenem O-ADR O-ADR
1 O-ADR O-ADR
g O-ADR O-ADR
every O-ADR O-ADR
8 O-ADR O-ADR
hours O-ADR O-ADR
in O-ADR O-ADR
cIAI O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
14 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
included O-ADR O-ADR
suicidal B-ADR B-ADR
ideation I-ADR I-ADR
and O-ADR O-ADR
suicide B-ADR B-ADR
attempt I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
or O-ADR O-ADR
psychiatric O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
or O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TIVICAY O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FIRAZYR O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
could O-ADR O-ADR
receive O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
FIRAZYR O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
administered O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
apart O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
attack O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Serious O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Complete O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Obstruction O-ADR O-ADR
No O-ADR O-ADR
studies O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
complete O-ADR O-ADR
gastrointestinal O-ADR O-ADR
obstruction O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
surgery O-ADR O-ADR
for O-ADR O-ADR
correction O-ADR O-ADR
of O-ADR O-ADR
complete O-ADR O-ADR
bowel O-ADR O-ADR
obstruction O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
as O-ADR O-ADR
a O-ADR O-ADR
complication O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
dysphagia B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
aged O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
437 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
13 O-ADR O-ADR
to O-ADR O-ADR
466 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Instances O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1308 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
OTEZLA O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
506 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
Premedicate O-ADR O-ADR
with O-ADR O-ADR
corticosteroids O-ADR O-ADR
and O-ADR O-ADR
H2 O-ADR O-ADR
antagonists O-ADR O-ADR
. O-ADR O-ADR
BOXED O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUICIDAL B-ADR B-ADR
THOUGHTS I-ADR I-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
SUICIDAL B-ADR B-ADR
THOUGHTS I-ADR I-ADR
Antidepressants O-ADR O-ADR
increased O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
in O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
adolescents O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adults O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Renal B-ADR B-ADR
failure I-ADR I-ADR
: O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
some O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Advanced O-ADR B-ADR
HR O-ADR I-ADR
+ O-ADR O-ADR
BC O-ADR I-ADR
, O-ADR O-ADR
advanced O-ADR B-ADR
PNET O-ADR I-ADR
, O-ADR O-ADR
advanced O-ADR O-ADR
RCC O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
include O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
fever B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Carcinogenicity O-ADR O-ADR
of O-ADR O-ADR
albiglutide O-ADR O-ADR
could O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
other O-ADR O-ADR
glucagon O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
peptide O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
receptor O-ADR O-ADR
agonists O-ADR O-ADR
have O-ADR O-ADR
caused O-ADR O-ADR
thyroid B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
tumors I-ADR I-ADR
in O-ADR O-ADR
rodents O-ADR O-ADR
at O-ADR O-ADR
clinically O-ADR O-ADR
relevant O-ADR O-ADR
exposures O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
trametinib O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
hemorrhagic O-ADR O-ADR
events O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
improved O-ADR O-ADR
, O-ADR O-ADR
resume O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Bleeding B-ADR B-ADR
Results O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
Study O-ADR O-ADR
ELIQUISN O-ADR O-ADR
= O-ADR O-ADR
2676n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
WarfarinN O-ADR O-ADR
= O-ADR O-ADR
2689n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
( O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
CRNM B-ADR B-ADR
= O-ADR O-ADR
clinically B-ADR B-ADR
relevant I-ADR I-ADR
nonmajor I-ADR I-ADR
bleeding O-ADR O-ADR
. O-ADR O-ADR
Events O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
each O-ADR O-ADR
endpoint O-ADR O-ADR
were O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
per O-ADR O-ADR
subject O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
subjects O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
contributed O-ADR O-ADR
events O-ADR O-ADR
to O-ADR O-ADR
multiple O-ADR O-ADR
endpoints O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
definite O-ADR O-ADR
causality O-ADR O-ADR
assessment O-ADR O-ADR
or O-ADR O-ADR
benefit O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
confounding O-ADR O-ADR
factors O-ADR O-ADR
and O-ADR O-ADR
lack O-ADR O-ADR
of O-ADR O-ADR
randomization O-ADR O-ADR
of O-ADR O-ADR
ESA O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Safety O-ADR O-ADR
Cardiovascular B-ADR B-ADR
events I-ADR I-ADR
and O-ADR O-ADR
deaths B-ADR B-ADR
were O-ADR O-ADR
adjudicated O-ADR O-ADR
to O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
defined O-ADR O-ADR
endpoints O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
Platelet O-ADR O-ADR
Trialists O-ADR O-ADR
' O-ADR O-ADR
Collaborations O-ADR O-ADR
( O-ADR O-ADR
APTC O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
cardiovascular B-ADR B-ADR
death I-ADR I-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
stroke B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
active O-ADR O-ADR
TB O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
even O-ADR O-ADR
if O-ADR O-ADR
initial O-ADR O-ADR
latent O-ADR O-ADR
TB O-ADR O-ADR
test O-ADR O-ADR
is O-ADR O-ADR
negative O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Lymphoma B-ADR B-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
and O-ADR O-ADR
adolescent O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Adrenocortical B-ADR B-ADR
Insufficiency I-ADR I-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
lists O-ADR O-ADR
selected O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
and O-ADR O-ADR
second O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Keep O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
blister O-ADR O-ADR
until O-ADR O-ADR
you O-ADR O-ADR
are O-ADR O-ADR
ready O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
it O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
the O-ADR O-ADR
tablet O-ADR O-ADR
from O-ADR O-ADR
moisture O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
loss O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
report O-ADR O-ADR
them O-ADR O-ADR
immediately O-ADR O-ADR
or O-ADR O-ADR
go O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
emergency O-ADR O-ADR
room O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
for O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
bradycardia O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
XALKORI O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
hypotension O-ADR O-ADR
, O-ADR O-ADR
hold O-ADR O-ADR
XALKORI O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
asymptomatic O-ADR O-ADR
bradycardia O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
heart O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
60 O-ADR O-ADR
bpm O-ADR O-ADR
or O-ADR O-ADR
above O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
if O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
adjusted O-ADR O-ADR
or O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
restart O-ADR O-ADR
XALKORI O-ADR O-ADR
at O-ADR O-ADR
250 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hepatic O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
promptly O-ADR O-ADR
discontinue O-ADR O-ADR
MULTAQ O-ADR O-ADR
and O-ADR O-ADR
test O-ADR O-ADR
serum O-ADR O-ADR
enzymes O-ADR O-ADR
, O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
alanine O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
serum O-ADR O-ADR
bilirubin O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
establish O-ADR O-ADR
whether O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
Torsade B-ADR B-ADR
de I-ADR I-ADR
Pointes I-ADR I-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
delayed B-ADR B-ADR
ventricular I-ADR I-ADR
repolarization I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
ribavirin O-ADR O-ADR
is O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
anemia O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
VICTRELIS O-ADR O-ADR
must O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Endophthalmitis O-ADR O-ADR
and O-ADR O-ADR
Retinal O-ADR O-ADR
Detachments O-ADR O-ADR
Intravitreal O-ADR O-ADR
injections O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
endophthalmitis B-ADR B-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
detachments I-ADR I-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Significantly O-ADR O-ADR
elevated O-ADR O-ADR
serum O-ADR O-ADR
calcitonin O-ADR O-ADR
may O-ADR O-ADR
indicate O-ADR O-ADR
MTC O-ADR O-ADR
and O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MTC O-ADR O-ADR
usually O-ADR O-ADR
have O-ADR O-ADR
calcitonin O-ADR O-ADR
values O-ADR O-ADR
> O-ADR O-ADR
50 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Increased O-ADR O-ADR
From O-ADR O-ADR
Baseline O-ADR O-ADR
Occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
Higher O-ADR O-ADR
Incidence O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
With O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
[ O-ADR O-ADR
Between O-ADR O-ADR
- O-ADR O-ADR
Arm O-ADR O-ADR
Difference O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
Grades O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Test O-ADR O-ADR
TAFINLAR O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
187 O-ADR O-ADR
DTIC O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
59 O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grades O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grades O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
50 O-ADR O-ADR
6 O-ADR O-ADR
43 O-ADR O-ADR
0 O-ADR O-ADR
Hypophosphatemia B-ADR B-ADR
37 O-ADR O-ADR
6a O-ADR O-ADR
14 O-ADR O-ADR
2 O-ADR O-ADR
Increased B-ADR B-ADR
alkaline I-ADR I-ADR
phosphatase I-ADR I-ADR
19 O-ADR O-ADR
0 O-ADR O-ADR
14 O-ADR O-ADR
2 O-ADR O-ADR
Hyponatremia B-ADR B-ADR
8 O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
laboratory O-ADR O-ADR
abnormality O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
hypophosphatemia B-ADR B-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Severe O-ADR O-ADR
Visual O-ADR O-ADR
Loss O-ADR O-ADR
Across O-ADR O-ADR
all O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
visual B-ADR B-ADR
field I-ADR I-ADR
defect I-ADR I-ADR
with O-ADR O-ADR
vision B-ADR B-ADR
loss I-ADR I-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
1669 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
histoplasmosis B-ADR O-ADR
, O-ADR O-ADR
rather O-ADR O-ADR
than O-ADR O-ADR
localized O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorder O-ADR O-ADR
: O-ADR O-ADR
hypersensitivity B-ADR B-ADR
. O-ADR O-ADR
Table1 O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
FOR O-ADR O-ADR
HEPATIC B-ADR B-ADR
DECOMPENSATION I-ADR I-ADR
IN O-ADR O-ADR
PATIENTS O-ADR O-ADR
WITH O-ADR O-ADR
CHRONIC O-ADR O-ADR
HEPATITIS O-ADR O-ADR
C O-ADR O-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
Marketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
otherwise O-ADR O-ADR
important O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
ADRs O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
another O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Anemia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Pancytopenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
35 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
investigator O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
causality O-ADR O-ADR
assessment O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dysgeusia B-ADR B-ADR
when O-ADR O-ADR
VICTRELIS O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
and O-ADR O-ADR
REBETOL O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
eligible O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
initially O-ADR O-ADR
assigned O-ADR O-ADR
to O-ADR O-ADR
STENDRA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
any O-ADR O-ADR
point O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
could O-ADR O-ADR
request O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
increased O-ADR O-ADR
to O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
decreased O-ADR O-ADR
to O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
their O-ADR O-ADR
individual O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Progressive B-ADR B-ADR
Multifocal I-ADR I-ADR
Leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
: O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
; O-ADR O-ADR
consider O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
reporting O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
neurological O-ADR O-ADR
, O-ADR O-ADR
cognitive O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
behavioral O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
15 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
49 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
31 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
p O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0001 O-ADR O-ADR
CRNM O-ADR O-ADR
* O-ADR O-ADR
103 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
215 O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
Major O-ADR O-ADR
+ O-ADR O-ADR
CRNM B-ADR B-ADR
115 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
261 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
Minor O-ADR O-ADR
313 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
505 O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
402 O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
) O-ADR O-ADR
676 O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
study O-ADR O-ADR
are O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Only O-ADR O-ADR
physicians O-ADR O-ADR
experienced O-ADR O-ADR
in O-ADR O-ADR
immunosuppressive O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
kidney O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
prescribe O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
hemorrhagic O-ADR O-ADR
events O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
improved O-ADR O-ADR
resume O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
level O-ADR O-ADR
. O-ADR O-ADR
Reduction O-ADR O-ADR
of O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Stroke O-ADR O-ADR
and O-ADR O-ADR
Systemic O-ADR O-ADR
Embolism O-ADR O-ADR
in O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
valvular O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
Reduce O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
PRADAXA O-ADR O-ADR
to O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
when O-ADR O-ADR
dronedarone O-ADR O-ADR
or O-ADR O-ADR
systemic O-ADR O-ADR
ketoconazole O-ADR O-ADR
is O-ADR O-ADR
coadministered O-ADR O-ADR
with O-ADR O-ADR
PRADAXA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
CrCl O-ADR O-ADR
30 O-ADR O-ADR
- O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neuropathy O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
hypoesthesia O-ADR O-ADR
, O-ADR O-ADR
hyperesthesia O-ADR O-ADR
, O-ADR O-ADR
paresthesia O-ADR O-ADR
, O-ADR O-ADR
discomfort O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
burning O-ADR O-ADR
sensation O-ADR O-ADR
, O-ADR O-ADR
neuropathic O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
weakness O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
accidental O-ADR O-ADR
exposure O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
area O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
flushed O-ADR O-ADR
with O-ADR O-ADR
water O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
should O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
as O-ADR O-ADR
soon O-ADR O-ADR
as O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
liver B-ADR B-ADR
function I-ADR I-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
rash B-ADR B-ADR
. O-ADR O-ADR
CAPS O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
investigated O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
Part O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
randomized O-ADR O-ADR
withdrawal O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
Part O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
16 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
period O-ADR O-ADR
( O-ADR O-ADR
Part O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
criterion O-ADR O-ADR
for O-ADR O-ADR
allowing O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
a O-ADR O-ADR
second O-ADR O-ADR
glucarpidase O-ADR O-ADR
dose O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
specified O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
Safety O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
99 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
females O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
ongoing O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
prospective O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
160 O-ADR O-ADR
L O-ADR O-ADR
scale O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
switched O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
4000 O-ADR O-ADR
L O-ADR O-ADR
scale O-ADR O-ADR
of O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
Toviaz O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
and O-ADR O-ADR
therefore O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
patient O-ADR O-ADR
population O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
supine O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
when O-ADR O-ADR
increasing O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
blinded O-ADR O-ADR
study O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
115 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
45 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
9 O-ADR O-ADR
to O-ADR O-ADR
115 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
those O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
liver O-ADR O-ADR
aminotransferases O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
therapy O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
excluded O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
, O-ADR O-ADR
whereas O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
permitted O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
medications O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
among O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
diagnostic O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
and O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
with O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
contrast O-ADR O-ADR
MRI O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
modalities O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
immunogenicity O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Tumor O-ADR O-ADR
Lysis O-ADR O-ADR
Syndrome O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
TLS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
chronic B-ADR B-ADR
leukemia I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
rheumatoid O-ADR O-ADR
arthritis O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
or O-ADR O-ADR
moderate O-ADR O-ADR
in O-ADR O-ADR
severity O-ADR O-ADR
and O-ADR O-ADR
transient O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
. O-ADR O-ADR
PML B-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
opportunistic B-ADR O-ADR
viral I-ADR O-ADR
infection I-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
brain I-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
JC B-ADR O-ADR
virus I-ADR O-ADR
( O-ADR O-ADR
JCV B-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
typically O-ADR O-ADR
only O-ADR O-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
immunocompromised O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
that O-ADR O-ADR
usually O-ADR O-ADR
leads O-ADR O-ADR
to O-ADR O-ADR
death B-ADR B-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
disability B-ADR B-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
osteoporosis O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
women O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
women O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
table O-ADR O-ADR
below O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
initiate O-ADR O-ADR
in O-ADR O-ADR
acutely O-ADR O-ADR
deteriorating O-ADR O-ADR
COPD O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
for O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiovascular O-ADR O-ADR
or O-ADR O-ADR
convulsive O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
thyrotoxicosis O-ADR O-ADR
or O-ADR O-ADR
sensitivity O-ADR O-ADR
to O-ADR O-ADR
sympathomimetic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Unintended O-ADR O-ADR
Skin O-ADR O-ADR
Exposure O-ADR O-ADR
If O-ADR O-ADR
skin O-ADR O-ADR
not O-ADR O-ADR
intended O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
comes O-ADR O-ADR
in O-ADR O-ADR
contact O-ADR O-ADR
with O-ADR O-ADR
Qutenza O-ADR O-ADR
, O-ADR O-ADR
apply O-ADR O-ADR
Cleansing O-ADR O-ADR
Gel O-ADR O-ADR
for O-ADR O-ADR
one O-ADR O-ADR
minute O-ADR O-ADR
and O-ADR O-ADR
wipe O-ADR O-ADR
off O-ADR O-ADR
with O-ADR O-ADR
dry O-ADR O-ADR
gauze O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryo B-ADR B-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Fetal B-ADR B-ADR
harm I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trial O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
Elevations B-ADR B-ADR
of I-ADR I-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
to O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
small O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
both O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
balanced O-ADR O-ADR
between O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
titers O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
determined O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Urinary B-ADR B-ADR
retention I-ADR I-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
urologic O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
was O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
blood B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
all O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
close O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
warranted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
change O-ADR O-ADR
in O-ADR O-ADR
vision O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
intraocular O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
glaucoma O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
cataracts O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
patient O-ADR O-ADR
had O-ADR O-ADR
pretreatment O-ADR O-ADR
calcitonin O-ADR O-ADR
levels O-ADR O-ADR
approximately O-ADR O-ADR
8 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
the O-ADR O-ADR
64 O-ADR O-ADR
dulaglutide O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
that O-ADR O-ADR
developed O-ADR O-ADR
dulaglutide O-ADR O-ADR
ADAs O-ADR O-ADR
, O-ADR O-ADR
34 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
population O-ADR O-ADR
) O-ADR O-ADR
had O-ADR O-ADR
dulaglutide O-ADR O-ADR
- O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
36 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
overall O-ADR O-ADR
population O-ADR O-ADR
) O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
against O-ADR O-ADR
native O-ADR O-ADR
GLP O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
: O-ADR O-ADR
Healthcare O-ADR O-ADR
providers O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
prepared O-ADR O-ADR
to O-ADR O-ADR
address O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis O-ADR O-ADR
, O-ADR O-ADR
following O-ADR O-ADR
XIAFLEX O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
Eleven O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
13 O-ADR O-ADR
fractures B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
52 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
367 O-ADR O-ADR
RA O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
030 O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
663 O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
and O-ADR O-ADR
282 O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
774 O-ADR O-ADR
in O-ADR O-ADR
adequate O-ADR O-ADR
and O-ADR O-ADR
well O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
developed O-ADR O-ADR
skin B-ADR B-ADR
discoloration I-ADR I-ADR
, O-ADR O-ADR
generally O-ADR O-ADR
after O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
900 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
VTE B-ADR B-ADR
is O-ADR O-ADR
highest O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
corporal B-ADR O-ADR
rupture I-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
penile B-ADR O-ADR
injury I-ADR O-ADR
, O-ADR O-ADR
XIAFLEX O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
a O-ADR O-ADR
restricted O-ADR O-ADR
program O-ADR O-ADR
under O-ADR O-ADR
a O-ADR O-ADR
Risk O-ADR O-ADR
Evaluation O-ADR O-ADR
and O-ADR O-ADR
Mitigation O-ADR O-ADR
Strategy O-ADR O-ADR
( O-ADR O-ADR
REMS O-ADR O-ADR
) O-ADR O-ADR
called O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Dizziness O-ADR O-ADR
and O-ADR O-ADR
Somnolence O-ADR O-ADR
POTIGA O-ADR O-ADR
causes O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases O-ADR O-ADR
in O-ADR O-ADR
dizziness B-ADR B-ADR
and O-ADR O-ADR
somnolence B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
d O-ADR O-ADR
Includes O-ADR O-ADR
: O-ADR O-ADR
contusion B-ADR B-ADR
, O-ADR O-ADR
ecchymoses B-ADR B-ADR
, O-ADR O-ADR
penile B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
rash B-ADR B-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
men O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
rash B-ADR B-ADR
> O-ADR O-ADR
= O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
60 O-ADR O-ADR
[ O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
women O-ADR O-ADR
versus O-ADR O-ADR
51 O-ADR O-ADR
/ O-ADR O-ADR
539 O-ADR O-ADR
[ O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
men O-ADR O-ADR
; O-ADR O-ADR
discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
rash B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
60 O-ADR O-ADR
[ O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
women O-ADR O-ADR
versus O-ADR O-ADR
10 O-ADR O-ADR
/ O-ADR O-ADR
539 O-ADR O-ADR
[ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
] O-ADR O-ADR
men O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
can O-ADR O-ADR
have O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
site O-ADR O-ADR
of O-ADR O-ADR
bleeding B-ADR B-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
: O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Stevens B-ADR B-ADR
- O-ADR O-ADR
Johnson O-ADR O-ADR
syndrome I-ADR I-ADR
, O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
, O-ADR O-ADR
erythema B-ADR B-ADR
multiforme I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
new O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
psoriasis B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
resumption O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
dose O-ADR O-ADR
, O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
recurrence B-ADR O-ADR
of I-ADR O-ADR
ALT I-ADR B-ADR
and I-ADR I-ADR
AST I-ADR B-ADR
elevations I-ADR I-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
patient O-ADR O-ADR
diaries O-ADR O-ADR
from O-ADR O-ADR
three O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
evaluating O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
Natazia O-ADR O-ADR
for O-ADR O-ADR
contraception O-ADR O-ADR
, O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
23 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
women O-ADR O-ADR
experienced O-ADR O-ADR
intracyclic B-ADR B-ADR
bleeding I-ADR I-ADR
per O-ADR O-ADR
cycle O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
YERVOY O-ADR O-ADR
dosing O-ADR O-ADR
for O-ADR O-ADR
moderate O-ADR O-ADR
enterocolitis O-ADR O-ADR
; O-ADR O-ADR
administer O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheal O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
persistent O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
initiate O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
hypoglycemia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
when O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
with O-ADR O-ADR
prandial O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
in O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
was O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
COMETRIQ O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
recent O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hemorrhage O-ADR O-ADR
or O-ADR O-ADR
hemoptysis O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
Active O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
The O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
larger O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
evaluating O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
and O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
to O-ADR O-ADR
oral O-ADR O-ADR
medications O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Acute B-ADR O-ADR
Respiratory I-ADR O-ADR
Complications I-ADR O-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
febrile O-ADR O-ADR
or O-ADR O-ADR
respiratory O-ADR O-ADR
illness O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
complications O-ADR O-ADR
from O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
. O-ADR O-ADR
Reduced B-ADR B-ADR
fetal I-ADR I-ADR
weights I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
exposures O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
in O-ADR O-ADR
Elderly O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Dementia O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Psychosis O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
( O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
ACE O-ADR O-ADR
inhibitors O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
unilateral O-ADR O-ADR
or O-ADR O-ADR
bilateral O-ADR O-ADR
renal O-ADR O-ADR
artery O-ADR O-ADR
stenosis O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Amyvid O-ADR O-ADR
scan O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
amyloid O-ADR O-ADR
plaque O-ADR O-ADR
content O-ADR O-ADR
only O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
image O-ADR O-ADR
acquisition O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
scan O-ADR O-ADR
result O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
preclude O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
amyloid O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
future O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Fat B-ADR B-ADR
Redistribution I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
rechallenged O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
using O-ADR O-ADR
lower O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
pretreatment O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
inflammatory O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
corticosteroids O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
continue O-ADR O-ADR
treatment O-ADR O-ADR
under O-ADR O-ADR
close O-ADR O-ADR
clinical O-ADR O-ADR
supervision O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
hypertension O-ADR O-ADR
, O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
dyslipidemia O-ADR O-ADR
, O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
unstable O-ADR O-ADR
angina O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
no O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
prolactin B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
Endpoint O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
45 O-ADR O-ADR
- O-ADR O-ADR
77 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
63 O-ADR O-ADR
% O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
100 O-ADR O-ADR
% O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
treatment O-ADR O-ADR
naive O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
stomatitis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
- O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
S O-ADR O-ADR
On O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
analysis O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
ITT O-ADR O-ADR
analysis O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Section O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
was O-ADR O-ADR
55 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
was O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
and O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
participants O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
in O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
JARDIANCE O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Hyperglycemia O-ADR O-ADR
Hyperglycemia B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
function O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
particularly O-ADR O-ADR
where O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
additional O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
further O-ADR O-ADR
impair O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
d O-ADR O-ADR
Includes O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
terms O-ADR O-ADR
: O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
lower I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
. O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
without O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
body B-ADR B-ADR
temperature I-ADR I-ADR
increases I-ADR I-ADR
( O-ADR O-ADR
pyrexia B-ADR B-ADR
and O-ADR O-ADR
feeling B-ADR B-ADR
hot I-ADR I-ADR
) O-ADR O-ADR
was O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity O-ADR B-ADR
reaction O-ADR I-ADR
to O-ADR O-ADR
Gadavist O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
mammography O-ADR O-ADR
examinations O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
scheduled O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
patient O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
prior O-ADR O-ADR
mammogram O-ADR O-ADR
results O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
vasodilators O-ADR O-ADR
are O-ADR O-ADR
taken O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
blood O-ADR O-ADR
- O-ADR O-ADR
pressure O-ADR O-ADR
- O-ADR O-ADR
lowering O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
individual O-ADR O-ADR
compound O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
increased O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
QT O-ADR O-ADR
prolongation O-ADR O-ADR
, O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
hypokalemia O-ADR O-ADR
or O-ADR O-ADR
hypomagnesemia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
those O-ADR O-ADR
taking O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
azathioprine O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
MP O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
carefully O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
Urinary O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
tubulointerstitial B-ADR B-ADR
nephritis I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PRISTIQ O-ADR O-ADR
with O-ADR O-ADR
MAOIs O-ADR O-ADR
intended O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Another O-ADR O-ADR
patient O-ADR O-ADR
developed O-ADR O-ADR
severe O-ADR O-ADR
inflammatory B-ADR B-ADR
arthropathy I-ADR I-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
pyrexia B-ADR B-ADR
and O-ADR O-ADR
elevated B-ADR B-ADR
erythrocyte I-ADR I-ADR
sedimentation I-ADR I-ADR
rate I-ADR I-ADR
. O-ADR O-ADR
Ventricular B-ADR B-ADR
arrhythmias I-ADR I-ADR
and O-ADR O-ADR
bradycardia B-ADR B-ADR
, O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
cardiac B-ADR O-ADR
arrest I-ADR O-ADR
or O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
requiring O-ADR O-ADR
cardiac O-ADR O-ADR
resuscitation O-ADR O-ADR
or O-ADR O-ADR
defibrillation O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
Pompe O-ADR O-ADR
disease O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cardiac O-ADR O-ADR
hypertrophy O-ADR O-ADR
during O-ADR O-ADR
general O-ADR O-ADR
anesthesia O-ADR O-ADR
for O-ADR O-ADR
central O-ADR O-ADR
venous O-ADR O-ADR
catheter O-ADR O-ADR
placement O-ADR O-ADR
. O-ADR O-ADR
Blood O-ADR O-ADR
and O-ADR O-ADR
lymphatic O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
. O-ADR O-ADR
All O-ADR O-ADR
women O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
yearly O-ADR O-ADR
breast O-ADR O-ADR
examinations O-ADR O-ADR
by O-ADR O-ADR
a O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
and O-ADR O-ADR
perform O-ADR O-ADR
monthly O-ADR O-ADR
breast O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
examinations O-ADR O-ADR
. O-ADR O-ADR
Whether O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
symptoms O-ADR O-ADR
described O-ADR O-ADR
above O-ADR O-ADR
represent O-ADR O-ADR
such O-ADR O-ADR
a O-ADR O-ADR
conversion O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
New O-ADR O-ADR
Onset O-ADR O-ADR
or O-ADR O-ADR
Worsening O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
heart I-ADR I-ADR
failure I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
mild O-ADR O-ADR
taste B-ADR B-ADR
following I-ADR I-ADR
instillation I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
potential O-ADR O-ADR
role O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
through O-ADR O-ADR
Week O-ADR O-ADR
24 O-ADR O-ADR
, O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
* O-ADR O-ADR
ULN O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Death O-ADR O-ADR
and O-ADR O-ADR
Heart O-ADR O-ADR
Failure O-ADR O-ADR
in O-ADR O-ADR
Permanent O-ADR O-ADR
AF O-ADR O-ADR
MULTAQ O-ADR O-ADR
doubles O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cardiovascular B-ADR B-ADR
death I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
heart B-ADR B-ADR
failure I-ADR I-ADR
events I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
permanent O-ADR O-ADR
AF O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Administer O-ADR O-ADR
Gadavist O-ADR O-ADR
only O-ADR O-ADR
in O-ADR O-ADR
situations O-ADR O-ADR
where O-ADR O-ADR
trained O-ADR O-ADR
personnel O-ADR O-ADR
and O-ADR O-ADR
therapies O-ADR O-ADR
are O-ADR O-ADR
promptly O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
personnel O-ADR O-ADR
trained O-ADR O-ADR
in O-ADR O-ADR
resuscitation O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Elevated B-ADR B-ADR
Blood I-ADR I-ADR
Pressure I-ADR I-ADR
: O-ADR O-ADR
Control O-ADR O-ADR
hypertension O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Impairment B-ADR O-ADR
in I-ADR O-ADR
Renal I-ADR O-ADR
Function I-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
JARDIANCE O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
eGFR I-ADR I-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
to O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
Available O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
LABA O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
hospitalization O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
and O-ADR O-ADR
adolescent O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
worsening O-ADR O-ADR
and O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behaviors O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Fetal O-ADR O-ADR
Risk O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
animal O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
GILENYA O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
surveillance O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
KALBITOR O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
known O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
VORAXAZE O-ADR O-ADR
are O-ADR O-ADR
paraesthesias B-ADR B-ADR
, O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
A O-ADR O-ADR
routine O-ADR O-ADR
oral O-ADR O-ADR
exam O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
prescriber O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
GILENYA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
tested O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
pool O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
116 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
type O-ADR O-ADR
2 O-ADR O-ADR
diabetes O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
75 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
Hypertension O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR O-ADR
are O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
uncontrolled O-ADR O-ADR
study O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR O-ADR
( O-ADR O-ADR
VELOCITY O-ADR O-ADR
, O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
126 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Obesity O-ADR O-ADR
and O-ADR O-ADR
prolonged O-ADR O-ADR
nucleoside O-ADR O-ADR
exposure O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Once O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
is O-ADR O-ADR
achieved O-ADR O-ADR
and O-ADR O-ADR
maintained O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
at O-ADR O-ADR
regular O-ADR O-ADR
intervals O-ADR O-ADR
and O-ADR O-ADR
step O-ADR O-ADR
down O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
) O-ADR O-ADR
if O-ADR O-ADR
possible O-ADR O-ADR
without O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
and O-ADR O-ADR
maintain O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
medication O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
ICS O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
diabetes O-ADR O-ADR
was O-ADR O-ADR
seven O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
body O-ADR O-ADR
mass O-ADR O-ADR
index O-ADR O-ADR
( O-ADR O-ADR
BMI O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
31 O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
BMI O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
confirmed O-ADR O-ADR
PML O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
stopping O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bullous O-ADR B-ADR
and O-ADR O-ADR
Exfoliative O-ADR B-ADR
Skin B-ADR O-ADR
Disorders I-ADR O-ADR
: I-ADR O-ADR
Severe I-ADR O-ADR
bullous I-ADR B-ADR
, I-ADR O-ADR
blistering I-ADR B-ADR
, I-ADR O-ADR
and I-ADR O-ADR
exfoliating I-ADR B-ADR
lesions I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Following O-ADR O-ADR
resolution O-ADR O-ADR
of O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
resuming O-ADR O-ADR
KALYDECO O-ADR O-ADR
dosing O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
Month O-ADR O-ADR
Trial O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
evaluated O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
201 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
200 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fluticasone O-ADR O-ADR
propionate O-ADR O-ADR
500 O-ADR O-ADR
mcg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
100 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
adolescent O-ADR O-ADR
and O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
asthma O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
serum O-ADR O-ADR
liver O-ADR I-ADR
biochemistries O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
less O-ADR O-ADR
frequently O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
infusion O-ADR O-ADR
rate O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
slowed O-ADR O-ADR
or O-ADR O-ADR
interrupted O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
an O-ADR O-ADR
infusion O-ADR O-ADR
reaction O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Candida B-ADR B-ADR
albicans I-ADR I-ADR
infection I-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
mouth I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
versus O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Rd O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
dosage O-ADR O-ADR
of O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
over O-ADR O-ADR
a O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
safety O-ADR O-ADR
concerns O-ADR O-ADR
require O-ADR O-ADR
abrupt O-ADR O-ADR
withdrawal O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Hepatic O-ADR O-ADR
Impairment O-ADR O-ADR
The O-ADR O-ADR
systemic O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
axitinib O-ADR O-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
observed O-ADR O-ADR
across O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
type O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
as O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
with O-ADR O-ADR
periodic O-ADR O-ADR
liver O-ADR O-ADR
testing O-ADR O-ADR
. O-ADR O-ADR
Anyone O-ADR O-ADR
considering O-ADR O-ADR
prescribing O-ADR O-ADR
POTIGA O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
AED O-ADR O-ADR
must O-ADR O-ADR
balance O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
Follow O-ADR O-ADR
Up O-ADR O-ADR
Renal O-ADR O-ADR
Function O-ADR O-ADR
Status O-ADR O-ADR
n O-ADR O-ADR
Normaln O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Mildn O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Mild O-ADR O-ADR
to O-ADR O-ADR
Moderaten O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Moderate O-ADR O-ADR
to O-ADR O-ADR
Severen O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Severen O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Kidney B-ADR B-ADR
Failuren O-ADR I-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Notes O-ADR O-ADR
: O-ADR O-ADR
Grading O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
Modification O-ADR O-ADR
in O-ADR O-ADR
Diet O-ADR O-ADR
in O-ADR O-ADR
Renal O-ADR O-ADR
Disease O-ADR O-ADR
method O-ADR O-ADR
( O-ADR O-ADR
MDRD O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
KDIGO O-ADR O-ADR
Classification O-ADR O-ADR
by O-ADR O-ADR
eGFR O-ADR O-ADR
: O-ADR O-ADR
Normal O-ADR O-ADR
: O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
90 O-ADR O-ADR
, O-ADR O-ADR
Mild O-ADR O-ADR
: O-ADR O-ADR
60 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
90 O-ADR O-ADR
, O-ADR O-ADR
Mild O-ADR O-ADR
to O-ADR O-ADR
Moderate O-ADR O-ADR
: O-ADR O-ADR
45 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
, O-ADR O-ADR
Moderate O-ADR O-ADR
to O-ADR O-ADR
Severe O-ADR O-ADR
: O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
45 O-ADR O-ADR
, O-ADR O-ADR
Severe O-ADR O-ADR
: O-ADR O-ADR
15 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
30 O-ADR O-ADR
, O-ADR O-ADR
Kidney O-ADR O-ADR
Failure O-ADR I-ADR
: O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
15 O-ADR O-ADR
ml O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Accredo O-ADR O-ADR
Health O-ADR O-ADR
Group O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
454 O-ADR O-ADR
- O-ADR O-ADR
8860 O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
eGFR O-ADR O-ADR
81 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Additionally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
positive O-ADR O-ADR
antibody O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
neutralizing O-ADR O-ADR
antibody O-ADR O-ADR
) O-ADR O-ADR
test O-ADR O-ADR
result O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
influenced O-ADR O-ADR
by O-ADR O-ADR
several O-ADR O-ADR
factors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
assay O-ADR O-ADR
methodology O-ADR O-ADR
, O-ADR O-ADR
sample O-ADR O-ADR
handling O-ADR O-ADR
, O-ADR O-ADR
timing O-ADR O-ADR
of O-ADR O-ADR
sample O-ADR O-ADR
collection O-ADR O-ADR
, O-ADR O-ADR
concomitant O-ADR O-ADR
medications O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
underlying O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
, O-ADR O-ADR
44 O-ADR O-ADR
of O-ADR O-ADR
235 O-ADR O-ADR
( O-ADR O-ADR
18 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
experienced O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
have O-ADR O-ADR
included O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
throat B-ADR B-ADR
tightness I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
airway I-ADR I-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urticaria B-ADR B-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
with O-ADR O-ADR
food O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
flushing B-ADR B-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Reports O-ADR O-ADR
include O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
pulmonary B-ADR B-ADR
TB I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
abnormal O-ADR O-ADR
coagulation O-ADR O-ADR
( O-ADR O-ADR
except O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
aspirin O-ADR O-ADR
, O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
participating O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
were O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
graft B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
, O-ADR O-ADR
hyperkalemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
leukopenia B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
POTIGA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
damage B-ADR B-ADR
to I-ADR I-ADR
the I-ADR I-ADR
photoreceptors I-ADR I-ADR
and O-ADR O-ADR
vision B-ADR B-ADR
loss I-ADR I-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
whose O-ADR O-ADR
asthma O-ADR O-ADR
is O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
on O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
medium O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
four O-ADR O-ADR
suicides B-ADR B-ADR
in O-ADR O-ADR
drug O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
is O-ADR O-ADR
too O-ADR O-ADR
small O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
any O-ADR O-ADR
conclusion O-ADR O-ADR
about O-ADR O-ADR
drug O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Carbohydrate O-ADR O-ADR
and O-ADR O-ADR
Lipid O-ADR O-ADR
Metabolic O-ADR O-ADR
Effects O-ADR O-ADR
Carefully O-ADR O-ADR
monitor O-ADR O-ADR
prediabetic O-ADR O-ADR
and O-ADR O-ADR
diabetic O-ADR O-ADR
women O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
taking O-ADR O-ADR
Natazia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
lung O-ADR O-ADR
cancer O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
58 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
Caucasian O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infections O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
pneumonia B-ADR B-ADR
and O-ADR O-ADR
sepsis B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
Beleodaq O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
QT O-ADR O-ADR
Interval O-ADR O-ADR
Prolongation O-ADR O-ADR
QTc B-ADR B-ADR
interval I-ADR I-ADR
prolongation I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
ventricular B-ADR B-ADR
tachyarrhythmias I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
Torsade B-ADR B-ADR
de I-ADR I-ADR
pointes I-ADR I-ADR
) O-ADR O-ADR
or O-ADR O-ADR
sudden B-ADR B-ADR
death I-ADR I-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Steroid O-ADR O-ADR
hormones O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
poorly O-ADR O-ADR
metabolized O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
( O-ADR O-ADR
hepatic O-ADR O-ADR
transaminase O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
levels O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
assess O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
before O-ADR O-ADR
each O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
YERVOY O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
every O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
weekly O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
while O-ADR O-ADR
neutrophil O-ADR O-ADR
counts O-ADR O-ADR
are O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
Gi O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Control O-ADR O-ADR
hypertension O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
hypokalemia O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hepatotoxicity O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
serious O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
RA O-ADR O-ADR
- O-ADR O-ADR
III O-ADR O-ADR
, O-ADR O-ADR
too O-ADR O-ADR
few O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
for O-ADR O-ADR
meaningful O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
ACR20 O-ADR O-ADR
response O-ADR O-ADR
by O-ADR O-ADR
antibody O-ADR O-ADR
status O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
concurrent O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
into O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
cords O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
hand O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
historically O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
multi O-ADR O-ADR
- O-ADR O-ADR
center O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
715 O-ADR O-ADR
adult O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
before O-ADR O-ADR
neuraxial O-ADR O-ADR
intervention O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
anticoagulated O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
retinal O-ADR O-ADR
pigmentary O-ADR O-ADR
abnormalities O-ADR O-ADR
or O-ADR O-ADR
vision O-ADR O-ADR
changes O-ADR O-ADR
are O-ADR O-ADR
detected O-ADR O-ADR
, O-ADR O-ADR
POTIGA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
unless O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
suitable O-ADR O-ADR
treatment O-ADR O-ADR
options O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
study O-ADR O-ADR
, O-ADR O-ADR
159 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
XEOMIN O-ADR O-ADR
( O-ADR O-ADR
78 O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
120 O-ADR O-ADR
Units O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
81 O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
240 O-ADR O-ADR
Units O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
perforation O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
fistula O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
86 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
studied O-ADR O-ADR
was O-ADR O-ADR
Caucasian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
was O-ADR O-ADR
aged O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
Infections B-ADR B-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
females O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
males O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Severe O-ADR O-ADR
and O-ADR O-ADR
Disabling O-ADR O-ADR
Arthralgia O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
postmarketing O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
disabling O-ADR O-ADR
arthralgia B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
DPP O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Same O-ADR O-ADR
Active O-ADR O-ADR
Ingredient O-ADR O-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
Prolia O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
receive O-ADR O-ADR
XGEVA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
including O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypocalcemia O-ADR O-ADR
and O-ADR O-ADR
Mineral O-ADR O-ADR
Metabolism O-ADR O-ADR
Hypocalcemia B-ADR B-ADR
may I-ADR O-ADR
be I-ADR O-ADR
exacerbated I-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
premarketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
of O-ADR O-ADR
235 O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
experienced O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
anaphylaxis B-ADR B-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
exclude O-ADR O-ADR
cases O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
presentation O-ADR O-ADR
includes O-ADR O-ADR
both O-ADR O-ADR
serious O-ADR O-ADR
medical O-ADR O-ADR
illness O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
this O-ADR O-ADR
pool O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
loss B-ADR B-ADR
of I-ADR I-ADR
strength I-ADR I-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
comparator O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
was O-ADR O-ADR
30 O-ADR O-ADR
and O-ADR O-ADR
33 O-ADR O-ADR
days O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
was O-ADR O-ADR
21 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Depression O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
psychiatric B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
related O-ADR O-ADR
primarily O-ADR O-ADR
to O-ADR O-ADR
depression O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anxiety B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Management O-ADR O-ADR
of O-ADR O-ADR
cardiac O-ADR O-ADR
failure O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
pneumonia O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
venous B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
, O-ADR O-ADR
deep B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
, O-ADR O-ADR
retinal B-ADR B-ADR
vein I-ADR I-ADR
occlusion I-ADR I-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
vein I-ADR I-ADR
thrombosis I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increase O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
larger O-ADR O-ADR
when O-ADR O-ADR
coadministered O-ADR O-ADR
with O-ADR O-ADR
chlorthalidone O-ADR O-ADR
or O-ADR O-ADR
hydrochlorothiazide O-ADR O-ADR
. O-ADR O-ADR
XEOMIN O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
24 O-ADR O-ADR
to O-ADR O-ADR
74 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
predominantly O-ADR O-ADR
female O-ADR O-ADR
( O-ADR O-ADR
88 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
acute O-ADR O-ADR
onset O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
pulmonary O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Opioid O-ADR O-ADR
- O-ADR O-ADR
Tolerant O-ADR O-ADR
Patients O-ADR O-ADR
Patients O-ADR O-ADR
recently O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
opioids O-ADR O-ADR
are O-ADR O-ADR
expected O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
sensitive O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
mu O-ADR O-ADR
- O-ADR O-ADR
opioid O-ADR O-ADR
receptor O-ADR O-ADR
antagonists O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
ENTEREG O-ADR O-ADR
. O-ADR O-ADR
Asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
hospitalizations O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
100 O-ADR O-ADR
/ O-ADR O-ADR
25 O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
7 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
fluticasone O-ADR O-ADR
furoate O-ADR O-ADR
100 O-ADR O-ADR
mcg O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
blister O-ADR O-ADR
package O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
open O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
60 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reactions O-ADR O-ADR
listed O-ADR O-ADR
are O-ADR O-ADR
those O-ADR O-ADR
that O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
importance O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
are O-ADR O-ADR
plausibly O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
on O-ADR O-ADR
pharmacologic O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
grounds O-ADR O-ADR
. O-ADR O-ADR
Over O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
typical O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
about O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
about O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
types O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
FANAPT O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Manifestations O-ADR O-ADR
included O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
or O-ADR O-ADR
other O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
. O-ADR O-ADR
In O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
MS O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
seizures B-ADR B-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
dalfampridine O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
/ O-ADR O-ADR
100PY O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
over O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
/ O-ADR O-ADR
100PY O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
fatal B-ADR B-ADR
case O-ADR O-ADR
of O-ADR O-ADR
PML B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
receiving O-ADR O-ADR
higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
and O-ADR O-ADR
MMF O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
327 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
462 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
09 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
69 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
60 O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
80 O-ADR O-ADR
) O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
0001 O-ADR O-ADR
Intracranial O-ADR O-ADR
( O-ADR O-ADR
ICH B-ADR O-ADR
) O-ADR O-ADR
? O-ADR O-ADR
Beta O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
use O-ADR O-ADR
for O-ADR O-ADR
this O-ADR O-ADR
purpose O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Increased B-ADR O-ADR
Urination I-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
five O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR B-ADR
urination I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
polyuria B-ADR B-ADR
, O-ADR O-ADR
pollakiuria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nocturia B-ADR B-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
on O-ADR O-ADR
JARDIANCE O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuing O-ADR O-ADR
Prolia O-ADR O-ADR
if O-ADR O-ADR
severe O-ADR O-ADR
symptoms O-ADR O-ADR
develop O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Clinical B-ADR O-ADR
Worsening O-ADR O-ADR
/ O-ADR O-ADR
Suicide O-ADR O-ADR
Risk B-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
worsening O-ADR O-ADR
and O-ADR O-ADR
suicide O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Generally O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
observed O-ADR O-ADR
infections B-ADR B-ADR
responded O-ADR O-ADR
to O-ADR O-ADR
standard O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Cognitive O-ADR O-ADR
and O-ADR O-ADR
Motor O-ADR O-ADR
Impairment O-ADR O-ADR
Somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
experiencing O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
stop O-ADR O-ADR
taking O-ADR O-ADR
STENDRA O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
prompt O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
. O-ADR O-ADR
Autoimmune O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Autoantibodies O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
formation B-ADR O-ADR
of I-ADR O-ADR
autoantibodies I-ADR O-ADR
and O-ADR O-ADR
, O-ADR O-ADR
rarely O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
lupus B-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
QT O-ADR B-ADR
prolonging O-ADR I-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
quinine O-ADR O-ADR
and O-ADR O-ADR
quinidine O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
following O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Cardiac O-ADR O-ADR
Arrhythmia O-ADR O-ADR
and O-ADR O-ADR
Sudden O-ADR O-ADR
Cardiac O-ADR O-ADR
Death O-ADR O-ADR
During O-ADR O-ADR
General O-ADR O-ADR
Anesthesia O-ADR O-ADR
for O-ADR O-ADR
Central O-ADR O-ADR
Venous O-ADR O-ADR
Catheter O-ADR O-ADR
Placement O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
general O-ADR O-ADR
anesthesia O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
severe O-ADR O-ADR
cardiac O-ADR O-ADR
and O-ADR O-ADR
skeletal O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
respiratory O-ADR O-ADR
) O-ADR O-ADR
muscle O-ADR O-ADR
weakness O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
permanent O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
, O-ADR O-ADR
MULTAQ O-ADR O-ADR
doubles O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
stroke B-ADR B-ADR
and O-ADR O-ADR
hospitalization O-ADR O-ADR
for O-ADR O-ADR
heart B-ADR B-ADR
failure I-ADR I-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Bone B-ADR B-ADR
Effects I-ADR I-ADR
of O-ADR O-ADR
Tenofovir O-ADR I-ADR
DF O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
to O-ADR O-ADR
EOVIST O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
entire O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
and O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
Week O-ADR O-ADR
20 O-ADR O-ADR
in O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
newly B-ADR O-ADR
ANA I-ADR B-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
( O-ADR O-ADR
at O-ADR O-ADR
titers O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
160 O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
report O-ADR O-ADR
upper O-ADR O-ADR
abdominal O-ADR O-ADR
or O-ADR O-ADR
shoulder O-ADR O-ADR
pain O-ADR O-ADR
after O-ADR O-ADR
receiving O-ADR O-ADR
GRANIX O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
GRANIX O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
enlarged O-ADR O-ADR
spleen O-ADR O-ADR
or O-ADR O-ADR
splenic O-ADR O-ADR
rupture O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
25 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
glucarpidase O-ADR O-ADR
binding O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
DAMPA O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
deoxy O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
amino O-ADR O-ADR
- O-ADR O-ADR
N O-ADR O-ADR
10 O-ADR O-ADR
- O-ADR O-ADR
methylpteroic O-ADR O-ADR
acid O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
inactive O-ADR O-ADR
metabolite O-ADR O-ADR
of O-ADR O-ADR
methotrexate O-ADR O-ADR
resulting O-ADR O-ADR
from O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
VORAXAZE O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
diarrhea B-ADR B-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
gastrointestinal B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TANZEUM O-ADR O-ADR
: O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
gastroesophageal B-ADR B-ADR
reflux I-ADR I-ADR
disease I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dyspepsia B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
versus O-ADR O-ADR
TANZEUM O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
have O-ADR O-ADR
included O-ADR O-ADR
respiratory B-ADR B-ADR
compromise I-ADR I-ADR
, O-ADR O-ADR
urticaria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
throat I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
basal B-ADR B-ADR
cell I-ADR I-ADR
carcinoma I-ADR I-ADR
was O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
: O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
Cleviprex O-ADR O-ADR
in O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR B-ADR
included O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
lupus O-ADR O-ADR
- O-ADR O-ADR
like O-ADR O-ADR
syndrome O-ADR O-ADR
following O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
treatment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adequately O-ADR O-ADR
supplement O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
calcium O-ADR O-ADR
and O-ADR O-ADR
vitamin O-ADR O-ADR
D O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Demographic O-ADR O-ADR
Differences O-ADR O-ADR
in O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
An O-ADR O-ADR
examination O-ADR O-ADR
of O-ADR O-ADR
population O-ADR O-ADR
subgroups O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
reveal O-ADR O-ADR
any O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
differences O-ADR O-ADR
in O-ADR O-ADR
safety O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
basis O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
, O-ADR O-ADR
gender O-ADR O-ADR
or O-ADR O-ADR
race O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
diarrhea B-ADR B-ADR
. O-ADR O-ADR
Particular O-ADR O-ADR
caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
when O-ADR O-ADR
administering O-ADR O-ADR
nucleoside O-ADR O-ADR
analogs O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
patient O-ADR O-ADR
with O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
liver O-ADR O-ADR
disease O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
, O-ADR O-ADR
cases O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
no O-ADR O-ADR
known O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
YERVOY O-ADR O-ADR
for O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Take O-ADR O-ADR
DUAVEE O-ADR O-ADR
exactly O-ADR O-ADR
as O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
tells O-ADR O-ADR
you O-ADR O-ADR
to O-ADR O-ADR
take O-ADR O-ADR
it O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
hyperparathyroidism B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Further O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
at O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
ENTEREGREMS O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
or O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
278 O-ADR O-ADR
- O-ADR O-ADR
0340 O-ADR O-ADR
. O-ADR O-ADR
Extreme O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
resuscitation O-ADR O-ADR
measures O-ADR O-ADR
available O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
is O-ADR O-ADR
made O-ADR O-ADR
to O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administer O-ADR O-ADR
the O-ADR O-ADR
product O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
additional O-ADR O-ADR
medicine O-ADR O-ADR
containing O-ADR O-ADR
a O-ADR O-ADR
LABA O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
overdose O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
KRd O-ADR O-ADR
arm O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
Rd O-ADR O-ADR
arm O-ADR O-ADR
were O-ADR O-ADR
pneumonia B-ADR B-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pulmonary B-ADR B-ADR
embolism I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
following O-ADR O-ADR
injection O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
See O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
for O-ADR O-ADR
steps O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
or O-ADR O-ADR
manage O-ADR O-ADR
these O-ADR O-ADR
possible O-ADR O-ADR
and O-ADR O-ADR
known O-ADR O-ADR
significant O-ADR O-ADR
drug O-ADR O-ADR
interactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
dosing O-ADR O-ADR
recommendations O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neuroleptic B-ADR B-ADR
Malignant I-ADR I-ADR
Syndrome I-ADR I-ADR
: O-ADR O-ADR
Manage O-ADR O-ADR
with O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
monitoring O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
reports O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
patient O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
8 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
had O-ADR O-ADR
serious O-ADR O-ADR
events O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
one O-ADR O-ADR
death B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Trials O-ADR O-ADR
evaluating O-ADR O-ADR
JARDIANCE O-ADR O-ADR
10 O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
are O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
four O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
18 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Withdrawal O-ADR O-ADR
of O-ADR O-ADR
AEDs O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
withdrawn O-ADR O-ADR
gradually O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
seizure O-ADR O-ADR
frequency O-ADR O-ADR
and O-ADR O-ADR
status O-ADR O-ADR
epilepticus O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
denosumab O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
following O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
therapy O-ADR O-ADR
varied O-ADR O-ADR
from O-ADR O-ADR
one O-ADR O-ADR
day O-ADR O-ADR
to O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
hematologic O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
and O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
each O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
countries O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
endemic O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
TB B-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hemorrhage O-ADR O-ADR
Serious O-ADR O-ADR
and O-ADR O-ADR
sometimes O-ADR O-ADR
fatal B-ADR B-ADR
hemorrhage B-ADR B-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
COMETRIQ O-ADR O-ADR
. O-ADR O-ADR
Long B-ADR O-ADR
- O-ADR O-ADR
standing O-ADR O-ADR
hyperprolactinemia I-ADR B-ADR
when O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
hypogonadism B-ADR B-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
decreased B-ADR B-ADR
bone I-ADR I-ADR
density I-ADR I-ADR
in O-ADR O-ADR
both O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Cervical O-ADR O-ADR
Dystonia O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
intramuscular O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hypotension B-ADR B-ADR
: O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
FARXIGA O-ADR O-ADR
, O-ADR O-ADR
assess O-ADR O-ADR
volume O-ADR O-ADR
status O-ADR O-ADR
and O-ADR O-ADR
correct O-ADR O-ADR
hypovolemia O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
elderly O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
or O-ADR O-ADR
low O-ADR O-ADR
systolic O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
diuretics O-ADR O-ADR
. O-ADR O-ADR
Approximately O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
; O-ADR O-ADR
67 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
black O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
other O-ADR O-ADR
races O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
COMETRIQ O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Chloasma B-ADR B-ADR
may O-ADR O-ADR
occasionally O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
chloasma O-ADR O-ADR
gravidarum O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
studies O-ADR O-ADR
who O-ADR O-ADR
rolled O-ADR O-ADR
over O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
SONATE O-ADR O-ADR
study O-ADR O-ADR
had O-ADR O-ADR
combined O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
9 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
mean O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
165 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
findings O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
, O-ADR O-ADR
Zydelig O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Long B-ADR B-ADR
- O-ADR O-ADR
term O-ADR O-ADR
cumulative I-ADR I-ADR
radiation I-ADR I-ADR
exposure I-ADR I-ADR
is O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
cancer B-ADR B-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Clinical O-ADR O-ADR
ADRs O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
intensity O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
occurring O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
excess O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
reduce O-ADR O-ADR
this O-ADR O-ADR
risk O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
coverage O-ADR O-ADR
with O-ADR O-ADR
another O-ADR O-ADR
anticoagulant O-ADR O-ADR
if O-ADR O-ADR
PRADAXA O-ADR O-ADR
is O-ADR O-ADR
discontinued O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
pathological O-ADR O-ADR
bleeding O-ADR O-ADR
or O-ADR O-ADR
completion O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Local O-ADR O-ADR
Effects O-ADR O-ADR
of O-ADR O-ADR
Inhaled O-ADR O-ADR
Corticosteroids O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
localized O-ADR B-ADR
infections B-ADR I-ADR
of I-ADR I-ADR
the I-ADR I-ADR
mouth I-ADR I-ADR
and I-ADR I-ADR
pharynx I-ADR I-ADR
with I-ADR O-ADR
Candida I-ADR B-ADR
albicans I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
Endometrial O-ADR O-ADR
biopsies O-ADR O-ADR
performed O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
subset O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
Natazia O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
reveal O-ADR O-ADR
any O-ADR O-ADR
unexpected O-ADR O-ADR
or O-ADR O-ADR
concerning O-ADR O-ADR
findings O-ADR O-ADR
for O-ADR O-ADR
subjects O-ADR O-ADR
taking O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
222 O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
women O-ADR O-ADR
( O-ADR O-ADR
82 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
58 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
26 O-ADR O-ADR
to O-ADR O-ADR
91 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
or O-ADR O-ADR
sedation B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
at O-ADR O-ADR
all O-ADR O-ADR
effective O-ADR O-ADR
doses O-ADR O-ADR
and O-ADR O-ADR
was O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
Beleodaq O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
myocardial O-ADR O-ADR
infarction O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
clinically O-ADR O-ADR
significant O-ADR O-ADR
arterial O-ADR O-ADR
thromboembolic O-ADR O-ADR
complication O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
NULOJIX O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
only O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Increase O-ADR O-ADR
in O-ADR O-ADR
Low O-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR O-ADR
Cholesterol O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
13 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
changes B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
mean I-ADR I-ADR
lipid I-ADR I-ADR
values I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
FARXIGA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
included O-ADR O-ADR
tuberculosis B-ADR B-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
cellulitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyelonephritis B-ADR B-ADR
. O-ADR O-ADR
Hemodialysis O-ADR O-ADR
can O-ADR O-ADR
remove O-ADR O-ADR
dabigatran O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
experience O-ADR O-ADR
supporting O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
hemodialysis O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
bleeding O-ADR O-ADR
is O-ADR O-ADR
limited O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Overdosage O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
if O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Blepharospasm O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
eye I-ADR I-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
visual B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
respiratory B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
antihistamines O-ADR O-ADR
with O-ADR O-ADR
or O-ADR O-ADR
without O-ADR O-ADR
antipyretics O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
increased B-ADR B-ADR
bilirubin I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
families O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
informed O-ADR O-ADR
that O-ADR O-ADR
AEDs O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
; O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
mood O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
; O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
, O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
thoughts O-ADR O-ADR
about O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
harm O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
altered O-ADR O-ADR
pharmacokinetic O-ADR O-ADR
profile O-ADR O-ADR
, O-ADR O-ADR
toxicity B-ADR O-ADR
profile O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
clinical O-ADR O-ADR
response O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
binding O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
alsoBoxed O-ADR O-ADR
Warningand O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Similar O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
although O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
EPS B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events I-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
bradykinesia B-ADR B-ADR
, O-ADR O-ADR
dyskinesia B-ADR B-ADR
, O-ADR O-ADR
dystonia B-ADR B-ADR
, O-ADR O-ADR
oromandibular B-ADR B-ADR
dystonia I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
contractions I-ADR I-ADR
involuntary I-ADR I-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
twitching I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
stiffness I-ADR I-ADR
, O-ADR O-ADR
parkinsonism B-ADR B-ADR
, O-ADR O-ADR
protrusion B-ADR B-ADR
tongue I-ADR I-ADR
, O-ADR O-ADR
resting B-ADR B-ADR
tremor I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
discontinuation O-ADR O-ADR
was O-ADR O-ADR
seizure B-ADR B-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Eosinophilia B-ADR B-ADR
is O-ADR O-ADR
often O-ADR O-ADR
present O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
cardiac B-ADR B-ADR
disorders I-ADR I-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
infections B-ADR B-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
disorders I-ADR I-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Administer O-ADR O-ADR
DOTAREM O-ADR O-ADR
only O-ADR O-ADR
in O-ADR O-ADR
situations O-ADR O-ADR
where O-ADR O-ADR
trained O-ADR O-ADR
personnel O-ADR O-ADR
and O-ADR O-ADR
therapies O-ADR O-ADR
are O-ADR O-ADR
promptly O-ADR O-ADR
available O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
personnel O-ADR O-ADR
trained O-ADR O-ADR
in O-ADR O-ADR
resuscitation O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
its O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
BENLYSTA O-ADR O-ADR
may O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
immunizations O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Psoriatic O-ADR B-ADR
Arthritis O-ADR I-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Psoriasis O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
tension B-ADR B-ADR
headache I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Celgene O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
423 O-ADR O-ADR
- O-ADR O-ADR
5436 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
discontinuations O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
STRIBILD O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
group O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypophysitis O-ADR O-ADR
, O-ADR O-ADR
adrenal O-ADR O-ADR
insufficiency O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
adrenal O-ADR O-ADR
crisis O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hyper O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
hypothyroidism O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
effectiveness O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
epilepsy O-ADR O-ADR
have O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
For O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
VORAXAZE O-ADR O-ADR
administration O-ADR O-ADR
, O-ADR O-ADR
determine O-ADR O-ADR
the O-ADR O-ADR
leucovorin O-ADR O-ADR
dose O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
VORAXAZE O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
. O-ADR O-ADR
Permanently O-ADR O-ADR
discontinue O-ADR O-ADR
TAFINLAR O-ADR O-ADR
for O-ADR O-ADR
RAS O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
cutaneous O-ADR O-ADR
malignancies O-ADR O-ADR
. O-ADR O-ADR
Figure O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Major O-ADR O-ADR
Bleeding B-ADR B-ADR
Hazard O-ADR O-ADR
Ratios O-ADR O-ADR
by O-ADR O-ADR
Baseline O-ADR O-ADR
Characteristics O-ADR O-ADR
- O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
Study O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
figure O-ADR O-ADR
above O-ADR O-ADR
presents O-ADR O-ADR
effects O-ADR O-ADR
in O-ADR O-ADR
various O-ADR O-ADR
subgroups O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
are O-ADR O-ADR
baseline O-ADR O-ADR
characteristics O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
specified O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
not O-ADR O-ADR
the O-ADR O-ADR
groupings O-ADR O-ADR
. O-ADR O-ADR
Corticosteroid O-ADR O-ADR
utilization O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
requiring O-ADR O-ADR
invasive O-ADR O-ADR
dental O-ADR O-ADR
procedures O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
judgment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
treating O-ADR O-ADR
physician O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
oral O-ADR O-ADR
surgeon O-ADR O-ADR
should O-ADR O-ADR
guide O-ADR O-ADR
the O-ADR O-ADR
management O-ADR O-ADR
plan O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
patient O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
individual O-ADR O-ADR
benefit O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postapproval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ULORIC O-ADR O-ADR
. O-ADR O-ADR
Almost O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
immunosuppressants O-ADR O-ADR
azathioprine O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
mercaptopurine O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
MP O-ADR O-ADR
) O-ADR O-ADR
concomitantly O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
blocker O-ADR O-ADR
at O-ADR O-ADR
or O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
diagnosis O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Alpha O-ADR O-ADR
- O-ADR O-ADR
Blockers O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Antihypertensives O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
discuss O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
STENDRA O-ADR O-ADR
to O-ADR O-ADR
augment O-ADR O-ADR
the O-ADR O-ADR
blood O-ADR O-ADR
pressure O-ADR O-ADR
- O-ADR O-ADR
lowering O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
antihypertensive O-ADR O-ADR
medications O-ADR O-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
andClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
6 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
older O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
) O-ADR O-ADR
across O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
for O-ADR O-ADR
PROMACTA O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
586 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cuSCC B-ADR B-ADR
was O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Combination O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
PDE5 O-ADR O-ADR
Inhibitors O-ADR O-ADR
or O-ADR O-ADR
Erectile O-ADR O-ADR
Dysfunction O-ADR O-ADR
Therapies O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
efficacy O-ADR O-ADR
of O-ADR O-ADR
combinations O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
treatments O-ADR O-ADR
for O-ADR O-ADR
ED O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
therapeutic O-ADR O-ADR
doses O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
90 O-ADR O-ADR
/ O-ADR O-ADR
379 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
SAPHRIS O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
/ O-ADR O-ADR
203 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Such O-ADR O-ADR
an O-ADR O-ADR
event O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
non B-ADR O-ADR
- O-ADR O-ADR
arteritic O-ADR O-ADR
anterior I-ADR O-ADR
ischemic I-ADR O-ADR
optic I-ADR O-ADR
neuropathy I-ADR O-ADR
( O-ADR O-ADR
NAION B-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
rare O-ADR O-ADR
condition O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
cause O-ADR O-ADR
of O-ADR O-ADR
decreased B-ADR B-ADR
vision I-ADR I-ADR
including O-ADR O-ADR
permanent B-ADR B-ADR
loss I-ADR I-ADR
of I-ADR I-ADR
vision I-ADR I-ADR
that O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
rarely O-ADR O-ADR
postmarketing O-ADR O-ADR
in O-ADR O-ADR
temporal O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
WHI O-ADR O-ADR
estrogen O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
substudy O-ADR O-ADR
, O-ADR O-ADR
after O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
daily O-ADR O-ADR
conjugated O-ADR O-ADR
estrogen O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
625 O-ADR O-ADR
mg O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
alone O-ADR O-ADR
was O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
invasive B-ADR O-ADR
breast I-ADR O-ADR
cancer I-ADR O-ADR
( O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
[ O-ADR O-ADR
RR O-ADR O-ADR
] O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
80 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
Body O-ADR O-ADR
Temperature O-ADR O-ADR
Regulation O-ADR O-ADR
Disruption B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
body I-ADR I-ADR
' I-ADR I-ADR
s O-ADR O-ADR
ability I-ADR I-ADR
to I-ADR I-ADR
reduce I-ADR I-ADR
core I-ADR I-ADR
body I-ADR I-ADR
temperature I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
antipsychotic O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
MULTAQ O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
atrial O-ADR O-ADR
fibrillation O-ADR O-ADR
( O-ADR O-ADR
AF O-ADR O-ADR
) O-ADR O-ADR
who O-ADR O-ADR
will O-ADR O-ADR
not O-ADR O-ADR
or O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
cardioverted O-ADR O-ADR
into O-ADR O-ADR
normal O-ADR O-ADR
sinus O-ADR O-ADR
rhythm O-ADR O-ADR
. O-ADR O-ADR
ULORIC O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
another O-ADR O-ADR
explanation O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
liver O-ADR O-ADR
test O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
is O-ADR O-ADR
permanently O-ADR O-ADR
discontinued O-ADR O-ADR
, O-ADR O-ADR
then O-ADR O-ADR
ribavirin O-ADR O-ADR
and O-ADR O-ADR
VICTRELIS O-ADR O-ADR
must O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
representing O-ADR O-ADR
hemolytic B-ADR B-ADR
anemia I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
first O-ADR O-ADR
cuSCC B-ADR B-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
weeks O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
53 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Pediatric O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
median O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
PROMACTA O-ADR O-ADR
of O-ADR O-ADR
91 O-ADR O-ADR
days O-ADR O-ADR
for O-ADR O-ADR
82 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
aged O-ADR O-ADR
6 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
52 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
across O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
phase O-ADR O-ADR
of O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
renal O-ADR O-ADR
biopsy O-ADR O-ADR
was O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
immune B-ADR B-ADR
complex I-ADR I-ADR
deposition I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Need O-ADR O-ADR
for O-ADR O-ADR
Aseptic O-ADR O-ADR
Technique O-ADR O-ADR
Use O-ADR O-ADR
aseptic O-ADR O-ADR
technique O-ADR O-ADR
and O-ADR O-ADR
discard O-ADR O-ADR
any O-ADR O-ADR
unused O-ADR O-ADR
product O-ADR O-ADR
within O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
of O-ADR O-ADR
stopper O-ADR O-ADR
puncture O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Immunizations O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
but O-ADR O-ADR
not O-ADR O-ADR
limited O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
intranasal O-ADR O-ADR
influenza O-ADR O-ADR
, O-ADR O-ADR
measles O-ADR O-ADR
, O-ADR O-ADR
mumps O-ADR O-ADR
, O-ADR O-ADR
rubella O-ADR O-ADR
, O-ADR O-ADR
oral O-ADR O-ADR
polio O-ADR O-ADR
, O-ADR O-ADR
BCG O-ADR O-ADR
, O-ADR O-ADR
yellow O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
varicella O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
TY21a O-ADR O-ADR
typhoid O-ADR O-ADR
vaccines O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
hyperglycemia B-ADR B-ADR
based O-ADR O-ADR
on O-ADR O-ADR
laboratory O-ADR O-ADR
values O-ADR O-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
ANAPHYLAXIS B-ADR B-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
closely O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
cutaneous O-ADR O-ADR
malignancies O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
portion O-ADR O-ADR
of O-ADR O-ADR
SJIA O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
high B-ADR B-ADR
ALT I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
ILARIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
placebo O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
advanced O-ADR O-ADR
HR O-ADR O-ADR
+ O-ADR O-ADR
BC O-ADR O-ADR
, O-ADR O-ADR
advanced O-ADR O-ADR
PNET O-ADR O-ADR
, O-ADR O-ADR
advanced O-ADR O-ADR
RCC O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
renal O-ADR O-ADR
angiomyolipoma O-ADR O-ADR
with O-ADR O-ADR
TSC O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic B-ADR O-ADR
impairment I-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
class O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
AFINITOR O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
desired O-ADR O-ADR
benefit O-ADR O-ADR
outweighs O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
ILARIS O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
positive O-ADR O-ADR
tuberculosis O-ADR O-ADR
screen O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
in O-ADR O-ADR
individuals O-ADR O-ADR
with O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
evaluated O-ADR O-ADR
for O-ADR O-ADR
LVEF O-ADR O-ADR
at O-ADR O-ADR
screening O-ADR O-ADR
and O-ADR O-ADR
every O-ADR O-ADR
9 O-ADR O-ADR
weeks O-ADR O-ADR
thereafter O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
GILOTRIF O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Eye O-ADR B-ADR
disorders O-ADR I-ADR
: O-ADR O-ADR
infrequent O-ADR O-ADR
: O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
vision B-ADR B-ADR
blurred I-ADR I-ADR
* O-ADR O-ADR
Gastrointestinal O-ADR B-ADR
disorders O-ADR I-ADR
: O-ADR O-ADR
infrequent O-ADR O-ADR
: O-ADR O-ADR
gastroesophageal B-ADR B-ADR
reflux I-ADR I-ADR
disease I-ADR I-ADR
* O-ADR O-ADR
Injury O-ADR B-ADR
, O-ADR O-ADR
Poisoning O-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Procedural O-ADR B-ADR
Complications O-ADR I-ADR
: O-ADR O-ADR
infrequent O-ADR O-ADR
: O-ADR O-ADR
fall B-ADR B-ADR
* O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
infrequent O-ADR O-ADR
: O-ADR O-ADR
photosensitivity B-ADR B-ADR
reaction I-ADR I-ADR
* O-ADR O-ADR
Renal O-ADR O-ADR
and O-ADR O-ADR
urinary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
infrequent O-ADR O-ADR
: O-ADR O-ADR
enuresis B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
exercise O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
considering O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
alvimopan O-ADR O-ADR
for O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Lactic O-ADR O-ADR
Acidosis O-ADR O-ADR
/ O-ADR O-ADR
Severe O-ADR O-ADR
Hepatomegaly O-ADR O-ADR
with O-ADR O-ADR
Steatosis O-ADR O-ADR
Lactic B-ADR B-ADR
acidosis I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hepatomegaly B-ADR B-ADR
with O-ADR O-ADR
steatosis B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
nucleoside O-ADR O-ADR
analogs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
antiretrovirals O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
or O-ADR O-ADR
interruptions O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
increased B-ADR B-ADR
ALT I-ADR I-ADR
( O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
AST I-ADR I-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
( O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
Biologic O-ADR O-ADR
Therapies O-ADR O-ADR
or O-ADR O-ADR
Intravenous O-ADR O-ADR
Cyclophosphamide O-ADR O-ADR
BENLYSTA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
biologic O-ADR O-ADR
therapies O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
B O-ADR O-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
targeted O-ADR O-ADR
therapies O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
intravenous O-ADR O-ADR
cyclophosphamide O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
should O-ADR O-ADR
use O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
stopping O-ADR O-ADR
GILENYA O-ADR O-ADR
. O-ADR O-ADR
Lymphomas O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
lymphoma B-ADR B-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
premarketing O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
setting O-ADR O-ADR
. O-ADR O-ADR
Deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
within O-ADR O-ADR
30 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
last O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
Kyprolis O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
30 O-ADR O-ADR
/ O-ADR O-ADR
598 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Kyprolis O-ADR O-ADR
monotherapy O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Immune B-ADR B-ADR
Reconstitution I-ADR I-ADR
Syndrome I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
enterocolitis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
discontinued O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Neuroleptic O-ADR O-ADR
Malignant O-ADR O-ADR
Syndrome O-ADR O-ADR
A O-ADR O-ADR
potentially O-ADR O-ADR
fatal B-ADR O-ADR
symptom O-ADR O-ADR
complex O-ADR O-ADR
sometimes O-ADR O-ADR
referred O-ADR O-ADR
to O-ADR O-ADR
as O-ADR O-ADR
Neuroleptic B-ADR B-ADR
Malignant I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
NMS B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
and O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
was O-ADR O-ADR
assessed O-ADR O-ADR
using O-ADR O-ADR
a O-ADR O-ADR
chemiluminescent O-ADR O-ADR
cell O-ADR O-ADR
- O-ADR O-ADR
based O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
biological O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
available O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
live O-ADR O-ADR
vaccinations O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
secondary O-ADR O-ADR
transmission O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
by O-ADR O-ADR
live O-ADR O-ADR
vaccines O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
identifies O-ADR O-ADR
the O-ADR O-ADR
shift O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
lowest O-ADR O-ADR
observed O-ADR O-ADR
estimated O-ADR O-ADR
glomerular O-ADR O-ADR
filtration O-ADR O-ADR
rate O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
BOSULIF O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
global O-ADR O-ADR
Ph O-ADR O-ADR
+ O-ADR O-ADR
Leukemia O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
Motor B-ADR B-ADR
Impairment I-ADR I-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
operating O-ADR O-ADR
machinery O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
DPP O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
inhibitors O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
possible O-ADR O-ADR
cause O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
joint O-ADR O-ADR
pain O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
drug O-ADR O-ADR
if O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
addition O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
An O-ADR O-ADR
8 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
crossover O-ADR O-ADR
design O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
involving O-ADR O-ADR
39 O-ADR O-ADR
patients O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
and O-ADR O-ADR
57 O-ADR O-ADR
years O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
G1244E O-ADR O-ADR
, O-ADR O-ADR
G1349D O-ADR O-ADR
, O-ADR O-ADR
G178R O-ADR O-ADR
, O-ADR O-ADR
G551S O-ADR O-ADR
, O-ADR O-ADR
G970R O-ADR O-ADR
, O-ADR O-ADR
S1251N O-ADR O-ADR
, O-ADR O-ADR
S1255P O-ADR O-ADR
, O-ADR O-ADR
S549N O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
S549R O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
NULOJIX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
cytomegalovirus B-ADR B-ADR
infection I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
complications B-ADR B-ADR
of I-ADR I-ADR
transplanted I-ADR I-ADR
kidney I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
POTIGA O-ADR O-ADR
caused O-ADR O-ADR
this O-ADR O-ADR
decreased B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
retinal B-ADR O-ADR
abnormalities I-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
found O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
abnormal B-ADR O-ADR
visual I-ADR O-ADR
acuity I-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
cautioned O-ADR O-ADR
about O-ADR O-ADR
operating O-ADR O-ADR
hazardous O-ADR O-ADR
machinery O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
automobiles O-ADR O-ADR
, O-ADR O-ADR
until O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
reasonably O-ADR O-ADR
certain O-ADR O-ADR
that O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
affect O-ADR O-ADR
them O-ADR O-ADR
adversely O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypotension O-ADR O-ADR
FARXIGA O-ADR O-ADR
causes O-ADR O-ADR
intravascular B-ADR B-ADR
volume I-ADR I-ADR
contraction I-ADR I-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
Summary O-ADR O-ADR
of O-ADR O-ADR
PTLD B-ADR B-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
Through O-ADR O-ADR
Three O-ADR O-ADR
Years O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
NULOJIX O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
* O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
477 O-ADR O-ADR
) O-ADR O-ADR
NULOJIX O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
472 O-ADR O-ADR
) O-ADR O-ADR
Cyclosporine O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
476 O-ADR O-ADR
) O-ADR O-ADR
Trial O-ADR O-ADR
EBV O-ADR O-ADR
Positive O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
406 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR O-ADR
Negative O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
43 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR O-ADR
Unknown O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
28 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR O-ADR
Positive O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
404 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR O-ADR
Negative O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
48 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR B-ADR
Unknown O-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR B-ADR
Positive O-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
399 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR B-ADR
Negative O-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
57 O-ADR O-ADR
) O-ADR O-ADR
EBV O-ADR B-ADR
Unknown O-ADR I-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Regimen O-ADR O-ADR
with O-ADR O-ADR
higher O-ADR O-ADR
cumulative O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
dosing O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
NULOJIX O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
for O-ADR O-ADR
FIRAZYR O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
HALAVEN O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
222 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
multiple O-ADR O-ADR
tumor O-ADR O-ADR
types O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
240 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
HALAVEN O-ADR O-ADR
for O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
a O-ADR O-ADR
complete O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
( O-ADR O-ADR
CBC O-ADR O-ADR
) O-ADR O-ADR
count O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
a O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
( O-ADR O-ADR
WBC O-ADR O-ADR
) O-ADR O-ADR
count O-ADR O-ADR
corrected O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
nucleated O-ADR O-ADR
red O-ADR O-ADR
blood O-ADR O-ADR
cells O-ADR O-ADR
, O-ADR O-ADR
an O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
platelet O-ADR O-ADR
count O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
recovery O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x O-ADR O-ADR
10 O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
beginning O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
taking O-ADR O-ADR
oral O-ADR O-ADR
or O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
regular O-ADR O-ADR
basis O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
times O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
the O-ADR O-ADR
regular O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
use O-ADR O-ADR
them O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
symptomatic O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
respiratory O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Intestinal O-ADR O-ADR
Perforation O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
intestinal B-ADR B-ADR
perforation I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Fatal B-ADR B-ADR
and O-ADR O-ADR
serious O-ADR O-ADR
pneumonitis B-ADR B-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
or O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Risks O-ADR O-ADR
for O-ADR O-ADR
Benzyl O-ADR O-ADR
Alcohol O-ADR O-ADR
Toxicity O-ADR O-ADR
in O-ADR O-ADR
Infants O-ADR O-ADR
AdreView O-ADR O-ADR
contains O-ADR O-ADR
benzyl O-ADR O-ADR
alcohol O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
concentration O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
sinus B-ADR B-ADR
bradycardia I-ADR I-ADR
, O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
of I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
50 I-ADR I-ADR
beats I-ADR I-ADR
per I-ADR I-ADR
minute I-ADR I-ADR
, O-ADR O-ADR
was O-ADR O-ADR
noted O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
finding O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
255 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
following O-ADR O-ADR
AdreView O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Subjects O-ADR O-ADR
Who O-ADR O-ADR
Received O-ADR O-ADR
Two O-ADR O-ADR
Concurrent O-ADR O-ADR
Injections O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
XIAFLEXN O-ADR O-ADR
= O-ADR O-ADR
715 O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
Edema B-ADR B-ADR
peripheral I-ADR I-ADR
77 O-ADR O-ADR
% O-ADR O-ADR
Contusion B-ADR B-ADR
59 O-ADR O-ADR
% O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
51 O-ADR O-ADR
% O-ADR O-ADR
Laceration B-ADR B-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
Pruritus B-ADR B-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
Lymphadenopathy B-ADR B-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
Blood B-ADR B-ADR
blister I-ADR I-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
hematoma I-ADR I-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
Axillary B-ADR B-ADR
pain I-ADR I-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
swelling I-ADR I-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Ecchymosis B-ADR B-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Safety O-ADR O-ADR
of O-ADR O-ADR
Retreatment O-ADR O-ADR
of O-ADR O-ADR
Recurrent O-ADR O-ADR
Contractures O-ADR O-ADR
An O-ADR O-ADR
observational O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
label O-ADR O-ADR
study O-ADR O-ADR
was O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
XIAFLEX O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
In O-ADR O-ADR
other O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
penile B-ADR B-ADR
ecchymoses I-ADR I-ADR
, O-ADR O-ADR
sudden O-ADR O-ADR
penile B-ADR B-ADR
detumescence I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
penile B-ADR B-ADR
` O-ADR O-ADR
` O-ADR O-ADR
popping B-ADR B-ADR
' O-ADR O-ADR
' O-ADR O-ADR
sound B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
corporal B-ADR B-ADR
rupture I-ADR I-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
possible O-ADR O-ADR
, O-ADR O-ADR
avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congenital O-ADR O-ADR
long O-ADR O-ADR
QT O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Tumor B-ADR B-ADR
lysis I-ADR I-ADR
syndrome I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
advanced O-ADR O-ADR
stage O-ADR O-ADR
disease O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
high O-ADR O-ADR
tumor O-ADR O-ADR
burden O-ADR O-ADR
and O-ADR O-ADR
take O-ADR O-ADR
appropriate O-ADR O-ADR
precautions O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
had O-ADR O-ADR
diabetes O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
average O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
HbA1c O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
observed O-ADR O-ADR
included O-ADR O-ADR
viral B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
pneumonia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pyelonephritis B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
stop O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Similar O-ADR O-ADR
proportions O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
protective O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
vaccine O-ADR O-ADR
antibodies O-ADR O-ADR
between O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
; O-ADR O-ADR
however O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
concomitant O-ADR O-ADR
methotrexate O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
lower O-ADR O-ADR
humoral O-ADR O-ADR
response O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
CIMZIA O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
12 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
estimated O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
behavior I-ADR I-ADR
among O-ADR O-ADR
27 O-ADR O-ADR
, O-ADR O-ADR
863 O-ADR O-ADR
AED O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
43 O-ADR O-ADR
% O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
among O-ADR O-ADR
16 O-ADR O-ADR
, O-ADR O-ADR
029 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
representing O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
of O-ADR O-ADR
approximately O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
for O-ADR O-ADR
every O-ADR O-ADR
530 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
. O-ADR O-ADR
JARDIANCE O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
four O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
volume B-ADR B-ADR
depletion I-ADR I-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
postural B-ADR B-ADR
dizziness I-ADR I-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dehydration B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
4 O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
cerebral B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
hemoptysis B-ADR B-ADR
, O-ADR O-ADR
lower B-ADR B-ADR
gastrointestinal I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
melena B-ADR B-ADR
) O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
. O-ADR O-ADR
Moderate O-ADR O-ADR
endocrinopathy B-ADR B-ADR
( O-ADR O-ADR
requiring O-ADR O-ADR
hormone O-ADR O-ADR
replacement O-ADR O-ADR
or O-ADR O-ADR
medical O-ADR O-ADR
intervention O-ADR O-ADR
; O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
consisted O-ADR O-ADR
of O-ADR O-ADR
hypothyroidism B-ADR B-ADR
, O-ADR O-ADR
adrenal B-ADR B-ADR
insufficiency I-ADR I-ADR
, O-ADR O-ADR
hypopituitarism B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
case O-ADR O-ADR
each O-ADR O-ADR
of O-ADR O-ADR
hyperthyroidism B-ADR B-ADR
and O-ADR O-ADR
Cushing B-ADR B-ADR
' I-ADR I-ADR
s O-ADR O-ADR
syndrome I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Novartis O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Corporation O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
669 O-ADR O-ADR
- O-ADR O-ADR
6682 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
Initiate O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Reactions O-ADR O-ADR
are O-ADR O-ADR
further O-ADR O-ADR
categorized O-ADR O-ADR
by O-ADR O-ADR
MedDRA O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
decreasing O-ADR O-ADR
frequency O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
definitions O-ADR O-ADR
: O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
frequent O-ADR O-ADR
) O-ADR O-ADR
( O-ADR O-ADR
only O-ADR O-ADR
those O-ADR O-ADR
not O-ADR O-ADR
already O-ADR O-ADR
listed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
tabulated O-ADR O-ADR
results O-ADR O-ADR
from O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
appear O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
listing O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
100 O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1000 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
infrequent O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
those O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
fewer O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
1000 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
rare O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Thrombotic B-ADR B-ADR
events I-ADR I-ADR
included O-ADR O-ADR
five O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pulmonary B-ADR B-ADR
embolus I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
everolimus O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
three O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
thrombosis B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
everolimus O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
two O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Angioedema B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
face I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
fesoterodine O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
interrupting O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
a O-ADR O-ADR
new O-ADR O-ADR
infection O-ADR O-ADR
while O-ADR O-ADR
undergoing O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
closely O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
families O-ADR O-ADR
and O-ADR O-ADR
caregivers O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
close O-ADR O-ADR
observation O-ADR O-ADR
and O-ADR O-ADR
communication O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
prescriber O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
was O-ADR O-ADR
63 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
and O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
100 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
had O-ADR O-ADR
grade O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
one O-ADR O-ADR
had O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
of O-ADR O-ADR
Prolia O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
individual O-ADR O-ADR
benefit O-ADR O-ADR
- O-ADR O-ADR
risk O-ADR O-ADR
assessment O-ADR O-ADR
. O-ADR O-ADR
Careful O-ADR O-ADR
monitoring O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
dose O-ADR O-ADR
adjustments O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
VORAXAZE O-ADR O-ADR
is O-ADR O-ADR
confounded O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
population O-ADR O-ADR
in O-ADR O-ADR
which O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
toxic O-ADR O-ADR
plasma O-ADR O-ADR
methotrexate O-ADR O-ADR
levels O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
impaired O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Total B-ADR B-ADR
bilirubin I-ADR I-ADR
greater I-ADR I-ADR
than I-ADR I-ADR
or I-ADR I-ADR
equal I-ADR I-ADR
to I-ADR I-ADR
1 I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
x I-ADR I-ADR
ULN I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
76 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Appropriate O-ADR O-ADR
medical O-ADR O-ADR
support O-ADR O-ADR
and O-ADR O-ADR
monitoring O-ADR O-ADR
measures O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
during O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
infusion O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
prolonged O-ADR O-ADR
observation O-ADR O-ADR
times O-ADR O-ADR
that O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
individualized O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
needs O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
Interstitial B-ADR O-ADR
infiltration I-ADR O-ADR
and I-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
inflammation I-ADR O-ADR
were I-ADR O-ADR
observed I-ADR O-ADR
on I-ADR O-ADR
radiographs I-ADR O-ADR
and I-ADR O-ADR
computed I-ADR O-ADR
tomographic I-ADR O-ADR
imaging I-ADR O-ADR
of I-ADR O-ADR
the I-ADR O-ADR
chest I-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
circumstances O-ADR O-ADR
when O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
initiate O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
MAOI O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
linezolid O-ADR O-ADR
or O-ADR O-ADR
intravenous O-ADR O-ADR
methylene O-ADR O-ADR
blue O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
taking O-ADR O-ADR
PRISTIQ O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
IL O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
blockade O-ADR O-ADR
may O-ADR O-ADR
interfere O-ADR O-ADR
with O-ADR O-ADR
immune O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
infections O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
that O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
adult O-ADR O-ADR
and O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
receive O-ADR O-ADR
all O-ADR O-ADR
recommended O-ADR O-ADR
vaccinations O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
pneumococcal O-ADR O-ADR
vaccine O-ADR O-ADR
and O-ADR O-ADR
inactivated O-ADR O-ADR
influenza O-ADR O-ADR
vaccine O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Stomatitis B-ADR B-ADR
, O-ADR O-ADR
pancreatitis B-ADR B-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
uncertain O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
causal O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
typically O-ADR O-ADR
reported O-ADR O-ADR
cough B-ADR B-ADR
and O-ADR O-ADR
dyspnea B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
improved O-ADR O-ADR
following O-ADR O-ADR
treatment O-ADR O-ADR
interruption O-ADR O-ADR
. O-ADR O-ADR
Major O-ADR O-ADR
45 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
41 O-ADR O-ADR
) O-ADR O-ADR
29 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
92 O-ADR O-ADR
) O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
54 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
96 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
45 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
07 O-ADR O-ADR
Fatal B-ADR B-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
99 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
23 O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
29 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
Intracranial O-ADR B-ADR
11 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
11 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
35 O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
99 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
39 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
51 O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
ARISTOTLE O-ADR O-ADR
Major O-ADR O-ADR
Bleeding B-ADR B-ADR
Forest O-ADR O-ADR
Plot O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
drug B-ADR O-ADR
hypersensitivity I-ADR B-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
skin B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
allergic B-ADR B-ADR
edema I-ADR I-ADR
) O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
ELIQUIS O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
ecallantide O-ADR O-ADR
were O-ADR O-ADR
determined O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
present O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
efficacy O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
toxic O-ADR B-ADR
methotrexate O-ADR O-ADR
levels O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
prolonged O-ADR O-ADR
methotrexate O-ADR O-ADR
clearance O-ADR O-ADR
include O-ADR O-ADR
myelosuppression O-ADR B-ADR
, O-ADR O-ADR
mucositis O-ADR B-ADR
, O-ADR O-ADR
acute O-ADR B-ADR
hepatitis O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
renal O-ADR B-ADR
dysfunction O-ADR I-ADR
and O-ADR O-ADR
failure O-ADR B-ADR
. O-ADR O-ADR
There O-ADR O-ADR
was O-ADR O-ADR
considerable O-ADR O-ADR
variation O-ADR O-ADR
in O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidality B-ADR B-ADR
among O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
a O-ADR O-ADR
tendency O-ADR O-ADR
toward O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
younger O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
almost O-ADR O-ADR
all O-ADR O-ADR
drugs O-ADR O-ADR
studied O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Activation B-ADR B-ADR
of I-ADR I-ADR
Mania I-ADR I-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
cautiously O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Bipolar O-ADR O-ADR
Disorder O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Capillary O-ADR O-ADR
Leak O-ADR O-ADR
Syndrome O-ADR O-ADR
Capillary B-ADR B-ADR
leak I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
CLS B-ADR B-ADR
) O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
and O-ADR O-ADR
is O-ADR O-ADR
characterized O-ADR O-ADR
by O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
hypoalbuminemia B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
and O-ADR O-ADR
hemoconcentration B-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
trametinib O-ADR O-ADR
if O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
serious O-ADR O-ADR
febrile O-ADR O-ADR
reaction O-ADR O-ADR
or O-ADR O-ADR
fever O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
hypotension O-ADR O-ADR
, O-ADR O-ADR
rigors O-ADR O-ADR
or O-ADR O-ADR
chills O-ADR O-ADR
, O-ADR O-ADR
dehydration O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
renal O-ADR O-ADR
failure O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
possible O-ADR O-ADR
, O-ADR O-ADR
optimal O-ADR O-ADR
glucose O-ADR O-ADR
and O-ADR O-ADR
lipid O-ADR O-ADR
control O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
achieved O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
on O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
comprised O-ADR O-ADR
of O-ADR O-ADR
374 O-ADR O-ADR
patients O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
249 O-ADR O-ADR
and O-ADR O-ADR
125 O-ADR O-ADR
received O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Systemic O-ADR O-ADR
and O-ADR O-ADR
local O-ADR O-ADR
corticosteroid O-ADR O-ADR
use O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Candida B-ADR B-ADR
albicans I-ADR I-ADR
infection I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
pneumonia B-ADR B-ADR
in O-ADR O-ADR
COPD O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Immunosuppression B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Hypercorticism B-ADR B-ADR
and O-ADR O-ADR
adrenal B-ADR B-ADR
suppression I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Reduction B-ADR B-ADR
in I-ADR I-ADR
bone I-ADR I-ADR
mineral I-ADR I-ADR
density I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
PRISTIQ O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
GILOTRIF O-ADR O-ADR
for O-ADR O-ADR
confirmed O-ADR O-ADR
ulcerative O-ADR O-ADR
keratitis O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
fesoterodine O-ADR O-ADR
use O-ADR O-ADR
in O-ADR O-ADR
worldwide O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
experience O-ADR O-ADR
: O-ADR O-ADR
Eye O-ADR B-ADR
disorders O-ADR I-ADR
: O-ADR O-ADR
Blurred B-ADR B-ADR
vision I-ADR I-ADR
; O-ADR O-ADR
Cardiac O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Palpitations B-ADR B-ADR
; O-ADR O-ADR
General O-ADR O-ADR
disorders O-ADR O-ADR
and O-ADR O-ADR
administrative O-ADR O-ADR
site O-ADR O-ADR
conditions O-ADR O-ADR
: O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
angioedema B-ADR B-ADR
with O-ADR O-ADR
airway B-ADR B-ADR
obstruction I-ADR I-ADR
, O-ADR O-ADR
face B-ADR B-ADR
edema I-ADR I-ADR
; O-ADR O-ADR
Central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
; O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Urticaria B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
spontaneously O-ADR O-ADR
reported O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
worldwide O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
events O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
role O-ADR O-ADR
of O-ADR O-ADR
fesoterodine O-ADR O-ADR
in O-ADR O-ADR
their O-ADR O-ADR
causation O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
reliably O-ADR O-ADR
determined O-ADR O-ADR
. O-ADR O-ADR
Dosing O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
( O-ADR O-ADR
ULN O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
observed O-ADR O-ADR
for O-ADR O-ADR
selected O-ADR O-ADR
lipid O-ADR O-ADR
values O-ADR O-ADR
is O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
Progressive O-ADR O-ADR
Multifocal O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
( O-ADR O-ADR
PML O-ADR O-ADR
) O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
JC B-ADR B-ADR
virus O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
PML B-ADR B-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
neurological B-ADR B-ADR
deficits I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
SLE O-ADR O-ADR
receiving O-ADR O-ADR
immunosuppressants O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reasons O-ADR O-ADR
for O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
MULTAQ O-ADR O-ADR
were O-ADR O-ADR
gastrointestinal B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
per O-ADR O-ADR
day O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
( O-ADR O-ADR
rates O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
SAPHRIS O-ADR O-ADR
arm O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
somnolence B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
5mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
10mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
10mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
10mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
group O-ADR O-ADR
) O-ADR O-ADR
No O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
dropped O-ADR O-ADR
out O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
seeDosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
DUAVEE O-ADR O-ADR
comes O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
blister O-ADR O-ADR
package O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
ERWINAZE O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
thrombotic O-ADR O-ADR
or O-ADR O-ADR
hemorrhagic O-ADR O-ADR
event O-ADR O-ADR
until O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
; O-ADR O-ADR
after O-ADR O-ADR
resolution O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ERWINAZE O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
resumed O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
on O-ADR O-ADR
INVOKANA O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
comparator O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
Volume O-ADR B-ADR
Depletion O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
INVOKANA O-ADR O-ADR
results O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
osmotic B-ADR B-ADR
diuresis I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
reductions B-ADR B-ADR
in I-ADR I-ADR
intravascular I-ADR I-ADR
volume I-ADR I-ADR
. O-ADR O-ADR
When O-ADR O-ADR
beginning O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
taking O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta2 O-ADR O-ADR
- O-ADR O-ADR
agonists O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
regular O-ADR O-ADR
basis O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
four O-ADR O-ADR
times O-ADR O-ADR
a O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
discontinue O-ADR O-ADR
the O-ADR O-ADR
regular O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
and O-ADR O-ADR
use O-ADR O-ADR
them O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
symptomatic O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
respiratory O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
199 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
mono O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
adjunctive O-ADR O-ADR
- O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
11 O-ADR O-ADR
different O-ADR O-ADR
AEDs O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
AEDs O-ADR O-ADR
had O-ADR O-ADR
approximately O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
( O-ADR O-ADR
adjusted O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
, O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
confidence O-ADR O-ADR
interval O-ADR O-ADR
[ O-ADR O-ADR
CI O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
avoid O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
14 O-ADR O-ADR
consecutive O-ADR O-ADR
days O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
SIRTURO O-ADR O-ADR
, O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
benefit O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
combination O-ADR O-ADR
outweighs O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
DRESS B-ADR B-ADR
may O-ADR O-ADR
be O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
. O-ADR O-ADR
Bleeding B-ADR B-ADR
events O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
bruising B-ADR B-ADR
and O-ADR O-ADR
petechiae B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
approximately O-ADR O-ADR
half O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Bleeding B-ADR B-ADR
: O-ADR O-ADR
PRADAXA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
serious O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
bleeding B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bioprosthetic O-ADR B-ADR
heart O-ADR I-ADR
valves O-ADR I-ADR
: O-ADR O-ADR
PRADAXA O-ADR O-ADR
use O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Increased O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Thrombotic O-ADR O-ADR
Events O-ADR O-ADR
after O-ADR O-ADR
Premature O-ADR O-ADR
Discontinuation O-ADR O-ADR
Premature O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
oral O-ADR O-ADR
anticoagulant O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
PRADAXA O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
adequate O-ADR O-ADR
alternative O-ADR O-ADR
anticoagulation O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thrombotic O-ADR B-ADR
events O-ADR I-ADR
. O-ADR O-ADR
PRADAXA O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
anticoagulant O-ADR O-ADR
activity O-ADR O-ADR
and O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
life O-ADR O-ADR
are O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
YERVOY O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
Eight O-ADR O-ADR
of O-ADR O-ADR
79 O-ADR O-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
SIRTURO O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
16 O-ADR O-ADR
of O-ADR O-ADR
81 O-ADR O-ADR
( O-ADR O-ADR
19 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Measure O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
) O-ADR O-ADR
before O-ADR O-ADR
starting O-ADR O-ADR
Ferriprox O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
the O-ADR O-ADR
ANC O-ADR O-ADR
weekly O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Clinically O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular O-ADR O-ADR
effects O-ADR O-ADR
and O-ADR O-ADR
fatalities B-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
excessive O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
sympathomimetic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
relief O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptoms O-ADR O-ADR
, O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
rescue O-ADR O-ADR
therapy O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
episodes O-ADR O-ADR
of O-ADR O-ADR
bronchospasm O-ADR O-ADR
. O-ADR O-ADR
Concurrent O-ADR O-ADR
elevations B-ADR B-ADR
in I-ADR I-ADR
ALT I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
ULN O-ADR O-ADR
and O-ADR O-ADR
total B-ADR B-ADR
bilirubin I-ADR I-ADR
greater I-ADR O-ADR
than I-ADR O-ADR
2 I-ADR O-ADR
times I-ADR O-ADR
the I-ADR O-ADR
ULN I-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
usually O-ADR O-ADR
resolve O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
Ferriprox O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
there O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
agranulocytosis B-ADR B-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
weekly O-ADR O-ADR
for O-ADR O-ADR
liver O-ADR O-ADR
toxicity O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
ALT O-ADR O-ADR
or O-ADR O-ADR
AST O-ADR O-ADR
rises O-ADR O-ADR
above O-ADR O-ADR
3 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
upper O-ADR O-ADR
limit O-ADR O-ADR
of O-ADR O-ADR
normal O-ADR O-ADR
until O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Close O-ADR O-ADR
monitoring O-ADR O-ADR
for O-ADR O-ADR
glaucoma O-ADR O-ADR
and O-ADR O-ADR
cataracts O-ADR O-ADR
is O-ADR O-ADR
warranted O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
SJS O-ADR O-ADR
/ O-ADR O-ADR
TEN O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
8 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
introducing O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Genital O-ADR O-ADR
Mycotic O-ADR O-ADR
Infections O-ADR O-ADR
FARXIGA O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
Withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
occurred O-ADR O-ADR
following O-ADR O-ADR
abrupt O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ONFI O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
withdrawal O-ADR O-ADR
symptoms O-ADR O-ADR
is O-ADR O-ADR
greater O-ADR O-ADR
with O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
. O-ADR O-ADR
Clinical O-ADR O-ADR
Myocardial O-ADR O-ADR
Infarction O-ADR O-ADR
Events O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
VTE O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PRADAXA O-ADR O-ADR
[ O-ADR O-ADR
20 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
66 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
warfarin O-ADR O-ADR
[ O-ADR O-ADR
5 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
patient O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
migraine B-ADR B-ADR
during O-ADR O-ADR
COC O-ADR O-ADR
use O-ADR O-ADR
( O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
prodromal O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
cerebrovascular B-ADR O-ADR
event I-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
reason O-ADR O-ADR
for O-ADR O-ADR
immediate O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
COC O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Excessive O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
and O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Other O-ADR O-ADR
Long O-ADR O-ADR
- O-ADR O-ADR
Acting O-ADR O-ADR
Beta2 O-ADR O-ADR
- O-ADR O-ADR
Agonists O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
more O-ADR O-ADR
often O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
conjunction O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
medicines O-ADR O-ADR
containing O-ADR O-ADR
LABA O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
overdose O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
after O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
injections O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
through O-ADR O-ADR
Day O-ADR O-ADR
90 O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
blinatumomab O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
may O-ADR O-ADR
affect O-ADR O-ADR
pharmacokinetics O-ADR O-ADR
of O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
BLINCYTO O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
bronchospasm B-ADR B-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
some O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
those O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
control O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
XIAFLEX O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
of O-ADR O-ADR
corporal O-ADR O-ADR
rupture O-ADR O-ADR
( O-ADR O-ADR
penile O-ADR O-ADR
fracture O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
serious O-ADR O-ADR
penile O-ADR O-ADR
injury O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
XIAFLEX O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
only O-ADR O-ADR
through O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
REMS O-ADR O-ADR
Program O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Leading O-ADR O-ADR
to O-ADR O-ADR
Study O-ADR O-ADR
Discontinuation O-ADR O-ADR
: O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
women O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
menstrual B-ADR B-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
metrorrhagia B-ADR B-ADR
, O-ADR O-ADR
menorrhagia B-ADR B-ADR
, O-ADR O-ADR
menstruation B-ADR B-ADR
irregular I-ADR I-ADR
, O-ADR O-ADR
genital B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
vaginal B-ADR B-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
dysfunctional B-ADR B-ADR
uterine I-ADR I-ADR
bleeding I-ADR I-ADR
) O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
mood B-ADR B-ADR
changes I-ADR I-ADR
( O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
mood B-ADR B-ADR
swings I-ADR I-ADR
, O-ADR O-ADR
mood B-ADR B-ADR
altered I-ADR I-ADR
, O-ADR O-ADR
depressed B-ADR B-ADR
mood I-ADR I-ADR
, O-ADR O-ADR
dysthymic B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
crying B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
acne B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
migraines B-ADR B-ADR
) O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
increased I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
using O-ADR O-ADR
supplemental O-ADR O-ADR
oxygen O-ADR O-ADR
or O-ADR O-ADR
continuous O-ADR O-ADR
positive O-ADR O-ADR
airway O-ADR O-ADR
pressure O-ADR O-ADR
( O-ADR O-ADR
CPAP O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
sleep O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
these O-ADR O-ADR
treatments O-ADR O-ADR
readily O-ADR O-ADR
available O-ADR O-ADR
during O-ADR O-ADR
infusion O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
extreme O-ADR O-ADR
drowsiness O-ADR O-ADR
/ O-ADR O-ADR
sleep O-ADR O-ADR
induced O-ADR O-ADR
by O-ADR O-ADR
antihistamine O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Given O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
delay O-ADR O-ADR
in O-ADR O-ADR
lymphocyte O-ADR O-ADR
recovery O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
TECFIDERA O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
following O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
until O-ADR O-ADR
lymphopenia O-ADR O-ADR
is O-ADR O-ADR
resolved O-ADR O-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
cysts I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
chemotherapy O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
, O-ADR O-ADR
dose O-ADR O-ADR
reduce O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BOSULIF O-ADR O-ADR
as O-ADR O-ADR
necessary O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
using O-ADR O-ADR
the O-ADR O-ADR
NCI O-ADR O-ADR
CTC O-ADR O-ADR
Version O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Study O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
DaTscan O-ADR O-ADR
in O-ADR O-ADR
942 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
66 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
25 O-ADR O-ADR
to O-ADR O-ADR
90 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
500 O-ADR O-ADR
Units O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
muscular B-ADR B-ADR
weakness I-ADR I-ADR
, O-ADR O-ADR
dysphagia B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
neck B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
eye B-ADR B-ADR
disorders I-ADR I-ADR
( O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
reduced B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
generally O-ADR O-ADR
managed O-ADR O-ADR
with O-ADR O-ADR
infusion O-ADR O-ADR
interruption O-ADR O-ADR
, O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
antihistamines O-ADR O-ADR
, O-ADR O-ADR
corticosteroids O-ADR O-ADR
, O-ADR O-ADR
intravenous O-ADR O-ADR
fluids O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
oxygen O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
may O-ADR O-ADR
also O-ADR O-ADR
affect O-ADR O-ADR
how O-ADR O-ADR
your O-ADR O-ADR
other O-ADR O-ADR
medicines O-ADR O-ADR
work O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidences O-ADR O-ADR
of O-ADR O-ADR
EPS B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events I-ADR I-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
were O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Correct O-ADR O-ADR
volume O-ADR O-ADR
or O-ADR O-ADR
salt O-ADR O-ADR
depletion O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
currently O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
blood O-ADR O-ADR
clots O-ADR O-ADR
* O-ADR O-ADR
are O-ADR O-ADR
allergic O-ADR O-ADR
to O-ADR O-ADR
estrogens O-ADR O-ADR
or O-ADR O-ADR
bazedoxifene O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
ingredients O-ADR O-ADR
in O-ADR O-ADR
DUAVEE O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
its O-ADR O-ADR
ingredients O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
patients O-ADR O-ADR
may O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reaction I-ADR I-ADR
to O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
reported O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
most O-ADR O-ADR
had O-ADR O-ADR
their O-ADR O-ADR
first O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Elevated B-ADR B-ADR
transaminases I-ADR I-ADR
) O-ADR O-ADR
: O-ADR O-ADR
Transaminases O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
KALYDECO O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
annually O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
Risk O-ADR O-ADR
by O-ADR O-ADR
Indication O-ADR O-ADR
for O-ADR O-ADR
Antiepileptic O-ADR O-ADR
Drugs O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Pooled O-ADR O-ADR
Analysis O-ADR O-ADR
Indication O-ADR O-ADR
PlaceboPatients O-ADR O-ADR
WithEvents O-ADR O-ADR
Per1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Drug O-ADR O-ADR
PatientsWith O-ADR O-ADR
Events O-ADR O-ADR
Per1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Relative O-ADR O-ADR
Risk O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
of O-ADR O-ADR
Eventsin O-ADR O-ADR
DrugPatients O-ADR O-ADR
/ O-ADR O-ADR
Incidencein O-ADR O-ADR
Placebo O-ADR O-ADR
Patients O-ADR O-ADR
Risk O-ADR O-ADR
Difference O-ADR O-ADR
: O-ADR O-ADR
Additional O-ADR O-ADR
DrugPatients O-ADR O-ADR
WithEvents O-ADR O-ADR
Per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000Patients O-ADR O-ADR
Epilepsy O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Psychiatric O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Other O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Total O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
The O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
epilepsy O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
for O-ADR O-ADR
psychiatric O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
absolute O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
epilepsy O-ADR O-ADR
and O-ADR O-ADR
psychiatric O-ADR O-ADR
indications O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Liver O-ADR O-ADR
Transplant O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
in O-ADR O-ADR
liver O-ADR O-ADR
transplant O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
included O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
allowing O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
on O-ADR O-ADR
ONFI O-ADR O-ADR
at O-ADR O-ADR
several O-ADR O-ADR
doses O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
GI B-ADR B-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
individuals O-ADR O-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
develop O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
dyscrasias O-ADR O-ADR
or O-ADR O-ADR
infection O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
bruising O-ADR O-ADR
, O-ADR O-ADR
bleeding O-ADR O-ADR
, O-ADR O-ADR
pallor O-ADR B-ADR
) O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
CIMZIA O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
medications O-ADR O-ADR
that O-ADR O-ADR
work O-ADR O-ADR
through O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
IL O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR O-ADR
. O-ADR O-ADR
Perform O-ADR O-ADR
dermatologic O-ADR O-ADR
evaluations O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
following O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Interference O-ADR O-ADR
with O-ADR O-ADR
Visualization O-ADR O-ADR
of O-ADR O-ADR
Liver O-ADR O-ADR
Lesions O-ADR O-ADR
Severe O-ADR O-ADR
renal O-ADR O-ADR
or O-ADR O-ADR
hepatic O-ADR O-ADR
failure O-ADR O-ADR
may O-ADR O-ADR
impair O-ADR O-ADR
EOVIST O-ADR O-ADR
imaging O-ADR O-ADR
performance O-ADR O-ADR
. O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
consider O-ADR O-ADR
whether O-ADR O-ADR
their O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
underlying O-ADR O-ADR
NAION O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
adversely O-ADR O-ADR
affected O-ADR O-ADR
by O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
pediatric O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
somnolence B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
sedation B-ADR B-ADR
and O-ADR O-ADR
hypersomnia B-ADR B-ADR
) O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
SAPHRIS O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
/ O-ADR O-ADR
101 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
46 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
48 O-ADR O-ADR
/ O-ADR O-ADR
104 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
52 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
/ O-ADR O-ADR
99 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
reported O-ADR O-ADR
voluntarily O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
unknown O-ADR O-ADR
size O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
always O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
reliably O-ADR O-ADR
estimate O-ADR O-ADR
their O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
establish O-ADR O-ADR
a O-ADR O-ADR
casual O-ADR O-ADR
relationship O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Bacteria O-ADR O-ADR
Prescribing O-ADR O-ADR
DALVANCE O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
proven O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
bacterial O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
provide O-ADR O-ADR
benefit O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
bacteria O-ADR O-ADR
. O-ADR O-ADR
Malignancies B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
among O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
adolescents O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adults O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
( O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
18 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
which O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
member O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Effects O-ADR O-ADR
on O-ADR O-ADR
Eye O-ADR O-ADR
Physicians O-ADR O-ADR
should O-ADR O-ADR
advise O-ADR O-ADR
patients O-ADR O-ADR
to O-ADR O-ADR
stop O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
sudden O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
both O-ADR O-ADR
eyes O-ADR O-ADR
. O-ADR O-ADR
Obtain O-ADR O-ADR
a O-ADR O-ADR
liver O-ADR O-ADR
test O-ADR O-ADR
panel O-ADR O-ADR
( O-ADR O-ADR
serum O-ADR O-ADR
alanine O-ADR O-ADR
aminotransferase O-ADR O-ADR
[ O-ADR O-ADR
ALT O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
aspartate O-ADR O-ADR
aminotransferase O-ADR O-ADR
[ O-ADR O-ADR
AST O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
ULORIC O-ADR O-ADR
. O-ADR O-ADR
STENDRA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
anatomical O-ADR O-ADR
deformation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
penis O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
angulation O-ADR O-ADR
, O-ADR O-ADR
cavernosal O-ADR O-ADR
fibrosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
conditions O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
predispose O-ADR O-ADR
them O-ADR O-ADR
to O-ADR O-ADR
priapism O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
sickle O-ADR O-ADR
cell O-ADR O-ADR
anemia O-ADR O-ADR
, O-ADR O-ADR
multiple O-ADR O-ADR
myeloma O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
leukemia O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Adequate O-ADR O-ADR
diagnostic O-ADR O-ADR
measures O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
directed O-ADR O-ADR
or O-ADR O-ADR
random O-ADR O-ADR
endometrial O-ADR O-ADR
sampling O-ADR O-ADR
when O-ADR O-ADR
indicated O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
undertaken O-ADR O-ADR
to O-ADR O-ADR
rule O-ADR O-ADR
out O-ADR O-ADR
malignancy O-ADR O-ADR
in O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
undiagnosed O-ADR O-ADR
persistent O-ADR O-ADR
or O-ADR O-ADR
recurring O-ADR O-ADR
abnormal O-ADR O-ADR
genital O-ADR O-ADR
bleeding O-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
regardless O-ADR O-ADR
of O-ADR O-ADR
causality O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
sensory I-ADR I-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
VTE B-ADR B-ADR
risk O-ADR O-ADR
was O-ADR O-ADR
demonstrated O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
2 O-ADR O-ADR
years O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Somnolence B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
sedation B-ADR B-ADR
) O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
/ O-ADR O-ADR
1953 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Immunizations O-ADR O-ADR
Live O-ADR O-ADR
vaccines O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
concurrently O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
From O-ADR O-ADR
this O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
possible O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
are O-ADR O-ADR
related O-ADR O-ADR
directly O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
or O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
factors O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
taking O-ADR O-ADR
AFINITOR O-ADR O-ADR
, O-ADR O-ADR
be O-ADR O-ADR
vigilant O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
; O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
made O-ADR O-ADR
, O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
treatment O-ADR O-ADR
promptly O-ADR O-ADR
and O-ADR O-ADR
consider O-ADR O-ADR
interruption O-ADR O-ADR
or O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
The O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
documented O-ADR O-ADR
symptomatic O-ADR B-ADR
hypoglycemic B-ADR I-ADR
episode I-ADR I-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
severe O-ADR O-ADR
hypoglycemic B-ADR B-ADR
episode I-ADR I-ADR
on O-ADR O-ADR
TANZEUM O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
is O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Interleukin O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
blockade O-ADR O-ADR
may O-ADR O-ADR
interfere O-ADR B-ADR
with O-ADR I-ADR
immune O-ADR I-ADR
response O-ADR I-ADR
to O-ADR I-ADR
infections O-ADR B-ADR
. O-ADR O-ADR
Pooled O-ADR O-ADR
analyses O-ADR O-ADR
of O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
antidepressant O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
SSRIs O-ADR O-ADR
and O-ADR O-ADR
others O-ADR O-ADR
) O-ADR O-ADR
showed O-ADR O-ADR
that O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thinking I-ADR I-ADR
( O-ADR O-ADR
suicidality B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
adolescents O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adults O-ADR O-ADR
( O-ADR O-ADR
ages O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
major O-ADR O-ADR
depressive O-ADR O-ADR
disorder O-ADR O-ADR
( O-ADR O-ADR
MDD O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
psychiatric O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Respiratory O-ADR O-ADR
Effects O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
reductions B-ADR B-ADR
in I-ADR I-ADR
forced I-ADR I-ADR
expiratory I-ADR I-ADR
volume I-ADR I-ADR
over I-ADR I-ADR
1 I-ADR I-ADR
second I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
initiation O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
confirmed O-ADR O-ADR
significant O-ADR O-ADR
hematologic O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
below O-ADR O-ADR
is O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
2 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
EDEMA3 O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
EDEMA4 O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
143 O-ADR O-ADR
unique O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
. O-ADR O-ADR
Through O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
darunavir O-ADR O-ADR
/ O-ADR O-ADR
ritonavir O-ADR O-ADR
. O-ADR O-ADR
Anyone O-ADR O-ADR
considering O-ADR O-ADR
prescribing O-ADR O-ADR
HORIZANT O-ADR O-ADR
must O-ADR O-ADR
balance O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
untreated O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
24 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
plus O-ADR O-ADR
exemestane O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
primarily O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
psychiatric O-ADR O-ADR
illness O-ADR O-ADR
. O-ADR O-ADR
Two O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
four O-ADR O-ADR
subjects O-ADR O-ADR
had O-ADR O-ADR
renal O-ADR B-ADR
impairment O-ADR I-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
Alternatives O-ADR O-ADR
to O-ADR O-ADR
NSAIDs O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
needed O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
dysfunction O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
. O-ADR O-ADR
Falls O-ADR O-ADR
and O-ADR O-ADR
Fall O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
Injuries O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
randomized O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
falls B-ADR B-ADR
including O-ADR O-ADR
fall B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
injuries I-ADR I-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Although O-ADR O-ADR
cobicistat O-ADR O-ADR
( O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
modest O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
modest O-ADR O-ADR
declines B-ADR B-ADR
in I-ADR I-ADR
estimated I-ADR I-ADR
creatinine I-ADR I-ADR
clearance I-ADR I-ADR
without O-ADR O-ADR
affecting O-ADR O-ADR
renal O-ADR O-ADR
glomerular O-ADR O-ADR
function O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
a O-ADR O-ADR
confirmed O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
renal O-ADR O-ADR
safety O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
, O-ADR O-ADR
arterial B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
including O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attack I-ADR I-ADR
, O-ADR O-ADR
cerebrovascular B-ADR B-ADR
accident I-ADR I-ADR
, O-ADR O-ADR
myocardial B-ADR B-ADR
infarction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
retinal B-ADR B-ADR
artery I-ADR I-ADR
occlusion I-ADR I-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
17 O-ADR O-ADR
/ O-ADR O-ADR
715 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
two O-ADR O-ADR
deaths B-ADR B-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
cerebrovascular B-ADR B-ADR
accident I-ADR I-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
EDARBI O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
transaminase I-ADR I-ADR
levels I-ADR I-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
units O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
units O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
take O-ADR O-ADR
DUAVEE O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
test O-ADR O-ADR
is O-ADR O-ADR
positive O-ADR O-ADR
and O-ADR O-ADR
talk O-ADR O-ADR
to O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
discernible O-ADR O-ADR
pattern O-ADR O-ADR
between O-ADR O-ADR
death B-ADR B-ADR
and O-ADR O-ADR
sputum O-ADR O-ADR
culture O-ADR O-ADR
conversion O-ADR O-ADR
, O-ADR O-ADR
relapse O-ADR O-ADR
, O-ADR O-ADR
sensitivity O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
used O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
tuberculosis O-ADR O-ADR
, O-ADR O-ADR
HIV O-ADR O-ADR
status O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
disease O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
were O-ADR O-ADR
4 O-ADR O-ADR
suicides B-ADR B-ADR
in O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
but O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
is O-ADR O-ADR
too O-ADR O-ADR
small O-ADR O-ADR
to O-ADR O-ADR
allow O-ADR O-ADR
any O-ADR O-ADR
conclusion O-ADR O-ADR
about O-ADR O-ADR
drug O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
suicide B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patient O-ADR O-ADR
recovered O-ADR O-ADR
fully O-ADR O-ADR
following O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
cysts I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
XALKORI O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
chemotherapy O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
hemorrhage B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
antiplatelet O-ADR O-ADR
or O-ADR O-ADR
anticoagulant O-ADR O-ADR
therapies O-ADR O-ADR
. O-ADR O-ADR
Evaluation O-ADR O-ADR
of O-ADR O-ADR
airway O-ADR O-ADR
patency O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Vimizim O-ADR O-ADR
. O-ADR O-ADR
NESINA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
without O-ADR O-ADR
another O-ADR O-ADR
explanation O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
liver O-ADR O-ADR
test O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
syncope B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
chemotherapy O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
nephrotic O-ADR O-ADR
syndrome O-ADR O-ADR
. O-ADR O-ADR
Administer O-ADR O-ADR
systemic O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
corticosteroids O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
recurring O-ADR O-ADR
immune O-ADR O-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
good O-ADR O-ADR
oral O-ADR O-ADR
hygiene O-ADR O-ADR
practices O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
arms O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
56 O-ADR O-ADR
years O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
and O-ADR O-ADR
53 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
. O-ADR O-ADR
Infliximab O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
62 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
immune B-ADR B-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
enterocolitis I-ADR I-ADR
following O-ADR O-ADR
inadequate O-ADR O-ADR
response O-ADR O-ADR
to O-ADR O-ADR
corticosteroids O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
association O-ADR O-ADR
was O-ADR O-ADR
seen O-ADR O-ADR
between O-ADR O-ADR
antibody O-ADR O-ADR
development O-ADR O-ADR
and O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Avoidance O-ADR O-ADR
of O-ADR O-ADR
Contact O-ADR O-ADR
Lenses O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
wear O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
have O-ADR O-ADR
signs O-ADR O-ADR
or O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
bacterial O-ADR O-ADR
conjunctivitis O-ADR O-ADR
or O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
Besivance O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
dose O-ADR O-ADR
related O-ADR O-ADR
( O-ADR O-ADR
especially O-ADR O-ADR
those O-ADR O-ADR
classified O-ADR O-ADR
as O-ADR O-ADR
psychiatric O-ADR O-ADR
and O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
symptoms O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
confusional B-ADR B-ADR
state I-ADR I-ADR
, O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
abnormal B-ADR B-ADR
coordination I-ADR I-ADR
, O-ADR O-ADR
memory B-ADR B-ADR
impairment I-ADR I-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
gait B-ADR B-ADR
disturbance I-ADR I-ADR
, O-ADR O-ADR
aphasia B-ADR B-ADR
, O-ADR O-ADR
balance B-ADR B-ADR
disorder I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
dysuria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
chromaturia B-ADR B-ADR
. O-ADR O-ADR
Measure O-ADR O-ADR
serum O-ADR O-ADR
transaminases O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
AST O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
levels O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ZYTIGA O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
two O-ADR O-ADR
weeks O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
three O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
monthly O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
Management O-ADR O-ADR
of O-ADR O-ADR
hyperammonemia O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
NAGS O-ADR O-ADR
deficiency O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
done O-ADR O-ADR
in O-ADR O-ADR
coordination O-ADR O-ADR
with O-ADR O-ADR
medical O-ADR O-ADR
personnel O-ADR O-ADR
experienced O-ADR O-ADR
in O-ADR O-ADR
metabolic O-ADR O-ADR
disorders O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
events O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
ONFI O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
withdrawn O-ADR O-ADR
gradually O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
precipitating O-ADR O-ADR
seizures O-ADR O-ADR
, O-ADR O-ADR
seizure O-ADR O-ADR
exacerbation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
status O-ADR O-ADR
epilepticus O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Headache O-ADR O-ADR
If O-ADR O-ADR
a O-ADR O-ADR
woman O-ADR O-ADR
taking O-ADR O-ADR
Natazia O-ADR O-ADR
develops O-ADR O-ADR
new O-ADR O-ADR
headaches B-ADR O-ADR
that I-ADR O-ADR
are I-ADR O-ADR
recurrent I-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
evaluate O-ADR O-ADR
the O-ADR O-ADR
cause O-ADR O-ADR
and O-ADR O-ADR
discontinue O-ADR O-ADR
Natazia O-ADR O-ADR
if O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Disease O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Immune O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Severe O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions O-ADR I-ADR
including O-ADR O-ADR
DRESS B-ADR B-ADR
and O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
hepatic B-ADR B-ADR
failure I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
from O-ADR O-ADR
ventricular B-ADR B-ADR
fibrillation I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
another O-ADR O-ADR
monotherapy O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
with O-ADR O-ADR
Beleodaq O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
convulsive O-ADR O-ADR
disorders O-ADR O-ADR
, O-ADR O-ADR
thyrotoxicosis O-ADR O-ADR
, O-ADR O-ADR
diabetes O-ADR O-ADR
mellitus O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ketoacidosis O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
genital O-ADR O-ADR
mycotic O-ADR O-ADR
infections O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
develop O-ADR O-ADR
genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
other O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
flushing B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
included O-ADR O-ADR
edema B-ADR B-ADR
peripheral I-ADR I-ADR
( O-ADR O-ADR
mostly O-ADR O-ADR
swelling B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
injected I-ADR I-ADR
hand I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
contusion B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
the I-ADR I-ADR
treated I-ADR I-ADR
extremity I-ADR I-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
Bleeding B-ADR B-ADR
Events O-ADR O-ADR
in O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
MEDY O-ADR O-ADR
Treated O-ADR O-ADR
Patients O-ADR O-ADR
Note O-ADR O-ADR
: O-ADR O-ADR
MBE B-ADR B-ADR
can O-ADR O-ADR
belong O-ADR O-ADR
to O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
one O-ADR O-ADR
criterion O-ADR O-ADR
. O-ADR O-ADR
Promptly O-ADR O-ADR
measure O-ADR O-ADR
serum O-ADR O-ADR
total O-ADR O-ADR
bilirubin O-ADR O-ADR
, O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ALT O-ADR O-ADR
if O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
or O-ADR O-ADR
signs O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
hepatotoxicity O-ADR O-ADR
develop O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
FANAPT O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
modest O-ADR O-ADR
levels O-ADR O-ADR
of O-ADR O-ADR
prolactin B-ADR B-ADR
elevation I-ADR I-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
greater O-ADR O-ADR
prolactin B-ADR B-ADR
elevations I-ADR I-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
some O-ADR O-ADR
other O-ADR O-ADR
antipsychotic O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
was O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
when O-ADR O-ADR
FARXIGA O-ADR O-ADR
was O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Possible O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
include O-ADR O-ADR
preexisting O-ADR O-ADR
low O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
WBC O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
induced O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
. O-ADR O-ADR
Further O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
available O-ADR O-ADR
at O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
XIAFLEXREMS O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
or O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
877 O-ADR O-ADR
- O-ADR O-ADR
313 O-ADR O-ADR
- O-ADR O-ADR
1235 O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
patient O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
previous O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
XIAFLEX O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
To O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
contamination O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
touch O-ADR O-ADR
dropper O-ADR O-ADR
tip O-ADR O-ADR
to O-ADR O-ADR
any O-ADR O-ADR
surface O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
Trial O-ADR O-ADR
6 O-ADR O-ADR
were O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
G551D O-ADR O-ADR
, O-ADR O-ADR
G1244E O-ADR O-ADR
, O-ADR O-ADR
G1349D O-ADR O-ADR
, O-ADR O-ADR
G178R O-ADR O-ADR
, O-ADR O-ADR
G551S O-ADR O-ADR
, O-ADR O-ADR
G970R O-ADR O-ADR
, O-ADR O-ADR
S1251N O-ADR O-ADR
, O-ADR O-ADR
S1255P O-ADR O-ADR
, O-ADR O-ADR
S549N O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
S549R O-ADR O-ADR
mutation O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
CFTR O-ADR O-ADR
gene O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
frequently O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
neurological O-ADR O-ADR
impairment O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
numbness O-ADR O-ADR
or O-ADR O-ADR
weakness O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
legs O-ADR O-ADR
, O-ADR O-ADR
bowel O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
bladder O-ADR O-ADR
dysfunction O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Local B-ADR B-ADR
cystic I-ADR I-ADR
invasion I-ADR I-ADR
beyond I-ADR I-ADR
the I-ADR I-ADR
kidney I-ADR I-ADR
occurred O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
with O-ADR O-ADR
imaging O-ADR O-ADR
characteristics O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
abscess B-ADR B-ADR
formation O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
SIRTURO O-ADR O-ADR
and O-ADR O-ADR
all O-ADR O-ADR
other O-ADR O-ADR
QT O-ADR O-ADR
prolonging O-ADR O-ADR
drugs O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
develops O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Clinically O-ADR O-ADR
significant O-ADR O-ADR
ventricular O-ADR B-ADR
arrhythmia O-ADR I-ADR
* O-ADR O-ADR
A O-ADR O-ADR
QTcF O-ADR B-ADR
interval O-ADR I-ADR
of O-ADR I-ADR
greater O-ADR I-ADR
than O-ADR I-ADR
500 O-ADR I-ADR
ms O-ADR I-ADR
( O-ADR O-ADR
confirmed O-ADR O-ADR
by O-ADR O-ADR
repeat O-ADR O-ADR
ECG O-ADR O-ADR
) O-ADR O-ADR
If O-ADR O-ADR
syncope O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
obtain O-ADR O-ADR
an O-ADR O-ADR
ECG O-ADR O-ADR
to O-ADR O-ADR
detect O-ADR O-ADR
QT O-ADR O-ADR
prolongation O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Drug O-ADR O-ADR
Reaction O-ADR O-ADR
With O-ADR O-ADR
Eosinophilia O-ADR O-ADR
and O-ADR O-ADR
Systemic O-ADR O-ADR
Symptoms O-ADR O-ADR
( O-ADR O-ADR
DRESS O-ADR O-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
Multiorgan O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Drug B-ADR B-ADR
Reaction I-ADR I-ADR
with I-ADR I-ADR
Eosinophilia I-ADR I-ADR
and I-ADR I-ADR
Systemic I-ADR I-ADR
Symptoms I-ADR I-ADR
( O-ADR O-ADR
DRESS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
also O-ADR O-ADR
known O-ADR O-ADR
as O-ADR O-ADR
multiorgan B-ADR B-ADR
hypersensitivity I-ADR I-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
gabapentin O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Infections B-ADR B-ADR
: O-ADR O-ADR
GILENYA O-ADR O-ADR
may O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
experienced O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
withdrawal O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
no O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
Findings O-ADR O-ADR
: O-ADR O-ADR
Oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
oral B-ADR B-ADR
paresthesia I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
directly O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
and O-ADR O-ADR
usually O-ADR O-ADR
resolves O-ADR O-ADR
within O-ADR O-ADR
1 O-ADR O-ADR
hour O-ADR O-ADR
. O-ADR O-ADR
Correct O-ADR O-ADR
volume O-ADR O-ADR
or O-ADR O-ADR
salt O-ADR O-ADR
depletion O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
Edarbi O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
start O-ADR O-ADR
treatment O-ADR O-ADR
at O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Postmenopausal O-ADR B-ADR
osteoporosis O-ADR I-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
hypercholesterolemia B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cystitis B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
XEOMIN O-ADR O-ADR
with O-ADR O-ADR
glabellar O-ADR O-ADR
lines O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
GBCA O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
NSF B-ADR B-ADR
risk O-ADR O-ADR
appears O-ADR O-ADR
highest O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
, O-ADR O-ADR
severe O-ADR O-ADR
kidney O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
GFR O-ADR O-ADR
< O-ADR O-ADR
30 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
as O-ADR O-ADR
well O-ADR O-ADR
as O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
. O-ADR O-ADR
More O-ADR O-ADR
than O-ADR O-ADR
two O-ADR O-ADR
- O-ADR O-ADR
thirds O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
from O-ADR O-ADR
Asia O-ADR O-ADR
( O-ADR O-ADR
GILOTRIF O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
; O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
72 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
Acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Toviaz O-ADR O-ADR
was O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
were O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
AFINITOR O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Common O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FANAPT O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
: O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nasal B-ADR B-ADR
congestion I-ADR I-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
, O-ADR O-ADR
orthostatic B-ADR B-ADR
hypotension I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
increased I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
transaminase O-ADR O-ADR
elevations O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
dermatitis O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
localized O-ADR O-ADR
rash O-ADR O-ADR
and O-ADR O-ADR
pruritus O-ADR O-ADR
, O-ADR O-ADR
treat O-ADR O-ADR
symptomatically O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Continue O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
leucovorin O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
maintained O-ADR O-ADR
below O-ADR O-ADR
the O-ADR O-ADR
leucovorin O-ADR O-ADR
treatment O-ADR O-ADR
threshold O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
minimum O-ADR O-ADR
of O-ADR O-ADR
3 O-ADR O-ADR
days O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Asthma O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
candidiasis I-ADR I-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
influenza B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
dysphonia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
cough B-ADR B-ADR
. O-ADR O-ADR
Defined O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
overt O-ADR O-ADR
bleeding B-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
a O-ADR O-ADR
decrease B-ADR B-ADR
in I-ADR I-ADR
hemoglobin I-ADR I-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
g O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
transfusion O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
units O-ADR O-ADR
of O-ADR O-ADR
packed O-ADR O-ADR
red O-ADR O-ADR
blood O-ADR O-ADR
cells O-ADR O-ADR
, O-ADR O-ADR
compartment B-ADR B-ADR
syndrome I-ADR I-ADR
or O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcome I-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
administer O-ADR O-ADR
GRANIX O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
allergic O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
filgrastim O-ADR O-ADR
or O-ADR O-ADR
pegfilgrastim O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
TAFINLAR O-ADR O-ADR
for O-ADR O-ADR
fever O-ADR O-ADR
of O-ADR O-ADR
101 O-ADR O-ADR
. O-ADR O-ADR
3oF O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
. O-ADR O-ADR
Thus O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
differentiate O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
profile O-ADR O-ADR
between O-ADR O-ADR
treatments O-ADR O-ADR
is O-ADR O-ADR
limited O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Other O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
occur O-ADR O-ADR
following O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
granulocyte O-ADR O-ADR
colony O-ADR O-ADR
- O-ADR O-ADR
stimulating O-ADR O-ADR
factors O-ADR O-ADR
include O-ADR O-ADR
myalgia B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
Sweet B-ADR B-ADR
' I-ADR I-ADR
s O-ADR O-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
acute B-ADR B-ADR
febrile I-ADR I-ADR
neutrophilic I-ADR I-ADR
dermatosis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
cutaneous B-ADR B-ADR
vasculitis I-ADR I-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Age O-ADR O-ADR
Range O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Placebo O-ADR O-ADR
Difference O-ADR O-ADR
in O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
Suicidality B-ADR B-ADR
per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
Increases O-ADR O-ADR
Compared O-ADR O-ADR
to O-ADR O-ADR
Placebo O-ADR O-ADR
< O-ADR O-ADR
18 O-ADR O-ADR
14 O-ADR O-ADR
additional O-ADR O-ADR
cases O-ADR O-ADR
18 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
5 O-ADR O-ADR
additional O-ADR O-ADR
cases O-ADR O-ADR
Decreases O-ADR O-ADR
Compared O-ADR O-ADR
to O-ADR O-ADR
Placebo O-ADR O-ADR
25 O-ADR O-ADR
to O-ADR O-ADR
64 O-ADR O-ADR
1 O-ADR O-ADR
fewer O-ADR O-ADR
case O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
6 O-ADR O-ADR
fewer O-ADR O-ADR
cases O-ADR O-ADR
No O-ADR O-ADR
suicides B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
pediatric O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Pneumocystis B-ADR B-ADR
jiroveci I-ADR I-ADR
pneumonia I-ADR I-ADR
, O-ADR O-ADR
some O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
fatal B-ADR B-ADR
outcome O-ADR O-ADR
, O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
everolimus O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
osteosarcoma O-ADR O-ADR
were O-ADR O-ADR
eligible O-ADR O-ADR
for O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
plasma O-ADR O-ADR
methotrexate O-ADR O-ADR
concentration O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
50 O-ADR O-ADR
mumol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
at O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
, O-ADR O-ADR
greater O-ADR O-ADR
that O-ADR O-ADR
5 O-ADR O-ADR
mumol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
at O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
2 O-ADR O-ADR
standard O-ADR O-ADR
deviations O-ADR O-ADR
above O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
methotrexate O-ADR O-ADR
elimination O-ADR O-ADR
curve O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
12 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
methotrexate O-ADR O-ADR
administration O-ADR O-ADR
and O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
serum O-ADR O-ADR
creatinine O-ADR O-ADR
above O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trial O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
pruritus I-ADR I-ADR
also O-ADR O-ADR
contributed O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Thirty O-ADR O-ADR
- O-ADR O-ADR
three O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
DIFICID O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
trials O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
AR O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
, O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
New O-ADR O-ADR
Primary O-ADR O-ADR
Malignancies O-ADR O-ADR
New O-ADR O-ADR
primary B-ADR B-ADR
malignancies I-ADR I-ADR
, I-ADR O-ADR
cutaneous I-ADR O-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Ensure O-ADR O-ADR
safe O-ADR O-ADR
handling O-ADR O-ADR
to O-ADR O-ADR
protect O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
health O-ADR O-ADR
care O-ADR O-ADR
workers O-ADR O-ADR
from O-ADR O-ADR
unintentional O-ADR O-ADR
radiation O-ADR O-ADR
exposure O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Infestations O-ADR O-ADR
: O-ADR O-ADR
Cellulitis B-ADR B-ADR
, O-ADR O-ADR
folliculitis B-ADR B-ADR
, O-ADR O-ADR
paronychia B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
pustular I-ADR I-ADR
. O-ADR O-ADR
Among O-ADR O-ADR
299 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
ITP O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
PROMACTA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
arm O-ADR O-ADR
extension O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
pattern O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
results O-ADR O-ADR
suggest O-ADR O-ADR
an O-ADR O-ADR
approximate O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
fold O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
NAION B-ADR B-ADR
within O-ADR O-ADR
5 O-ADR O-ADR
half O-ADR O-ADR
- O-ADR O-ADR
lives O-ADR O-ADR
of O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitor O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
not O-ADR O-ADR
treated O-ADR O-ADR
immediately O-ADR O-ADR
, O-ADR O-ADR
penile O-ADR O-ADR
tissue O-ADR O-ADR
damage O-ADR O-ADR
and O-ADR O-ADR
permanent O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
potency O-ADR O-ADR
could O-ADR O-ADR
result O-ADR O-ADR
. O-ADR O-ADR
Extensive O-ADR O-ADR
brain O-ADR O-ADR
atrophy O-ADR O-ADR
may O-ADR O-ADR
limit O-ADR O-ADR
the O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
distinguish O-ADR O-ADR
grey O-ADR O-ADR
and O-ADR O-ADR
white O-ADR O-ADR
matter O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
Vizamyl O-ADR O-ADR
scan O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
9 O-ADR O-ADR
cycles O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
16 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hemorrhage B-ADR B-ADR
: O-ADR O-ADR
Major O-ADR O-ADR
hemorrhagic B-ADR B-ADR
events I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
risk O-ADR O-ADR
differences O-ADR O-ADR
( O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
placebo O-ADR O-ADR
difference O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
suicidality B-ADR B-ADR
per O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
provided O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
XTANDI O-ADR O-ADR
160 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
treatment O-ADR O-ADR
arm O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
than O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Measurement O-ADR O-ADR
of O-ADR O-ADR
methotrexate O-ADR O-ADR
using O-ADR O-ADR
immunoassays O-ADR O-ADR
is O-ADR O-ADR
unreliable O-ADR O-ADR
for O-ADR O-ADR
samples O-ADR O-ADR
collected O-ADR O-ADR
within O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
following O-ADR O-ADR
VORAXAZE O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
give O-ADR O-ADR
JEVTANA O-ADR O-ADR
if O-ADR O-ADR
neutrophil O-ADR O-ADR
counts O-ADR O-ADR
are O-ADR O-ADR
< O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
500 O-ADR O-ADR
cells O-ADR O-ADR
/ O-ADR O-ADR
mm3 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
2 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Trial O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
for O-ADR O-ADR
48 O-ADR O-ADR
weeks O-ADR O-ADR
, O-ADR O-ADR
while O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
other O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
for O-ADR O-ADR
72 O-ADR O-ADR
weeks O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
injections O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
58 O-ADR O-ADR
mg O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
with O-ADR O-ADR
approximately O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
intervals O-ADR O-ADR
between O-ADR O-ADR
injections O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
finger O-ADR O-ADR
extension O-ADR O-ADR
procedures O-ADR O-ADR
the O-ADR O-ADR
day O-ADR O-ADR
after O-ADR O-ADR
injection O-ADR O-ADR
, O-ADR O-ADR
if O-ADR O-ADR
needed O-ADR O-ADR
, O-ADR O-ADR
to O-ADR O-ADR
facilitate O-ADR O-ADR
disruption O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
cord O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Serious O-ADR O-ADR
Skin O-ADR O-ADR
Toxicity O-ADR O-ADR
Serious O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
[ O-ADR O-ADR
refer O-ADR O-ADR
to O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
trametinib O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
? O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
increased O-ADR O-ADR
transaminase O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
abnormalities O-ADR O-ADR
resolve O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Embryofetal B-ADR B-ADR
toxicity I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
delay O-ADR O-ADR
or O-ADR O-ADR
reduction O-ADR O-ADR
was O-ADR O-ADR
necessary O-ADR O-ADR
in O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
everolimus O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
29 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
examinations O-ADR O-ADR
are O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
initiating O-ADR O-ADR
KALYDECO O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Lactic B-ADR B-ADR
acidosis I-ADR I-ADR
and O-ADR O-ADR
severe O-ADR O-ADR
hepatomegaly B-ADR B-ADR
with O-ADR O-ADR
steatosis B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
nucleoside O-ADR O-ADR
analogs O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
tenofovir O-ADR O-ADR
disoproxil O-ADR O-ADR
fumarate O-ADR O-ADR
( O-ADR O-ADR
DF O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
STRIBILD O-ADR O-ADR
. O-ADR O-ADR
Currently O-ADR O-ADR
available O-ADR O-ADR
data O-ADR O-ADR
are O-ADR O-ADR
inadequate O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
concurrent O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
inhaled O-ADR O-ADR
corticosteroids O-ADR O-ADR
( O-ADR O-ADR
ICS O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
asthma O-ADR O-ADR
control O-ADR O-ADR
drugs O-ADR O-ADR
mitigates O-ADR O-ADR
the O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
from O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
informed O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
acute O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reaction O-ADR O-ADR
and O-ADR O-ADR
be O-ADR O-ADR
instructed O-ADR O-ADR
to O-ADR O-ADR
seek O-ADR O-ADR
immediate O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
should O-ADR O-ADR
a O-ADR O-ADR
reaction O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
proteinuria B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
11 O-ADR O-ADR
/ O-ADR O-ADR
359 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
INLYTA O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
/ O-ADR O-ADR
355 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
receiving O-ADR O-ADR
sorafenib O-ADR O-ADR
[ O-ADR O-ADR
seeAdverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
could O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
If O-ADR O-ADR
paradoxical O-ADR O-ADR
bronchospasm O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
when O-ADR O-ADR
using O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
or O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
significant O-ADR O-ADR
cytopenias O-ADR O-ADR
. O-ADR O-ADR
Pancreatitis B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Male O-ADR B-ADR
Osteoporosis O-ADR I-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Bone O-ADR B-ADR
loss O-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
hormone O-ADR O-ADR
ablation O-ADR O-ADR
for O-ADR O-ADR
cancer O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
822 O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
either O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
or O-ADR O-ADR
raltegravir O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
both O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
dual O-ADR O-ADR
nucleoside O-ADR O-ADR
reverse O-ADR O-ADR
transcriptase O-ADR O-ADR
inhibitor O-ADR O-ADR
( O-ADR O-ADR
NRTI O-ADR O-ADR
) O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
either O-ADR O-ADR
abacavir O-ADR O-ADR
sulfate O-ADR O-ADR
and O-ADR O-ADR
lamivudine O-ADR O-ADR
[ O-ADR O-ADR
EPZICOM O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
emtricitabine O-ADR O-ADR
/ O-ADR O-ADR
tenofovir O-ADR O-ADR
[ O-ADR O-ADR
TRUVADA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
trial O-ADR O-ADR
comparing O-ADR O-ADR
Kyprolis O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
versus O-ADR O-ADR
corticosteroids O-ADR O-ADR
with O-ADR O-ADR
optional O-ADR O-ADR
oral O-ADR O-ADR
cyclophosphamide O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
relapsed O-ADR O-ADR
and O-ADR O-ADR
refractory O-ADR O-ADR
multiple O-ADR O-ADR
myeloma O-ADR O-ADR
, O-ADR O-ADR
mortality B-ADR B-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Kyprolis O-ADR O-ADR
in O-ADR O-ADR
comparison O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
arm O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
subgroup O-ADR O-ADR
of O-ADR O-ADR
48 O-ADR O-ADR
patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
adult O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
reported O-ADR O-ADR
EPS B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events I-ADR I-ADR
, O-ADR O-ADR
excluding O-ADR O-ADR
events O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
akathisia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
events O-ADR O-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
versus O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
months O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
recent O-ADR O-ADR
CBC O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Spectrum O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
, O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
292 O-ADR O-ADR
- O-ADR O-ADR
9617 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
Beleodaq O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
renal B-ADR B-ADR
cysts I-ADR I-ADR
. O-ADR O-ADR
If O-ADR O-ADR
traumatic O-ADR O-ADR
puncture O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
delay O-ADR O-ADR
the O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
for O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
3092 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
3085 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
comparator O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
3262 O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
TECFIDERA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
studied O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
lymphocyte O-ADR O-ADR
counts O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
laryngeal B-ADR B-ADR
edema I-ADR I-ADR
can O-ADR O-ADR
be O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
34 O-ADR O-ADR
patients O-ADR O-ADR
enrolled O-ADR O-ADR
, O-ADR O-ADR
32 O-ADR O-ADR
had O-ADR O-ADR
the O-ADR O-ADR
G551D O-ADR O-ADR
mutation O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
had O-ADR O-ADR
the O-ADR O-ADR
S549N O-ADR O-ADR
mutation O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
COMETRIQ O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
intolerable O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
PPES O-ADR O-ADR
or O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
PPES O-ADR O-ADR
until O-ADR O-ADR
improvement O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
1 O-ADR O-ADR
; O-ADR O-ADR
resume O-ADR O-ADR
COMETRIQ O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
infections B-ADR B-ADR
consisted O-ADR O-ADR
primarily O-ADR O-ADR
of O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
herpes B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
lower B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
The O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
by O-ADR O-ADR
study O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
is O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
estimated O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
60 O-ADR O-ADR
ml O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
95 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
TRULICITY O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
Resume O-ADR O-ADR
COMETRIQ O-ADR O-ADR
therapy O-ADR O-ADR
after O-ADR O-ADR
surgery O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
clinical O-ADR O-ADR
judgment O-ADR O-ADR
of O-ADR O-ADR
adequate O-ADR O-ADR
wound O-ADR O-ADR
healing O-ADR O-ADR
. O-ADR O-ADR
Laboratory O-ADR O-ADR
Tests O-ADR O-ADR
Increase O-ADR B-ADR
in O-ADR I-ADR
Hematocrit O-ADR I-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
13 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
in I-ADR I-ADR
mean I-ADR I-ADR
hematocrit I-ADR I-ADR
values I-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
FARXIGA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
starting O-ADR O-ADR
at O-ADR O-ADR
Week O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
continuing O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
Week O-ADR O-ADR
16 O-ADR O-ADR
, O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
maximum O-ADR O-ADR
mean O-ADR O-ADR
difference O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
represent O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
77 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
FIRAZYR O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
SC O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
75 O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
using O-ADR O-ADR
ZYKADIA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
agents O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
bradycardia O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
dihydropyridine O-ADR O-ADR
calcium O-ADR O-ADR
channel O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
clonidine O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
digoxin O-ADR O-ADR
) O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
extent O-ADR O-ADR
possible O-ADR O-ADR
. O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
rhabdomyolysis B-ADR B-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Fatal B-ADR B-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
information O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
interpretation O-ADR O-ADR
of O-ADR O-ADR
Neuraceq O-ADR O-ADR
images O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
errors O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Withdrawal O-ADR O-ADR
Symptoms O-ADR O-ADR
Abrupt O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ONFI O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
avoided O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Hyperammonemia O-ADR O-ADR
Any O-ADR O-ADR
episode O-ADR O-ADR
of O-ADR O-ADR
acute O-ADR O-ADR
symptomatic O-ADR O-ADR
hyperammonemia O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
emergency O-ADR O-ADR
. O-ADR O-ADR
Data O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
death B-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
by O-ADR O-ADR
LABA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
all O-ADR O-ADR
three O-ADR O-ADR
studies O-ADR O-ADR
a O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
Cycle O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
breast O-ADR O-ADR
cancer O-ADR O-ADR
study O-ADR O-ADR
only O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
US O-ADR O-ADR
- O-ADR O-ADR
approved O-ADR O-ADR
filgrastim O-ADR O-ADR
product O-ADR O-ADR
were O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
controls O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
( O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
lymphopenia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
anemia B-ADR B-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
blood O-ADR O-ADR
counts O-ADR O-ADR
and O-ADR O-ADR
modify O-ADR O-ADR
dosage O-ADR O-ADR
for O-ADR O-ADR
hematologic O-ADR O-ADR
toxicities O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
were O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
moderate O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Reversible O-ADR O-ADR
Posterior O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
Syndrome O-ADR O-ADR
Reversible B-ADR B-ADR
Posterior I-ADR I-ADR
Leukoencephalopathy I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
RPLS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
syndrome O-ADR O-ADR
of O-ADR O-ADR
subcortical B-ADR B-ADR
vasogenic I-ADR I-ADR
edema I-ADR I-ADR
diagnosed O-ADR O-ADR
by O-ADR O-ADR
characteristic O-ADR O-ADR
finding O-ADR O-ADR
on O-ADR O-ADR
MRI O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
( O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
bleeding O-ADR O-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Abnormal O-ADR O-ADR
Coagulation O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
XIAFLEX O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Dupuytren O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
contracture O-ADR O-ADR
( O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
38 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
developed O-ADR O-ADR
an O-ADR O-ADR
ecchymosis O-ADR O-ADR
/ O-ADR O-ADR
contusion O-ADR O-ADR
or O-ADR O-ADR
an O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hemorrhage I-ADR I-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
with O-ADR O-ADR
Concomitant O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
Insulin O-ADR O-ADR
and O-ADR O-ADR
Insulin O-ADR O-ADR
Secretagogues O-ADR O-ADR
Insulin O-ADR O-ADR
and O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
are O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
cause O-ADR O-ADR
hypoglycemia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
COMETRIQ O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
330 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
progressive O-ADR O-ADR
metastatic O-ADR O-ADR
medullary O-ADR O-ADR
thyroid O-ADR O-ADR
cancer O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
140 O-ADR O-ADR
mg O-ADR O-ADR
COMETRIQ O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
214 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
109 O-ADR O-ADR
) O-ADR O-ADR
administered O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
or O-ADR O-ADR
intolerable O-ADR O-ADR
toxicity O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
randomized O-ADR O-ADR
, O-ADR O-ADR
doubleblind O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
DRESS O-ADR O-ADR
reaction O-ADR O-ADR
with O-ADR O-ADR
either O-ADR O-ADR
oxcarbazepine O-ADR O-ADR
or O-ADR O-ADR
APTIOM O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
pulmonary O-ADR O-ADR
symptoms O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
ILD O-ADR O-ADR
/ O-ADR O-ADR
pneumonitis O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
pancreatitis O-ADR O-ADR
is O-ADR O-ADR
suspected O-ADR O-ADR
, O-ADR O-ADR
NESINA O-ADR O-ADR
should O-ADR O-ADR
promptly O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
management O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Wyeth O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
subsidiary O-ADR O-ADR
of O-ADR O-ADR
Pfizer O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
438 O-ADR O-ADR
- O-ADR O-ADR
1985 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Remove O-ADR O-ADR
contact O-ADR O-ADR
lenses O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
instillation O-ADR O-ADR
of O-ADR O-ADR
BEPREVE O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
metabolic B-ADR B-ADR
changes I-ADR I-ADR
include O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
dyslipidemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
. O-ADR O-ADR
This O-ADR O-ADR
case O-ADR O-ADR
represented O-ADR O-ADR
1 O-ADR O-ADR
out O-ADR O-ADR
of O-ADR O-ADR
1209 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
BOSULIF O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
start O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
active O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XTANDI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Similar O-ADR O-ADR
results O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
anticipated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Edarbi O-ADR O-ADR
[ O-ADR O-ADR
seeDrug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
andClinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
were O-ADR O-ADR
: O-ADR O-ADR
facial B-ADR B-ADR
paresis I-ADR I-ADR
( O-ADR O-ADR
brow B-ADR B-ADR
ptosis I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
disorder I-ADR I-ADR
( O-ADR O-ADR
elevation B-ADR B-ADR
of I-ADR I-ADR
eyebrow I-ADR I-ADR
) O-ADR O-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
decrease I-ADR I-ADR
during O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
period O-ADR O-ADR
is O-ADR O-ADR
more O-ADR O-ADR
pronounced O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
decrease O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
6 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
6Includes O-ADR O-ADR
the O-ADR O-ADR
preferred O-ADR O-ADR
terms O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
sedation B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hypersomnia B-ADR B-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
INLYTA O-ADR O-ADR
if O-ADR O-ADR
hypertension O-ADR O-ADR
is O-ADR O-ADR
severe O-ADR O-ADR
and O-ADR O-ADR
persistent O-ADR O-ADR
despite O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
of O-ADR O-ADR
INLYTA O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
discontinuation O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
if O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
hypertensive O-ADR O-ADR
crisis O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
these O-ADR O-ADR
symptoms O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
at O-ADR O-ADR
low O-ADR O-ADR
doses O-ADR O-ADR
, O-ADR O-ADR
they O-ADR O-ADR
occur O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
greater O-ADR O-ADR
severity O-ADR O-ADR
with O-ADR O-ADR
high O-ADR O-ADR
potency O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
first O-ADR O-ADR
generation O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
information O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
sections O-ADR O-ADR
was O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
4 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
flexible O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
daily O-ADR O-ADR
doses O-ADR O-ADR
within O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
to O-ADR O-ADR
24 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
874 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
should O-ADR O-ADR
have O-ADR O-ADR
their O-ADR O-ADR
weight O-ADR O-ADR
monitored O-ADR O-ADR
regularly O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
malignancies B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
non B-ADR O-ADR
- O-ADR O-ADR
melanoma O-ADR O-ADR
skin I-ADR O-ADR
cancers I-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Magnetic O-ADR O-ADR
resonance O-ADR O-ADR
imaging O-ADR O-ADR
is O-ADR O-ADR
necessary O-ADR O-ADR
to O-ADR O-ADR
confirm O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
RPLS O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Somnolence O-ADR O-ADR
/ O-ADR O-ADR
Sedation O-ADR O-ADR
and O-ADR O-ADR
Dizziness O-ADR O-ADR
HORIZANT O-ADR O-ADR
causes O-ADR O-ADR
somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Tables O-ADR O-ADR
4 O-ADR O-ADR
and O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Stop O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
scheduled O-ADR O-ADR
surgery O-ADR O-ADR
. O-ADR O-ADR
Diarrhea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
were O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
overall O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
bone B-ADR B-ADR
pain I-ADR I-ADR
in O-ADR O-ADR
Cycle O-ADR O-ADR
1 O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
was O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
GRANIX O-ADR O-ADR
, O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
US O-ADR O-ADR
- O-ADR O-ADR
approved O-ADR O-ADR
filgrastim O-ADR O-ADR
product O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
14 O-ADR O-ADR
Exacerbation O-ADR O-ADR
of O-ADR O-ADR
Other O-ADR O-ADR
Conditions O-ADR O-ADR
Estrogens O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
an O-ADR O-ADR
exacerbation O-ADR B-ADR
of O-ADR I-ADR
asthma O-ADR I-ADR
, O-ADR O-ADR
diabetes O-ADR B-ADR
mellitus O-ADR I-ADR
, O-ADR O-ADR
epilepsy O-ADR B-ADR
, O-ADR O-ADR
migraine O-ADR B-ADR
or O-ADR O-ADR
porphyria O-ADR B-ADR
, O-ADR O-ADR
systemic O-ADR B-ADR
lupus O-ADR I-ADR
erythematosus O-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hepatic O-ADR B-ADR
hemangiomas O-ADR I-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
these O-ADR O-ADR
conditions O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
of O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
NULOJIX O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
Atypical B-ADR B-ADR
femoral I-ADR I-ADR
fractures I-ADR I-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
minimal O-ADR O-ADR
or O-ADR O-ADR
no O-ADR O-ADR
trauma O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
affected O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Other O-ADR O-ADR
Serious O-ADR O-ADR
Infections O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
immunosuppressants O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
developing O-ADR O-ADR
protozoal B-ADR B-ADR
infections I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
opportunistic B-ADR B-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neutropenia B-ADR B-ADR
- O-ADR O-ADR
The O-ADR O-ADR
addition O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
to O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
worsening B-ADR B-ADR
of I-ADR I-ADR
neutropenia I-ADR I-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
therapy O-ADR O-ADR
alone O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
children O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
PDE5 O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
only O-ADR O-ADR
when O-ADR O-ADR
the O-ADR O-ADR
anticipated O-ADR O-ADR
benefits O-ADR O-ADR
outweigh O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
. O-ADR O-ADR
Rates O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
predict O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
when O-ADR O-ADR
CIMZIA O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
broader O-ADR O-ADR
patient O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
TB B-ADR B-ADR
cases O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
countries O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
high O-ADR O-ADR
incidence O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
TB O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Vizamyl O-ADR O-ADR
scan O-ADR O-ADR
results O-ADR O-ADR
are O-ADR O-ADR
indicative O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
brain O-ADR O-ADR
neuritic O-ADR O-ADR
amyloid O-ADR O-ADR
plaque O-ADR O-ADR
content O-ADR O-ADR
only O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
time O-ADR O-ADR
of O-ADR O-ADR
image O-ADR O-ADR
acquisition O-ADR O-ADR
and O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
scan O-ADR O-ADR
result O-ADR O-ADR
does O-ADR O-ADR
not O-ADR O-ADR
preclude O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
brain O-ADR O-ADR
amyloid O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
future O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Ocular B-ADR B-ADR
Toxicities I-ADR I-ADR
: O-ADR O-ADR
Perform O-ADR O-ADR
ophthalmologic O-ADR O-ADR
evaluation O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
visual O-ADR O-ADR
disturbances O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
trametinib O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
, O-ADR O-ADR
are O-ADR O-ADR
not O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Full O-ADR O-ADR
Prescribing O-ADR O-ADR
Information O-ADR O-ADR
for O-ADR O-ADR
TAFINLAR O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Retinal B-ADR B-ADR
vein I-ADR I-ADR
occlusion I-ADR I-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
* O-ADR O-ADR
New O-ADR O-ADR
primary B-ADR B-ADR
malignancies I-ADR I-ADR
, I-ADR I-ADR
cutaneous I-ADR I-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Cardiovascular O-ADR O-ADR
Events O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
randomized O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
cardiovascular B-ADR B-ADR
thromboembolic I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
cardiovascular B-ADR B-ADR
deaths I-ADR I-ADR
, O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
myocardial B-ADR B-ADR
infarctions I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
fatal O-ADR O-ADR
strokes B-ADR B-ADR
) O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ULORIC O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
74 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
Y O-ADR O-ADR
[ O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
Confidence O-ADR O-ADR
Interval O-ADR O-ADR
( O-ADR O-ADR
CI O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
36 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
37 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
allopurinol O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
60 O-ADR O-ADR
per O-ADR O-ADR
100 O-ADR O-ADR
P O-ADR O-ADR
- O-ADR O-ADR
Y O-ADR O-ADR
[ O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
16 O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
53 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
dental O-ADR O-ADR
examination O-ADR O-ADR
with O-ADR O-ADR
appropriate O-ADR O-ADR
preventive O-ADR O-ADR
dentistry O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
ONJ O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
invasive O-ADR O-ADR
dental O-ADR O-ADR
procedures O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections B-ADR B-ADR
was O-ADR O-ADR
also O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TNF O-ADR O-ADR
blockers O-ADR O-ADR
with O-ADR O-ADR
abatacept O-ADR O-ADR
and O-ADR O-ADR
rituximab O-ADR O-ADR
. O-ADR O-ADR
AMPYRA O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
seizures O-ADR O-ADR
or O-ADR O-ADR
with O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
epileptiform O-ADR O-ADR
activity O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
EEG O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
from O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
randomized O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
oncology O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
angioedema B-ADR B-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
everolimus O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
ACE O-ADR O-ADR
inhibitor O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
control O-ADR O-ADR
arm O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
ACE O-ADR O-ADR
inhibitor O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
did O-ADR O-ADR
so O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
( O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
seroconversion O-ADR O-ADR
was O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
Tremor B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
antibody O-ADR O-ADR
formation O-ADR O-ADR
is O-ADR O-ADR
highly O-ADR O-ADR
dependent O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
sensitivity O-ADR O-ADR
and O-ADR O-ADR
specificity O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
assay O-ADR O-ADR
. O-ADR O-ADR
Limited O-ADR O-ADR
data O-ADR O-ADR
suggest O-ADR O-ADR
that O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
multiple O-ADR O-ADR
drug O-ADR O-ADR
allergies O-ADR O-ADR
or O-ADR O-ADR
significant O-ADR O-ADR
hypersensitivity O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
Tell O-ADR O-ADR
your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
have O-ADR O-ADR
any O-ADR O-ADR
side O-ADR O-ADR
effects O-ADR O-ADR
that O-ADR O-ADR
bother O-ADR O-ADR
you O-ADR O-ADR
or O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
go O-ADR O-ADR
away O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
severe O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
is O-ADR O-ADR
exceeded O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
reduced O-ADR O-ADR
to O-ADR O-ADR
600 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
1 O-ADR O-ADR
week O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
withdrawal O-ADR O-ADR
seizure O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
bipolar O-ADR O-ADR
adult O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
transaminase I-ADR I-ADR
levels I-ADR I-ADR
for O-ADR O-ADR
SAPHRIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
units O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
of O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
units O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Screen O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
acute O-ADR O-ADR
kidney O-ADR O-ADR
injury O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
conditions O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
reduce O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
of O-ADR O-ADR
physiological O-ADR O-ADR
diurnal O-ADR O-ADR
variation O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
second O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
heart B-ADR B-ADR
rate I-ADR I-ADR
decrease I-ADR I-ADR
within O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Headache B-ADR B-ADR
was O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
, O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
57 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
followed O-ADR O-ADR
by O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
hematoma I-ADR I-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
STRIBILD O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
if O-ADR O-ADR
estimated O-ADR O-ADR
creatinine O-ADR O-ADR
clearance O-ADR O-ADR
declines O-ADR O-ADR
below O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
as O-ADR O-ADR
dose O-ADR O-ADR
interval O-ADR O-ADR
adjustment O-ADR O-ADR
required O-ADR O-ADR
for O-ADR O-ADR
emtricitabine O-ADR O-ADR
and O-ADR O-ADR
tenofovir O-ADR O-ADR
DF O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
achieved O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
combination O-ADR O-ADR
tablet O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
546 O-ADR O-ADR
patients O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
population O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
ALT B-ADR B-ADR
elevation I-ADR I-ADR
was O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
AST B-ADR B-ADR
elevation I-ADR I-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
Renal O-ADR O-ADR
Cysts O-ADR O-ADR
Renal B-ADR B-ADR
cysts I-ADR I-ADR
were O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
50 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
1669 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
Interrupt O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
BLINCYTO O-ADR O-ADR
as O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
Additional O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Observed O-ADR O-ADR
during O-ADR O-ADR
All O-ADR O-ADR
Phase O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Following O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
list O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
by O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
POTIGA O-ADR O-ADR
during O-ADR O-ADR
all O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
: O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
nystagmus B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
muscle B-ADR B-ADR
spasms I-ADR I-ADR
, O-ADR O-ADR
alopecia B-ADR B-ADR
, O-ADR O-ADR
nephrolithiasis B-ADR B-ADR
, O-ADR O-ADR
syncope B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
euphoric B-ADR B-ADR
mood I-ADR I-ADR
, O-ADR O-ADR
renal B-ADR B-ADR
colic I-ADR I-ADR
, O-ADR O-ADR
coma B-ADR B-ADR
, O-ADR O-ADR
encephalopathy B-ADR B-ADR
. O-ADR O-ADR
TRULICITY O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
heart I-ADR I-ADR
rate I-ADR I-ADR
) O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
beats O-ADR O-ADR
per O-ADR O-ADR
minute O-ADR O-ADR
( O-ADR O-ADR
bpm O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Baseline O-ADR O-ADR
estimated O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
was O-ADR O-ADR
normal O-ADR O-ADR
or O-ADR O-ADR
mildly O-ADR O-ADR
impaired O-ADR O-ADR
( O-ADR O-ADR
eGFR O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
60mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
96 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
study O-ADR O-ADR
populations O-ADR O-ADR
. O-ADR O-ADR
Immunogenicity O-ADR O-ADR
Patients O-ADR O-ADR
were O-ADR O-ADR
tested O-ADR O-ADR
at O-ADR O-ADR
multiple O-ADR O-ADR
time O-ADR O-ADR
points O-ADR O-ADR
for O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
certolizumab O-ADR O-ADR
pegol O-ADR O-ADR
during O-ADR O-ADR
Studies O-ADR O-ADR
CD1 O-ADR O-ADR
and O-ADR O-ADR
CD2 O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
increase B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
women O-ADR O-ADR
taking O-ADR O-ADR
COCs O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
this O-ADR O-ADR
increase O-ADR O-ADR
is O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
in O-ADR O-ADR
older O-ADR O-ADR
women O-ADR O-ADR
and O-ADR O-ADR
with O-ADR O-ADR
extended O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
use O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Bladder O-ADR O-ADR
Cancer O-ADR O-ADR
Across O-ADR O-ADR
22 O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
newly O-ADR O-ADR
diagnosed O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
bladder B-ADR B-ADR
cancer I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
/ O-ADR O-ADR
6045 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
17 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
3512 O-ADR O-ADR
patient O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
03 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
/ O-ADR O-ADR
comparator O-ADR O-ADR
. O-ADR O-ADR
Dosage O-ADR O-ADR
Modifications O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
dosage O-ADR O-ADR
adjustments O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
12 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Beleodaq O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Dyspepsia B-ADR B-ADR
( O-ADR O-ADR
including O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
upper I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
epigastric B-ADR B-ADR
discomfort I-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
PRADAXA O-ADR O-ADR
in O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
warfarin O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
gastritis O-ADR B-ADR
- O-ADR O-ADR
like O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
gastritis B-ADR B-ADR
, O-ADR O-ADR
GERD B-ADR B-ADR
, O-ADR O-ADR
esophagitis B-ADR B-ADR
, O-ADR O-ADR
erosive B-ADR B-ADR
gastritis I-ADR I-ADR
and O-ADR O-ADR
gastric B-ADR B-ADR
hemorrhage I-ADR I-ADR
) O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
trial O-ADR O-ADR
adequate O-ADR O-ADR
to O-ADR O-ADR
determine O-ADR O-ADR
whether O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR O-ADR
is O-ADR O-ADR
increased O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
bladder O-ADR O-ADR
cancer O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
glycemic O-ADR O-ADR
control O-ADR O-ADR
versus O-ADR O-ADR
unknown O-ADR O-ADR
risks O-ADR O-ADR
for O-ADR O-ADR
cancer O-ADR O-ADR
recurrence O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
small O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
women O-ADR O-ADR
will O-ADR O-ADR
have O-ADR O-ADR
adverse B-ADR B-ADR
lipid I-ADR I-ADR
changes I-ADR I-ADR
while O-ADR O-ADR
on O-ADR O-ADR
COCs O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
women O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
and O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
Zydelig O-ADR O-ADR
. O-ADR O-ADR
ECG O-ADR O-ADR
monitoring O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
if O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
congestive O-ADR O-ADR
heart O-ADR O-ADR
failure O-ADR O-ADR
, O-ADR O-ADR
bradyarrhythmias O-ADR O-ADR
, O-ADR O-ADR
drugs O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
Class O-ADR O-ADR
Ia O-ADR O-ADR
and O-ADR O-ADR
III O-ADR O-ADR
antiarrhythmics O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
electrolyte O-ADR O-ADR
abnormalities O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
HALAVEN O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
peripheral O-ADR O-ADR
neuropathy O-ADR O-ADR
until O-ADR O-ADR
resolution O-ADR O-ADR
to O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
less O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
during O-ADR O-ADR
pregnancy O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
becomes O-ADR O-ADR
pregnant O-ADR O-ADR
while O-ADR O-ADR
taking O-ADR O-ADR
this O-ADR O-ADR
drug O-ADR O-ADR
, O-ADR O-ADR
she O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
apprised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
hazard O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
fetus O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Neutropenia O-ADR O-ADR
Treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
neutropenia B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
31 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Zydelig O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Grade O-ADR O-ADR
2 O-ADR O-ADR
or O-ADR O-ADR
higher O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities B-ADR O-ADR
that I-ADR O-ADR
represent I-ADR O-ADR
a I-ADR O-ADR
worsening I-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
of I-ADR I-ADR
AST I-ADR I-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
27 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
25 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
as O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Low O-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR O-ADR
Cholesterol O-ADR O-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
fasting O-ADR O-ADR
serum O-ADR O-ADR
glucose O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
ZYKADIA O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
thereafter O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Co O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
corticosteroid O-ADR O-ADR
suppresses O-ADR O-ADR
adrenocorticotropic O-ADR O-ADR
hormone O-ADR O-ADR
( O-ADR O-ADR
ACTH O-ADR O-ADR
) O-ADR O-ADR
drive O-ADR O-ADR
, O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
COCs O-ADR O-ADR
may O-ADR O-ADR
decrease B-ADR B-ADR
glucose I-ADR I-ADR
tolerance I-ADR I-ADR
in O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
fashion O-ADR O-ADR
. O-ADR O-ADR
When O-ADR O-ADR
plasma O-ADR O-ADR
ammonia O-ADR O-ADR
level O-ADR O-ADR
is O-ADR O-ADR
normalized O-ADR O-ADR
, O-ADR O-ADR
dietary O-ADR O-ADR
protein O-ADR O-ADR
intake O-ADR O-ADR
can O-ADR O-ADR
usually O-ADR O-ADR
be O-ADR O-ADR
reintroduced O-ADR O-ADR
. O-ADR O-ADR
Reported O-ADR O-ADR
infections O-ADR B-ADR
include O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Active B-ADR B-ADR
tuberculosis I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
reactivation B-ADR B-ADR
of I-ADR I-ADR
latent I-ADR I-ADR
tuberculosis I-ADR I-ADR
. O-ADR O-ADR
A O-ADR O-ADR
28 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
US O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
compared O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
LABA O-ADR O-ADR
( O-ADR O-ADR
salmeterol O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
each O-ADR O-ADR
added O-ADR O-ADR
to O-ADR O-ADR
usual O-ADR O-ADR
asthma O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
showed O-ADR O-ADR
an O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
salmeterol O-ADR O-ADR
( O-ADR O-ADR
13 O-ADR O-ADR
/ O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
176 O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
salmeterol O-ADR O-ADR
vs O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
179 O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
; O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
: O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
37 O-ADR O-ADR
[ O-ADR O-ADR
95 O-ADR O-ADR
% O-ADR O-ADR
CI O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
25 O-ADR O-ADR
, O-ADR O-ADR
15 O-ADR O-ADR
. O-ADR O-ADR
34 O-ADR O-ADR
] O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
hypertension O-ADR O-ADR
that O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
controlled O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
hypertensive O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
present O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
on O-ADR O-ADR
TRULICITY O-ADR O-ADR
than O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
. O-ADR O-ADR
[ O-ADR O-ADR
See O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
] O-ADR O-ADR
Six O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
8 O-ADR O-ADR
cases O-ADR O-ADR
presented O-ADR O-ADR
with O-ADR O-ADR
CNS O-ADR O-ADR
involvement O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR B-ADR
from O-ADR I-ADR
baseline O-ADR I-ADR
to O-ADR I-ADR
endpoint O-ADR I-ADR
in O-ADR I-ADR
plasma B-ADR I-ADR
prolactin I-ADR I-ADR
levels I-ADR I-ADR
for I-ADR O-ADR
the I-ADR O-ADR
FANAPT I-ADR O-ADR
24 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group I-ADR O-ADR
was I-ADR O-ADR
an I-ADR O-ADR
increase I-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
decrease O-ADR O-ADR
of O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
ng O-ADR O-ADR
/ O-ADR O-ADR
mL O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
hypocalcemia O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
corrected O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
Prolia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
finding O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
with O-ADR O-ADR
AEDs O-ADR O-ADR
of O-ADR O-ADR
varying O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
and O-ADR O-ADR
across O-ADR O-ADR
a O-ADR O-ADR
range O-ADR O-ADR
of O-ADR O-ADR
indications O-ADR O-ADR
suggests O-ADR O-ADR
that O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
applies O-ADR O-ADR
to O-ADR O-ADR
all O-ADR O-ADR
AEDs O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
trials O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
discontinued O-ADR O-ADR
treatment O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
dizziness B-ADR B-ADR
; O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
POTIGA O-ADR O-ADR
and O-ADR O-ADR
< O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
discontinued O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
somnolence B-ADR B-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
occurred O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
; O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
of O-ADR O-ADR
any O-ADR O-ADR
grade O-ADR O-ADR
, O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
experienced O-ADR O-ADR
their O-ADR O-ADR
first O-ADR O-ADR
event O-ADR O-ADR
within O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
such O-ADR O-ADR
effects O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
may O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
for O-ADR O-ADR
pregnant O-ADR O-ADR
women O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Progressive B-ADR B-ADR
multifocal I-ADR I-ADR
leukoencephalopathy I-ADR I-ADR
( O-ADR O-ADR
PML B-ADR B-ADR
) O-ADR O-ADR
; O-ADR O-ADR
Withhold O-ADR O-ADR
GILENYA O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
sign O-ADR O-ADR
or O-ADR O-ADR
symptom O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
PML O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
immediately O-ADR O-ADR
discontinue O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
initiate O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
52 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
, O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
primarily O-ADR O-ADR
adult O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
schizophrenia O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
increase B-ADR B-ADR
from I-ADR I-ADR
baseline I-ADR I-ADR
of I-ADR I-ADR
ALT I-ADR I-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
units O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
. O-ADR O-ADR
An O-ADR O-ADR
elevated O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
dystonia I-ADR I-ADR
is O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
males O-ADR O-ADR
and O-ADR O-ADR
younger O-ADR O-ADR
age O-ADR O-ADR
groups O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
will O-ADR O-ADR
let O-ADR O-ADR
you O-ADR O-ADR
know O-ADR O-ADR
if O-ADR O-ADR
you O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
stop O-ADR O-ADR
taking O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
Abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
flatulence B-ADR B-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
abdominal I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
CLcr O-ADR O-ADR
, O-ADR O-ADR
urine O-ADR O-ADR
glucose O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
urine O-ADR O-ADR
protein O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
only O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
ADR O-ADR O-ADR
of O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
intensity O-ADR O-ADR
with O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
frequency O-ADR O-ADR
in O-ADR O-ADR
either O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
was O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
of O-ADR O-ADR
354 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
TIVICAY O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
+ O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
of O-ADR O-ADR
361 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
raltegravir O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
+ O-ADR O-ADR
background O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
YERVOY O-ADR O-ADR
dosing O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
neuropathy O-ADR O-ADR
( O-ADR O-ADR
not O-ADR O-ADR
interfering O-ADR O-ADR
with O-ADR O-ADR
daily O-ADR O-ADR
activities O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
extent O-ADR O-ADR
to O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
findings O-ADR O-ADR
of O-ADR O-ADR
increased O-ADR B-ADR
mortality O-ADR I-ADR
in O-ADR O-ADR
observational O-ADR O-ADR
studies O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
antipsychotic O-ADR O-ADR
drug O-ADR O-ADR
as O-ADR O-ADR
opposed O-ADR O-ADR
to O-ADR O-ADR
some O-ADR O-ADR
characteristic O-ADR O-ADR
( O-ADR O-ADR
s O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
clear O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
appropriate O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
after O-ADR O-ADR
administration O-ADR O-ADR
of O-ADR O-ADR
BENLYSTA O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Whether O-ADR O-ADR
the O-ADR O-ADR
impairment O-ADR O-ADR
is O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
somnolence B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
effects O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
biological O-ADR O-ADR
DMARDs O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
grade O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
4 O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
hematuria B-ADR B-ADR
, O-ADR O-ADR
back B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
anorexia B-ADR B-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
neuropathy I-ADR I-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
dysguesia B-ADR B-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
alopecia B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
Lung I-ADR I-ADR
Disease I-ADR I-ADR
and O-ADR O-ADR
Eosinophilic B-ADR B-ADR
Pneumonia I-ADR I-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
occur O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
DUAVEE O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Leukocytosis O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
leukocytosis B-ADR B-ADR
( O-ADR O-ADR
WBC B-ADR B-ADR
counts I-ADR I-ADR
> I-ADR I-ADR
100 I-ADR I-ADR
, O-ADR O-ADR
000 O-ADR O-ADR
x I-ADR I-ADR
10 I-ADR I-ADR
6 I-ADR I-ADR
/ I-ADR I-ADR
L O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
myeloid O-ADR O-ADR
malignancies O-ADR O-ADR
receiving O-ADR O-ADR
GRANIX O-ADR O-ADR
. O-ADR O-ADR
Recent O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
within O-ADR O-ADR
last O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
transaminase O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
GILENYA O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
Prolia O-ADR O-ADR
, O-ADR O-ADR
prescribers O-ADR O-ADR
should O-ADR O-ADR
assess O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
for O-ADR O-ADR
continued O-ADR O-ADR
Prolia O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
discontinue O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
product O-ADR O-ADR
containing O-ADR O-ADR
4 O-ADR O-ADR
- O-ADR O-ADR
aminopyridine O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
in O-ADR O-ADR
order O-ADR O-ADR
to O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
group O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TANZEUM O-ADR O-ADR
, O-ADR O-ADR
investigators O-ADR O-ADR
graded O-ADR O-ADR
the O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
GI B-ADR B-ADR
reactions I-ADR I-ADR
as O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
mild O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in O-ADR B-ADR
56 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
moderate O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in O-ADR B-ADR
37 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
severe O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
in O-ADR B-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
12 O-ADR O-ADR
Embryo O-ADR O-ADR
- O-ADR O-ADR
fetal O-ADR O-ADR
Toxicity O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
mechanism O-ADR O-ADR
of O-ADR O-ADR
action O-ADR O-ADR
, O-ADR O-ADR
AFINITOR O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
. O-ADR O-ADR
Recurrence O-ADR O-ADR
of O-ADR O-ADR
liver B-ADR B-ADR
transaminase I-ADR I-ADR
elevations I-ADR I-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
rechallenge O-ADR O-ADR
in O-ADR O-ADR
some O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
Teflaro O-ADR O-ADR
is O-ADR O-ADR
instituted O-ADR O-ADR
, O-ADR O-ADR
careful O-ADR O-ADR
inquiry O-ADR O-ADR
about O-ADR O-ADR
previous O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
cephalosporins O-ADR O-ADR
, O-ADR O-ADR
penicillins O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
carbapenems O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
made O-ADR O-ADR
. O-ADR O-ADR
Extreme O-ADR O-ADR
care O-ADR O-ADR
must O-ADR O-ADR
be O-ADR O-ADR
taken O-ADR O-ADR
to O-ADR O-ADR
avoid O-ADR O-ADR
pregnancy O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
female O-ADR O-ADR
partners O-ADR O-ADR
of O-ADR O-ADR
male O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Observe O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
following O-ADR O-ADR
Gadavist O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
Febrile B-ADR B-ADR
Reactions I-ADR I-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
pyrexia B-ADR B-ADR
are O-ADR O-ADR
increased O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Advise O-ADR O-ADR
females O-ADR O-ADR
of O-ADR O-ADR
reproductive O-ADR O-ADR
potential O-ADR O-ADR
of O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
fetus O-ADR O-ADR
. O-ADR O-ADR
Drugs O-ADR O-ADR
that O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
mixed O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
CYP3A4 O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
antiretroviral O-ADR O-ADR
drugs O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
HIV O-ADR O-ADR
protease O-ADR O-ADR
inhibitors O-ADR O-ADR
and O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
nucleoside O-ADR O-ADR
reverse O-ADR O-ADR
transcriptase O-ADR O-ADR
inhibitors O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
those O-ADR O-ADR
that O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
effect O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
Coartem O-ADR O-ADR
Tablets O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Maintain O-ADR O-ADR
clinical O-ADR O-ADR
supervision O-ADR O-ADR
if O-ADR O-ADR
this O-ADR O-ADR
product O-ADR O-ADR
is O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
given O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
penicillin O-ADR O-ADR
- O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
- O-ADR O-ADR
allergic O-ADR O-ADR
patient O-ADR O-ADR
, O-ADR O-ADR
because O-ADR O-ADR
cross O-ADR O-ADR
sensitivity O-ADR O-ADR
among O-ADR O-ADR
beta O-ADR O-ADR
- O-ADR O-ADR
lactam O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
clearly O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Acute O-ADR O-ADR
Kidney O-ADR O-ADR
Injury O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
, O-ADR O-ADR
acute B-ADR B-ADR
kidney I-ADR I-ADR
injury I-ADR I-ADR
sometimes O-ADR O-ADR
requiring O-ADR O-ADR
dialysis O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
some O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
experienced O-ADR O-ADR
by O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
PROMACTA O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
in O-ADR O-ADR
PROMACTA O-ADR O-ADR
versus O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
onset O-ADR O-ADR
of O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
was O-ADR O-ADR
37 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
225 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
median O-ADR O-ADR
time O-ADR O-ADR
to O-ADR O-ADR
resolution O-ADR O-ADR
of O-ADR O-ADR
skin B-ADR B-ADR
toxicity I-ADR I-ADR
was O-ADR O-ADR
33 O-ADR O-ADR
days O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
421 O-ADR O-ADR
days O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
shows O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
KALBITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
that O-ADR O-ADR
also O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
rate O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
EDEMA3 O-ADR O-ADR
and O-ADR O-ADR
EDEMA4 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
subcutaneous O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Constipation B-ADR B-ADR
also O-ADR O-ADR
contributed O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
Forty O-ADR O-ADR
- O-ADR O-ADR
eight O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
white O-ADR O-ADR
, O-ADR O-ADR
15 O-ADR O-ADR
% O-ADR O-ADR
African O-ADR O-ADR
/ O-ADR O-ADR
African O-ADR O-ADR
American O-ADR O-ADR
, O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
Asian O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
were O-ADR O-ADR
Hispanic O-ADR O-ADR
/ O-ADR O-ADR
Latino O-ADR O-ADR
. O-ADR O-ADR
Lipid O-ADR O-ADR
intake O-ADR O-ADR
restrictions O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
necessary O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
significant O-ADR O-ADR
disorders O-ADR O-ADR
of O-ADR O-ADR
lipid O-ADR O-ADR
metabolism O-ADR O-ADR
. O-ADR O-ADR
Dabrafenib O-ADR O-ADR
was O-ADR O-ADR
teratogenic B-ADR B-ADR
and O-ADR O-ADR
embryotoxic B-ADR B-ADR
in O-ADR O-ADR
rats O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
three O-ADR O-ADR
times O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
human O-ADR O-ADR
exposure O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
clinical O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
immunosuppressive O-ADR O-ADR
agents O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Hyponatremia B-ADR B-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
SIADH O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
were O-ADR O-ADR
judged O-ADR O-ADR
as O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
mild O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
by O-ADR O-ADR
investigators O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
groups O-ADR O-ADR
( O-ADR O-ADR
73 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
versus O-ADR O-ADR
94 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Laboratory O-ADR O-ADR
Findings O-ADR O-ADR
Hematology O-ADR O-ADR
During O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
ILARIS O-ADR O-ADR
, O-ADR O-ADR
mean O-ADR O-ADR
values O-ADR O-ADR
decreased B-ADR B-ADR
for I-ADR I-ADR
white I-ADR I-ADR
blood I-ADR I-ADR
cells I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Trial O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
resulted O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
and O-ADR O-ADR
severity O-ADR O-ADR
of O-ADR O-ADR
any O-ADR O-ADR
hemorrhagic B-ADR B-ADR
event I-ADR I-ADR
: O-ADR O-ADR
16 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
/ O-ADR O-ADR
55 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
compared O-ADR O-ADR
with O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
/ O-ADR O-ADR
53 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
191 O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
458 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
11 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
76 O-ADR O-ADR
/ O-ADR O-ADR
675 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
YERVOY O-ADR O-ADR
dosing O-ADR O-ADR
in O-ADR O-ADR
symptomatic O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Teva O-ADR O-ADR
Pharmaceuticals O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
896 O-ADR O-ADR
- O-ADR O-ADR
5855 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
that O-ADR O-ADR
ALT O-ADR O-ADR
and O-ADR O-ADR
AST O-ADR O-ADR
be O-ADR O-ADR
assessed O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
KALYDECO O-ADR O-ADR
, O-ADR O-ADR
every O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
year O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
annually O-ADR O-ADR
thereafter O-ADR O-ADR
. O-ADR O-ADR
cutaneous B-ADR B-ADR
immune I-ADR I-ADR
- O-ADR O-ADR
mediated O-ADR O-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
proteinuria B-ADR B-ADR
and O-ADR O-ADR
nephrotic B-ADR B-ADR
syndrome I-ADR I-ADR
secondary O-ADR O-ADR
to O-ADR O-ADR
membranous B-ADR B-ADR
glomerulonephritis I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
necrotizing B-ADR B-ADR
skin I-ADR I-ADR
lesions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
postmarketing O-ADR O-ADR
safety O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
[ O-ADR O-ADR
seeWarnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroids O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
1 O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
prednisone O-ADR O-ADR
or O-ADR O-ADR
equivalent O-ADR O-ADR
for O-ADR O-ADR
severe O-ADR O-ADR
neuropathies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
stated O-ADR O-ADR
frequencies O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
represent O-ADR O-ADR
the O-ADR O-ADR
proportions O-ADR O-ADR
of O-ADR O-ADR
individuals O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
type O-ADR O-ADR
listed O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
the O-ADR O-ADR
24 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
34 O-ADR O-ADR
patients O-ADR O-ADR
ages O-ADR O-ADR
2 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
6 O-ADR O-ADR
years O-ADR O-ADR
( O-ADR O-ADR
Trial O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
where O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
either O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
14 O-ADR O-ADR
kg O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
75 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
kg O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
) O-ADR O-ADR
ivacaftor O-ADR O-ADR
granules O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
transaminase B-ADR B-ADR
elevations I-ADR I-ADR
( O-ADR O-ADR
AST B-ADR B-ADR
) I-ADR I-ADR
> I-ADR I-ADR
3 I-ADR I-ADR
* I-ADR I-ADR
ULN I-ADR I-ADR
was O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
34 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Key O-ADR O-ADR
Laboratory O-ADR O-ADR
Abnormalities O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Advanced O-ADR O-ADR
HR O-ADR O-ADR
+ O-ADR O-ADR
BC O-ADR O-ADR
Grading O-ADR O-ADR
according O-ADR O-ADR
to O-ADR O-ADR
CTCAE O-ADR O-ADR
Version O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
a O-ADR O-ADR
Exemestane O-ADR O-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
) O-ADR O-ADR
b O-ADR O-ADR
Reflects O-ADR O-ADR
corresponding O-ADR O-ADR
adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
reports O-ADR O-ADR
of O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
, O-ADR O-ADR
lymphopenia B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
( O-ADR O-ADR
collectively O-ADR O-ADR
as O-ADR O-ADR
pancytopenia B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
occurred O-ADR O-ADR
at O-ADR O-ADR
lower O-ADR O-ADR
frequency O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
anaphylactoid B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
DOTAREM O-ADR O-ADR
, O-ADR O-ADR
involving O-ADR O-ADR
cardiovascular O-ADR O-ADR
, O-ADR O-ADR
respiratory O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
cutaneous O-ADR O-ADR
manifestations O-ADR O-ADR
. O-ADR O-ADR
One O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subject O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
developed O-ADR O-ADR
laboratory O-ADR O-ADR
findings O-ADR O-ADR
consistent O-ADR O-ADR
with O-ADR O-ADR
proximal B-ADR B-ADR
renal I-ADR I-ADR
tubular I-ADR I-ADR
dysfunction I-ADR I-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
ATV O-ADR O-ADR
+ O-ADR O-ADR
RTV O-ADR O-ADR
+ O-ADR O-ADR
TRUVADA O-ADR O-ADR
after O-ADR O-ADR
Week O-ADR O-ADR
96 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
symptomatic B-ADR B-ADR
bradycardia I-ADR I-ADR
following O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
GILENYA O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Acute O-ADR O-ADR
PE O-ADR O-ADR
in O-ADR O-ADR
Hemodynamically O-ADR O-ADR
Unstable O-ADR O-ADR
Patients O-ADR O-ADR
or O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
Require O-ADR O-ADR
Thrombolysis O-ADR O-ADR
or O-ADR O-ADR
Pulmonary O-ADR O-ADR
Embolectomy O-ADR O-ADR
Initiation O-ADR O-ADR
of O-ADR O-ADR
ELIQUIS O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
alternative O-ADR O-ADR
to O-ADR O-ADR
unfractionated O-ADR O-ADR
heparin O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
initial O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PE O-ADR O-ADR
who O-ADR O-ADR
present O-ADR O-ADR
with O-ADR O-ADR
hemodynamic O-ADR O-ADR
instability O-ADR O-ADR
or O-ADR O-ADR
who O-ADR O-ADR
may O-ADR O-ADR
receive O-ADR O-ADR
thrombolysis O-ADR O-ADR
or O-ADR O-ADR
pulmonary O-ADR O-ADR
embolectomy O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Orthostatic B-ADR B-ADR
Hypotension I-ADR I-ADR
, O-ADR O-ADR
Syncope B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Hemodynamic B-ADR O-ADR
Effects I-ADR O-ADR
: O-ADR O-ADR
Dizziness B-ADR B-ADR
, O-ADR O-ADR
tachycardia B-ADR B-ADR
or O-ADR O-ADR
bradycardia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
syncope B-ADR B-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Cerebrovascular B-ADR B-ADR
Adverse I-ADR I-ADR
Events I-ADR I-ADR
: O-ADR O-ADR
An O-ADR O-ADR
increased O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cerebrovascular B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
stroke B-ADR B-ADR
, O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attack I-ADR I-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychoses O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
. O-ADR O-ADR
Seventeen O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
required O-ADR O-ADR
permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
trial O-ADR O-ADR
carried O-ADR O-ADR
out O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
baseline O-ADR O-ADR
eGFR O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
to O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
50 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
mean O-ADR O-ADR
baseline O-ADR O-ADR
eGFR O-ADR O-ADR
39 O-ADR O-ADR
mL O-ADR O-ADR
/ O-ADR O-ADR
min O-ADR O-ADR
/ O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
73 O-ADR O-ADR
m O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
significant O-ADR O-ADR
renal B-ADR B-ADR
function I-ADR I-ADR
decline I-ADR I-ADR
, O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
eGFR B-ADR B-ADR
30 I-ADR I-ADR
% I-ADR I-ADR
lower I-ADR I-ADR
than I-ADR I-ADR
baseline I-ADR I-ADR
, O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
22 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
the O-ADR O-ADR
end O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
significant O-ADR O-ADR
renal B-ADR B-ADR
function I-ADR I-ADR
decline I-ADR I-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
symptoms O-ADR O-ADR
( O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
fatigue O-ADR O-ADR
, O-ADR O-ADR
anorexia O-ADR O-ADR
, O-ADR O-ADR
nausea O-ADR O-ADR
, O-ADR O-ADR
jaundice O-ADR O-ADR
, O-ADR O-ADR
dark O-ADR O-ADR
urine O-ADR O-ADR
, O-ADR O-ADR
liver O-ADR O-ADR
tenderness O-ADR O-ADR
and O-ADR O-ADR
hepatomegaly O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
tests O-ADR O-ADR
( O-ADR O-ADR
ALT O-ADR O-ADR
, O-ADR O-ADR
AST O-ADR O-ADR
, O-ADR O-ADR
alkaline O-ADR O-ADR
phosphatase O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
bilirubin O-ADR O-ADR
) O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
monthly O-ADR O-ADR
while O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
These O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
anaphylaxis B-ADR B-ADR
occurred O-ADR O-ADR
as O-ADR O-ADR
early O-ADR O-ADR
as O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
three O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
infusion O-ADR O-ADR
. O-ADR O-ADR
Measurement O-ADR O-ADR
of O-ADR O-ADR
serum O-ADR O-ADR
sodium O-ADR O-ADR
and O-ADR O-ADR
chloride O-ADR O-ADR
levels O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
during O-ADR O-ADR
maintenance O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
APTIOM O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
if O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
is O-ADR O-ADR
receiving O-ADR O-ADR
other O-ADR O-ADR
medications O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
decrease O-ADR O-ADR
serum O-ADR O-ADR
sodium O-ADR O-ADR
levels O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
performed O-ADR O-ADR
if O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hyponatremia O-ADR O-ADR
develop O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
nausea O-ADR O-ADR
/ O-ADR O-ADR
vomiting O-ADR O-ADR
, O-ADR O-ADR
malaise O-ADR O-ADR
, O-ADR O-ADR
headache O-ADR O-ADR
, O-ADR O-ADR
lethargy O-ADR O-ADR
, O-ADR O-ADR
confusion O-ADR O-ADR
, O-ADR O-ADR
irritability O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
weakness O-ADR O-ADR
/ O-ADR O-ADR
spasms O-ADR O-ADR
, O-ADR O-ADR
obtundation O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
increase O-ADR O-ADR
in O-ADR O-ADR
seizure O-ADR O-ADR
frequency O-ADR O-ADR
or O-ADR O-ADR
severity O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Four O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
stopping O-ADR O-ADR
TECFIDERA O-ADR O-ADR
, O-ADR O-ADR
mean O-ADR O-ADR
lymphocyte O-ADR B-ADR
counts O-ADR I-ADR
increased O-ADR I-ADR
but O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
return O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Shire O-ADR O-ADR
Human O-ADR O-ADR
Genetic O-ADR O-ADR
Therapies O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
OnePath O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
phone O-ADR O-ADR
# O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
866 O-ADR O-ADR
- O-ADR O-ADR
888 O-ADR O-ADR
- O-ADR O-ADR
0660 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
icatibant O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
three O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
223 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
FIRAZYR O-ADR O-ADR
30 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
113 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
75 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
comparator O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
38 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Genital B-ADR B-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
on O-ADR O-ADR
placebo O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
study O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
pool O-ADR O-ADR
. O-ADR O-ADR
Severe O-ADR O-ADR
penile B-ADR B-ADR
hematoma I-ADR I-ADR
was O-ADR O-ADR
also O-ADR O-ADR
reported O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
39 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
Peyronie O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Autoantibodies O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
in O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
placebo O-ADR O-ADR
that O-ADR O-ADR
had O-ADR O-ADR
negative O-ADR O-ADR
baseline O-ADR O-ADR
ANA B-ADR O-ADR
titers I-ADR O-ADR
developed I-ADR O-ADR
positive I-ADR O-ADR
titers O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
study O-ADR O-ADR
baseline O-ADR O-ADR
, O-ADR O-ADR
approximately O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
mild O-ADR O-ADR
, O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
moderate O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
had O-ADR O-ADR
severe O-ADR O-ADR
cervical O-ADR O-ADR
dystonia O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
COMETRIQ O-ADR O-ADR
for O-ADR O-ADR
hypertension O-ADR O-ADR
that O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
with O-ADR O-ADR
medical O-ADR O-ADR
management O-ADR O-ADR
; O-ADR O-ADR
when O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
resume O-ADR O-ADR
COMETRIQ O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
reduced O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
alternative O-ADR O-ADR
contraception O-ADR O-ADR
for O-ADR O-ADR
women O-ADR O-ADR
with O-ADR O-ADR
uncontrolled O-ADR O-ADR
dyslipidemia O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
type O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
second O-ADR O-ADR
week O-ADR O-ADR
of O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Suicidal O-ADR O-ADR
Behavior O-ADR O-ADR
and O-ADR O-ADR
Ideation O-ADR O-ADR
Antiepileptic O-ADR O-ADR
drugs O-ADR O-ADR
( O-ADR O-ADR
AEDs O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
ONFI O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
thoughts I-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
taking O-ADR O-ADR
these O-ADR O-ADR
drugs O-ADR O-ADR
for O-ADR O-ADR
any O-ADR O-ADR
indication O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
serious O-ADR O-ADR
allergic O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
Zydelig O-ADR O-ADR
permanently O-ADR O-ADR
and O-ADR O-ADR
institute O-ADR O-ADR
appropriate O-ADR O-ADR
supportive O-ADR O-ADR
measures O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
liver O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
before O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
cycle O-ADR O-ADR
. O-ADR O-ADR
Febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
ADCETRIS O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1393 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
FARXIGA O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1145 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
1193 O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
At O-ADR O-ADR
one O-ADR O-ADR
year O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
these O-ADR O-ADR
values O-ADR O-ADR
were O-ADR O-ADR
183 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
102 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
151 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
401 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
recommended O-ADR O-ADR
regimen O-ADR O-ADR
and O-ADR O-ADR
196 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
48 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
108 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
195 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
dL O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
405 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
Follow O-ADR O-ADR
instructions O-ADR O-ADR
for O-ADR O-ADR
preparation O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
admixing O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
administration O-ADR O-ADR
strictly O-ADR O-ADR
to O-ADR O-ADR
minimize O-ADR O-ADR
medication O-ADR O-ADR
errors O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
underdose O-ADR O-ADR
and O-ADR O-ADR
overdose O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
other O-ADR O-ADR
XIAFLEX O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
of O-ADR O-ADR
1044 O-ADR O-ADR
; O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
penile B-ADR B-ADR
ecchymoses I-ADR I-ADR
, O-ADR O-ADR
sudden O-ADR O-ADR
penile B-ADR B-ADR
detumescence I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
a O-ADR O-ADR
penile B-ADR B-ADR
` O-ADR O-ADR
` O-ADR O-ADR
popping B-ADR B-ADR
' O-ADR O-ADR
' O-ADR O-ADR
sound B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
corporal B-ADR B-ADR
rupture I-ADR I-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
information O-ADR O-ADR
below O-ADR O-ADR
is O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
database O-ADR O-ADR
for O-ADR O-ADR
FANAPT O-ADR O-ADR
consisting O-ADR O-ADR
of O-ADR O-ADR
2070 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
FANAPT O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
day O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
, O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
schizophrenia O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
54 O-ADR O-ADR
( O-ADR O-ADR
49 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
Zydelig O-ADR O-ADR
+ O-ADR O-ADR
rituximab O-ADR O-ADR
. O-ADR O-ADR
Serious O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
that O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
CRS B-ADR B-ADR
included O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
alanine I-ADR I-ADR
aminotransferase I-ADR I-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
aspartate I-ADR I-ADR
aminotransferase I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
total I-ADR I-ADR
bilirubin I-ADR I-ADR
; O-ADR O-ADR
these O-ADR O-ADR
events O-ADR O-ADR
infrequently O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
BLINCYTO O-ADR O-ADR
discontinuation O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Macrovascular O-ADR O-ADR
outcomes O-ADR O-ADR
: O-ADR O-ADR
There O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
no O-ADR O-ADR
studies O-ADR O-ADR
establishing O-ADR O-ADR
conclusive O-ADR O-ADR
evidence O-ADR O-ADR
of O-ADR O-ADR
macrovascular O-ADR O-ADR
risk O-ADR O-ADR
reduction O-ADR O-ADR
with O-ADR O-ADR
TRULICITY O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
drug O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
WARNING O-ADR O-ADR
: O-ADR O-ADR
RISK O-ADR O-ADR
OF O-ADR O-ADR
THYROID B-ADR B-ADR
C I-ADR I-ADR
- O-ADR O-ADR
CELL O-ADR O-ADR
TUMORS I-ADR I-ADR
See O-ADR O-ADR
full O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
complete O-ADR O-ADR
boxed O-ADR O-ADR
warning O-ADR O-ADR
. O-ADR O-ADR
While O-ADR O-ADR
all O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
produce O-ADR O-ADR
some O-ADR O-ADR
metabolic O-ADR B-ADR
changes O-ADR I-ADR
, O-ADR O-ADR
each O-ADR O-ADR
drug O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
class O-ADR O-ADR
has O-ADR O-ADR
its O-ADR O-ADR
own O-ADR O-ADR
specific O-ADR O-ADR
risk O-ADR O-ADR
profile O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
a O-ADR O-ADR
monotherapy O-ADR O-ADR
study O-ADR O-ADR
comparing O-ADR O-ADR
NESINA O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
sulfonylurea O-ADR O-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
was O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
with O-ADR O-ADR
glipizide O-ADR O-ADR
( O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
experience O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
worse O-ADR O-ADR
allergic O-ADR O-ADR
- O-ADR O-ADR
type O-ADR O-ADR
reactions O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
rechallenged O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
ENTEREG O-ADR O-ADR
12 O-ADR O-ADR
mg O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
793 O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
10 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
the O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
monotherapy O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
manic O-ADR O-ADR
or O-ADR O-ADR
mixed O-ADR O-ADR
episodes O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
were O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
extrapyramidal B-ADR B-ADR
symptoms I-ADR I-ADR
other O-ADR O-ADR
than O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
increased B-ADR B-ADR
weight I-ADR I-ADR
and O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
adjunctive O-ADR O-ADR
therapy O-ADR O-ADR
trial O-ADR O-ADR
in O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
were O-ADR O-ADR
somnolence B-ADR B-ADR
and O-ADR O-ADR
oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
- O-ADR O-ADR
cause O-ADR O-ADR
mortality B-ADR B-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
90 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
70 O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Prolia O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
QT O-ADR O-ADR
Prolongation O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
403 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
bipolar O-ADR O-ADR
I O-ADR O-ADR
disorder O-ADR O-ADR
who O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
blind O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
302 O-ADR O-ADR
patients O-ADR O-ADR
received O-ADR O-ADR
SAPHRIS O-ADR O-ADR
at O-ADR O-ADR
fixed O-ADR O-ADR
doses O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
to O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
Other O-ADR O-ADR
important O-ADR O-ADR
considerations O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
differential O-ADR O-ADR
diagnosis O-ADR O-ADR
include O-ADR O-ADR
central O-ADR O-ADR
anticholinergic O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
heat O-ADR O-ADR
stroke O-ADR O-ADR
, O-ADR O-ADR
drug O-ADR O-ADR
fever O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
primary O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
( O-ADR O-ADR
CNS O-ADR O-ADR
) O-ADR O-ADR
pathology O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
epistaxis B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
otitis B-ADR B-ADR
media I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
abnormal B-ADR B-ADR
taste I-ADR I-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
luteinizing I-ADR I-ADR
hormone I-ADR I-ADR
( I-ADR I-ADR
LH I-ADR I-ADR
) I-ADR I-ADR
levels I-ADR I-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
increased B-ADR B-ADR
blood I-ADR I-ADR
follicle I-ADR I-ADR
stimulating I-ADR I-ADR
hormone I-ADR I-ADR
( I-ADR I-ADR
FSH I-ADR I-ADR
) I-ADR I-ADR
levels I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypersensitivity B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
ovarian B-ADR B-ADR
cyst I-ADR I-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
pneumonitis B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Most O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
70 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
both O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
enrolled O-ADR O-ADR
in O-ADR O-ADR
Eastern O-ADR O-ADR
Europe O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
White O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
oropharyngeal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
hyperhidrosis O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
been O-ADR O-ADR
established O-ADR O-ADR
. O-ADR O-ADR
Creatinine B-ADR B-ADR
increases I-ADR I-ADR
were O-ADR O-ADR
comparable O-ADR O-ADR
by O-ADR O-ADR
background O-ADR O-ADR
NRTIs O-ADR O-ADR
and O-ADR O-ADR
were O-ADR O-ADR
similar O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
experienced O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Potential O-ADR O-ADR
for O-ADR O-ADR
motor B-ADR B-ADR
impairment I-ADR I-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
operating O-ADR O-ADR
machinery O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
chronic O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Oral B-ADR B-ADR
ulceration I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypotension O-ADR O-ADR
after O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
increase O-ADR O-ADR
monitoring O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
situations O-ADR O-ADR
where O-ADR O-ADR
volume O-ADR O-ADR
contraction O-ADR O-ADR
is O-ADR O-ADR
expected O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Rehydrate O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
with O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
emetics O-ADR O-ADR
and O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
diarrheals O-ADR O-ADR
as O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Promptly O-ADR O-ADR
evaluate O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
loss O-ADR O-ADR
. O-ADR O-ADR
Refer O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
for O-ADR O-ADR
peginterferon O-ADR O-ADR
alfa O-ADR O-ADR
and O-ADR O-ADR
ribavirin O-ADR O-ADR
for O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
, O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
laboratory O-ADR O-ADR
testing O-ADR O-ADR
recommendations O-ADR O-ADR
including O-ADR O-ADR
hematology O-ADR O-ADR
, O-ADR O-ADR
biochemistry O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
hepatic O-ADR O-ADR
function O-ADR O-ADR
tests O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pregnancy O-ADR O-ADR
testing O-ADR O-ADR
requirements O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
important O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
elsewhere O-ADR O-ADR
in O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
and O-ADR O-ADR
Angioedema B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
e O-ADR O-ADR
Rate O-ADR O-ADR
of O-ADR O-ADR
documented O-ADR O-ADR
symptomatic O-ADR B-ADR
hypoglycemia B-ADR I-ADR
for O-ADR O-ADR
active O-ADR O-ADR
controls O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
glimepiride O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
sitagliptin O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
including O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
on O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
were O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
: O-ADR O-ADR
Patients O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
likely O-ADR O-ADR
to O-ADR O-ADR
experience O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
not O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
and O-ADR O-ADR
certain O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
neutropenia B-ADR B-ADR
and O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
. O-ADR O-ADR
Hepatobiliary O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
with O-ADR O-ADR
DALVANCE O-ADR O-ADR
treatment O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Consultation O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
physician O-ADR O-ADR
with O-ADR O-ADR
expertise O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
to O-ADR O-ADR
aid O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
decision O-ADR O-ADR
of O-ADR O-ADR
whether O-ADR O-ADR
initiating O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
tuberculosis O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
appropriate O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
individual O-ADR O-ADR
patient O-ADR O-ADR
. O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
subcutaneous O-ADR O-ADR
tissue O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
Toxic B-ADR B-ADR
epidermal I-ADR I-ADR
necrolysis I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
11 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
prescribing O-ADR O-ADR
STENDRA O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
is O-ADR O-ADR
important O-ADR O-ADR
to O-ADR O-ADR
note O-ADR O-ADR
the O-ADR O-ADR
following O-ADR O-ADR
: O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
STENDRA O-ADR O-ADR
if O-ADR O-ADR
sexual O-ADR O-ADR
activity O-ADR O-ADR
is O-ADR O-ADR
inadvisable O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
cardiovascular O-ADR O-ADR
status O-ADR O-ADR
or O-ADR O-ADR
any O-ADR O-ADR
other O-ADR O-ADR
reason O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
STENDRA O-ADR O-ADR
with O-ADR O-ADR
alpha O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
, O-ADR O-ADR
other O-ADR O-ADR
antihypertensives O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
substantial O-ADR O-ADR
amounts O-ADR O-ADR
of O-ADR O-ADR
alcohol O-ADR O-ADR
( O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
3 O-ADR O-ADR
units O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
hypotension B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
seek O-ADR O-ADR
emergency O-ADR O-ADR
treatment O-ADR O-ADR
if O-ADR O-ADR
an O-ADR O-ADR
erection O-ADR O-ADR
lasts O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
4 O-ADR O-ADR
hours O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
stop O-ADR O-ADR
STENDRA O-ADR O-ADR
and O-ADR O-ADR
seek O-ADR O-ADR
medical O-ADR O-ADR
care O-ADR O-ADR
if O-ADR O-ADR
a O-ADR O-ADR
sudden O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
vision O-ADR O-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
both O-ADR O-ADR
eyes O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
a O-ADR O-ADR
sign O-ADR O-ADR
of O-ADR O-ADR
Non O-ADR O-ADR
Arteritic O-ADR O-ADR
Ischemic O-ADR O-ADR
Optic O-ADR O-ADR
Neuropathy O-ADR O-ADR
( O-ADR O-ADR
NAION O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
presents O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
STENDRA O-ADR O-ADR
. O-ADR O-ADR
Hypertoxin O-ADR O-ADR
- O-ADR O-ADR
producing O-ADR O-ADR
strains O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
cause O-ADR O-ADR
increased O-ADR O-ADR
morbidity O-ADR O-ADR
and O-ADR O-ADR
mortality O-ADR O-ADR
, O-ADR O-ADR
as O-ADR O-ADR
these O-ADR O-ADR
infections O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
refractory O-ADR O-ADR
to O-ADR O-ADR
antibacterial O-ADR O-ADR
therapy O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
require O-ADR O-ADR
colectomy O-ADR O-ADR
. O-ADR O-ADR
corticosteroids O-ADR O-ADR
or O-ADR O-ADR
methotrexate O-ADR O-ADR
) O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infection B-ADR B-ADR
. O-ADR O-ADR
Sixty O-ADR O-ADR
- O-ADR O-ADR
two O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
one O-ADR O-ADR
sample O-ADR O-ADR
that O-ADR O-ADR
was O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
TANZEUM O-ADR O-ADR
is O-ADR O-ADR
contraindicated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
personal O-ADR O-ADR
or O-ADR O-ADR
family O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
or O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
MEN O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
VICTRELIS O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
experienced O-ADR O-ADR
hemoglobin B-ADR B-ADR
values I-ADR I-ADR
less I-ADR I-ADR
than I-ADR I-ADR
10 I-ADR I-ADR
g I-ADR I-ADR
per I-ADR I-ADR
dL I-ADR I-ADR
was O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
combination O-ADR O-ADR
of O-ADR O-ADR
VICTRELIS O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
than O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
PegIntron O-ADR O-ADR
/ O-ADR O-ADR
REBETOL O-ADR O-ADR
alone O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
other O-ADR O-ADR
antidiabetic O-ADR O-ADR
therapies O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
. O-ADR O-ADR
Sustained B-ADR O-ADR
increases I-ADR B-ADR
in I-ADR I-ADR
intraocular I-ADR I-ADR
pressure I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
after O-ADR O-ADR
repeated O-ADR O-ADR
intravitreal O-ADR O-ADR
dosing O-ADR O-ADR
with O-ADR O-ADR
vascular O-ADR O-ADR
endothelial O-ADR O-ADR
growth O-ADR O-ADR
factor O-ADR O-ADR
( O-ADR O-ADR
VEGF O-ADR O-ADR
) O-ADR O-ADR
inhibitors O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
MI O-ADR O-ADR
and O-ADR O-ADR
stroke O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
NULOJIX O-ADR O-ADR
was O-ADR O-ADR
studied O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
frequency O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
401 O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
cyclosporine O-ADR O-ADR
control O-ADR O-ADR
regimen O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
405 O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Increased O-ADR O-ADR
Low O-ADR O-ADR
- O-ADR O-ADR
Density O-ADR O-ADR
Lipoprotein O-ADR O-ADR
Cholesterol O-ADR O-ADR
( O-ADR O-ADR
LDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
Increases B-ADR B-ADR
in I-ADR I-ADR
LDL I-ADR I-ADR
- O-ADR O-ADR
C O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
JARDIANCE O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
d O-ADR O-ADR
Event O-ADR O-ADR
requiring O-ADR O-ADR
another O-ADR O-ADR
person O-ADR O-ADR
to O-ADR O-ADR
administer O-ADR O-ADR
a O-ADR O-ADR
resuscitative O-ADR O-ADR
action O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
ILARIS O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
was O-ADR O-ADR
investigated O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
phase O-ADR O-ADR
3 O-ADR O-ADR
studies O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Administration O-ADR O-ADR
of O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
until O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
is O-ADR O-ADR
healed O-ADR O-ADR
from O-ADR O-ADR
any O-ADR O-ADR
previous O-ADR O-ADR
drug O-ADR O-ADR
or O-ADR O-ADR
surgical O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
population O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
55 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
men O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
treatment O-ADR O-ADR
- O-ADR O-ADR
naive O-ADR O-ADR
subjects O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
mean O-ADR O-ADR
change O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
of O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
15 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
: O-ADR O-ADR
- O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
32 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
65 O-ADR O-ADR
mg O-ADR O-ADR
per O-ADR O-ADR
dL O-ADR O-ADR
) O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
after O-ADR O-ADR
96 O-ADR O-ADR
weeks O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
DYSPORT O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
is O-ADR O-ADR
approved O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
intramuscular O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
Instances O-ADR O-ADR
of O-ADR O-ADR
suicidal B-ADR B-ADR
ideation I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
/ O-ADR O-ADR
1441 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
while O-ADR O-ADR
receiving O-ADR O-ADR
OTEZLA O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
none O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
treated O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
/ O-ADR O-ADR
495 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
Thrombocytopenia O-ADR O-ADR
Kyprolis O-ADR O-ADR
causes O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
with O-ADR O-ADR
platelet B-ADR O-ADR
nadirs I-ADR O-ADR
observed O-ADR O-ADR
between O-ADR O-ADR
Day O-ADR O-ADR
8 O-ADR O-ADR
and O-ADR O-ADR
Day O-ADR O-ADR
15 O-ADR O-ADR
of O-ADR O-ADR
each O-ADR O-ADR
28 O-ADR O-ADR
- O-ADR O-ADR
day O-ADR O-ADR
cycle O-ADR O-ADR
with O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
baseline O-ADR O-ADR
platelet O-ADR O-ADR
count O-ADR O-ADR
usually O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
cycle O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Somnolence O-ADR O-ADR
/ O-ADR O-ADR
sedation O-ADR O-ADR
and O-ADR O-ADR
dizziness B-ADR B-ADR
: O-ADR O-ADR
May O-ADR O-ADR
impair B-ADR B-ADR
the I-ADR I-ADR
patient I-ADR I-ADR
' I-ADR I-ADR
s O-ADR O-ADR
ability I-ADR I-ADR
to I-ADR O-ADR
operate I-ADR O-ADR
complex I-ADR O-ADR
machinery I-ADR O-ADR
. O-ADR O-ADR
Contact O-ADR O-ADR
lens O-ADR O-ADR
use O-ADR O-ADR
is O-ADR O-ADR
also O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
factor O-ADR O-ADR
for O-ADR O-ADR
keratitis O-ADR B-ADR
and O-ADR O-ADR
ulceration O-ADR B-ADR
. O-ADR O-ADR
Higher O-ADR O-ADR
than O-ADR O-ADR
recommended O-ADR O-ADR
dosing O-ADR O-ADR
or O-ADR O-ADR
repeat O-ADR O-ADR
dosing O-ADR O-ADR
appear O-ADR O-ADR
to O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Infections O-ADR O-ADR
Risk O-ADR O-ADR
of O-ADR O-ADR
Infections O-ADR O-ADR
GILENYA O-ADR O-ADR
causes O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
- O-ADR O-ADR
dependent O-ADR O-ADR
reduction B-ADR B-ADR
in I-ADR I-ADR
peripheral I-ADR I-ADR
lymphocyte I-ADR I-ADR
count I-ADR I-ADR
to O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
- O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
baseline O-ADR O-ADR
values O-ADR O-ADR
because O-ADR O-ADR
of O-ADR O-ADR
reversible O-ADR O-ADR
sequestration B-ADR O-ADR
of I-ADR O-ADR
lymphocytes I-ADR O-ADR
in I-ADR O-ADR
lymphoid I-ADR O-ADR
tissues I-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
unconfounded O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
NSF B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
DOTAREM O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
moderate O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
proteinuria O-ADR O-ADR
, O-ADR O-ADR
reduce O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
or O-ADR O-ADR
temporarily O-ADR O-ADR
interrupt O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
no O-ADR O-ADR
other O-ADR O-ADR
identified O-ADR O-ADR
systemic O-ADR O-ADR
medical O-ADR O-ADR
conditions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
compromised B-ADR O-ADR
immune I-ADR O-ADR
system I-ADR O-ADR
function O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
previously O-ADR O-ADR
been O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
natalizumab O-ADR O-ADR
, O-ADR O-ADR
which O-ADR O-ADR
has O-ADR O-ADR
a O-ADR O-ADR
known O-ADR O-ADR
association O-ADR O-ADR
with O-ADR O-ADR
PML B-ADR O-ADR
. O-ADR O-ADR
It O-ADR O-ADR
is O-ADR O-ADR
unknown O-ADR O-ADR
whether O-ADR O-ADR
this O-ADR O-ADR
finding O-ADR O-ADR
applies O-ADR O-ADR
to O-ADR O-ADR
younger O-ADR O-ADR
postmenopausal O-ADR O-ADR
women O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
comparable O-ADR O-ADR
data O-ADR O-ADR
, O-ADR O-ADR
these O-ADR O-ADR
risks O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
assumed O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
similar O-ADR O-ADR
for O-ADR O-ADR
other O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
conjugated O-ADR O-ADR
estrogens O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
dosage O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
estrogens O-ADR O-ADR
. O-ADR O-ADR
Nearly O-ADR O-ADR
all O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
reported O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
associated O-ADR O-ADR
cases O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Crohn O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
disease O-ADR O-ADR
or O-ADR O-ADR
ulcerative O-ADR O-ADR
colitis O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
ERWINAZE O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
prolong O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
additive O-ADR B-ADR
QT B-ADR I-ADR
prolongation I-ADR I-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Transient O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
blood I-ADR I-ADR
pressure I-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
shortly O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
Qutenza O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
section O-ADR O-ADR
reflect O-ADR O-ADR
Gadavist O-ADR O-ADR
exposure O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
, O-ADR O-ADR
330 O-ADR O-ADR
subjects O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
184 O-ADR O-ADR
pediatric O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
ages O-ADR O-ADR
0 O-ADR O-ADR
to O-ADR O-ADR
17 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
of O-ADR O-ADR
SAPHRIS O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
maintenance O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
schizophrenia O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
seen O-ADR O-ADR
with O-ADR O-ADR
acute O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
Decrease B-ADR B-ADR
of I-ADR I-ADR
Hemoglobin I-ADR I-ADR
in O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
WM O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
63 O-ADR O-ADR
) O-ADR O-ADR
Percent O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
63 O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Platelets B-ADR B-ADR
Decreased I-ADR I-ADR
43 O-ADR O-ADR
13 O-ADR O-ADR
Neutrophils B-ADR B-ADR
Decreased I-ADR I-ADR
44 O-ADR O-ADR
19 O-ADR O-ADR
Hemoglobin B-ADR B-ADR
Decreased I-ADR I-ADR
13 O-ADR O-ADR
8 O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
APTIOM O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
descending O-ADR O-ADR
order O-ADR O-ADR
of O-ADR O-ADR
frequency O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
ataxia B-ADR B-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
asthenia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
dysarthria B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
myelosuppression B-ADR O-ADR
following O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
TREANDA O-ADR O-ADR
are O-ADR O-ADR
more O-ADR O-ADR
susceptible O-ADR O-ADR
to O-ADR O-ADR
infections B-ADR B-ADR
. O-ADR O-ADR
These O-ADR O-ADR
metabolic O-ADR B-ADR
changes O-ADR I-ADR
include O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
dyslipidemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
body B-ADR B-ADR
weight I-ADR I-ADR
gain I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Patient O-ADR O-ADR
Counseling O-ADR O-ADR
Information O-ADR O-ADR
( O-ADR O-ADR
17 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
rate O-ADR O-ADR
of O-ADR O-ADR
progression O-ADR O-ADR
of O-ADR O-ADR
retinal B-ADR B-ADR
abnormalities I-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
reversibility O-ADR O-ADR
after O-ADR O-ADR
drug O-ADR O-ADR
discontinuation O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
significant O-ADR O-ADR
reductions O-ADR O-ADR
in O-ADR O-ADR
BMD O-ADR O-ADR
are O-ADR O-ADR
seen O-ADR O-ADR
and O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
is O-ADR O-ADR
still O-ADR O-ADR
considered O-ADR O-ADR
medically O-ADR O-ADR
important O-ADR O-ADR
for O-ADR O-ADR
that O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
COPD O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
medicine O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
or O-ADR O-ADR
prevent O-ADR O-ADR
osteoporosis O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
strongly O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
Infusion B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
BLINCYTO O-ADR O-ADR
infusion O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
clinically O-ADR O-ADR
indistinguishable O-ADR O-ADR
from O-ADR O-ADR
manifestations O-ADR O-ADR
of O-ADR O-ADR
CRS O-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
this O-ADR O-ADR
product O-ADR O-ADR
is O-ADR O-ADR
used O-ADR O-ADR
for O-ADR O-ADR
10 O-ADR O-ADR
days O-ADR O-ADR
or O-ADR O-ADR
longer O-ADR O-ADR
, O-ADR O-ADR
intraocular O-ADR O-ADR
pressure O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
monitored O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
, O-ADR O-ADR
806 O-ADR O-ADR
received O-ADR O-ADR
FANAPT O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
, O-ADR O-ADR
with O-ADR O-ADR
463 O-ADR O-ADR
exposed O-ADR O-ADR
to O-ADR O-ADR
FANAPT O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Women O-ADR O-ADR
over O-ADR O-ADR
35 O-ADR O-ADR
years O-ADR O-ADR
old O-ADR O-ADR
who O-ADR O-ADR
smoke O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
Natazia O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Controlled O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
In O-ADR O-ADR
three O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
14 O-ADR O-ADR
weeks O-ADR O-ADR
duration O-ADR O-ADR
, O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
15 O-ADR O-ADR
/ O-ADR O-ADR
400 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
AMPYRA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
experienced O-ADR O-ADR
one O-ADR O-ADR
or O-ADR O-ADR
more O-ADR O-ADR
treatment O-ADR O-ADR
emergent O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
discontinuation O-ADR O-ADR
, O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
/ O-ADR O-ADR
238 O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
shows O-ADR O-ADR
absolute O-ADR O-ADR
and O-ADR O-ADR
relative O-ADR O-ADR
risk O-ADR O-ADR
by O-ADR O-ADR
indication O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
evaluated O-ADR O-ADR
AEDs O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Ferriprox O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
caregivers O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
families O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
informed O-ADR O-ADR
that O-ADR O-ADR
AEDs O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
and O-ADR O-ADR
behavior O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
advised O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
need O-ADR O-ADR
to O-ADR O-ADR
be O-ADR O-ADR
alert O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
or O-ADR O-ADR
worsening O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
depression O-ADR O-ADR
, O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
changes O-ADR O-ADR
in O-ADR O-ADR
mood O-ADR O-ADR
or O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
the O-ADR O-ADR
emergence O-ADR O-ADR
of O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
, O-ADR O-ADR
behavior O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
thoughts O-ADR O-ADR
about O-ADR O-ADR
self O-ADR O-ADR
- O-ADR O-ADR
harm O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Severe O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Severe O-ADR O-ADR
, O-ADR O-ADR
potentially O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
fatal B-ADR B-ADR
skin B-ADR B-ADR
reactions I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
case O-ADR O-ADR
of O-ADR O-ADR
recurrent O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
same O-ADR O-ADR
category O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
event O-ADR O-ADR
was O-ADR O-ADR
considered O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
13 O-ADR O-ADR
, O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Thromboembolic O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Other O-ADR O-ADR
Vascular O-ADR O-ADR
Problems O-ADR O-ADR
Stop O-ADR O-ADR
Natazia O-ADR I-ADR
if O-ADR O-ADR
an O-ADR O-ADR
arterial O-ADR O-ADR
or O-ADR O-ADR
venous O-ADR O-ADR
thrombotic O-ADR O-ADR
event O-ADR O-ADR
( O-ADR O-ADR
VTE O-ADR O-ADR
) O-ADR O-ADR
occurs O-ADR O-ADR
. O-ADR O-ADR
Cleviprex O-ADR O-ADR
was O-ADR O-ADR
infused O-ADR O-ADR
for O-ADR O-ADR
< O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1199 O-ADR O-ADR
) O-ADR O-ADR
; O-ADR O-ADR
it O-ADR O-ADR
was O-ADR O-ADR
infused O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
continuous O-ADR O-ADR
infusion O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
additional O-ADR O-ADR
93 O-ADR O-ADR
patients O-ADR O-ADR
for O-ADR O-ADR
durations O-ADR O-ADR
between O-ADR O-ADR
24 O-ADR O-ADR
and O-ADR O-ADR
72 O-ADR O-ADR
hours O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
gives O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
partial O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
seizures O-ADR O-ADR
in O-ADR O-ADR
any O-ADR O-ADR
APTIOM O-ADR O-ADR
treatment O-ADR O-ADR
group O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
which O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
was O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Glabellar O-ADR O-ADR
Lines O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
reaction I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
sinusitis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Anaphylaxis O-ADR O-ADR
and O-ADR O-ADR
Infusion O-ADR O-ADR
Reactions O-ADR O-ADR
Infusion B-ADR B-ADR
reactions I-ADR I-ADR
to O-ADR O-ADR
TREANDA O-ADR O-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
commonly O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
7 O-ADR O-ADR
: O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
Hematologic O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Waldenstrom O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
Macroglobulinemia O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
63 O-ADR O-ADR
) O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
Preferred O-ADR O-ADR
Term O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
system O-ADR O-ADR
organ O-ADR O-ADR
class O-ADR O-ADR
and O-ADR O-ADR
individual O-ADR O-ADR
ADR O-ADR O-ADR
terms O-ADR O-ADR
are O-ADR O-ADR
sorted O-ADR O-ADR
in O-ADR O-ADR
descending O-ADR O-ADR
frequency O-ADR O-ADR
order O-ADR O-ADR
. O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Pooled O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
They O-ADR O-ADR
represent O-ADR O-ADR
an O-ADR O-ADR
evaluation O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
data O-ADR O-ADR
from O-ADR O-ADR
870 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Ph O-ADR O-ADR
+ O-ADR O-ADR
leukemia O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
1 O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
single O-ADR O-ADR
- O-ADR O-ADR
agent O-ADR O-ADR
BOSULIF O-ADR O-ADR
. O-ADR O-ADR
Only O-ADR O-ADR
use O-ADR O-ADR
SIRTURO O-ADR O-ADR
when O-ADR O-ADR
an O-ADR O-ADR
effective O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
otherwise O-ADR O-ADR
be O-ADR O-ADR
provided O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Indications O-ADR O-ADR
and O-ADR O-ADR
Usage O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
HAE O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
4 O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
developed O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
ERWINAZE O-ADR O-ADR
antibodies O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
experienced O-ADR O-ADR
hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
3 O-ADR O-ADR
of O-ADR O-ADR
30 O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
twice O-ADR O-ADR
that O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Schizophrenia O-ADR O-ADR
Adults O-ADR O-ADR
: O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
hypoesthesia I-ADR I-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
use O-ADR O-ADR
estrogens O-ADR O-ADR
to O-ADR O-ADR
prevent O-ADR O-ADR
heart O-ADR O-ADR
disease O-ADR O-ADR
, O-ADR O-ADR
heart O-ADR O-ADR
attacks O-ADR O-ADR
, O-ADR O-ADR
strokes O-ADR O-ADR
or O-ADR O-ADR
dementia O-ADR O-ADR
( O-ADR O-ADR
decline O-ADR O-ADR
in O-ADR O-ADR
brain O-ADR O-ADR
function O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
unless O-ADR O-ADR
the O-ADR O-ADR
diagnostic O-ADR O-ADR
information O-ADR O-ADR
is O-ADR O-ADR
essential O-ADR O-ADR
and O-ADR O-ADR
not O-ADR O-ADR
available O-ADR O-ADR
with O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
contrasted O-ADR O-ADR
MRI O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
modalities O-ADR O-ADR
. O-ADR O-ADR
Before O-ADR O-ADR
initiating O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
GILENYA O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
recent O-ADR O-ADR
CBC O-ADR O-ADR
( O-ADR O-ADR
i O-ADR O-ADR
. O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
within O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
or O-ADR O-ADR
after O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
prior O-ADR O-ADR
therapy O-ADR O-ADR
) O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
available O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
counseled O-ADR O-ADR
about O-ADR O-ADR
the O-ADR O-ADR
possibility O-ADR O-ADR
of O-ADR O-ADR
delayed O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
given O-ADR O-ADR
proper O-ADR O-ADR
follow O-ADR O-ADR
- O-ADR O-ADR
up O-ADR O-ADR
instructions O-ADR O-ADR
. O-ADR O-ADR
Afatinib O-ADR O-ADR
was O-ADR O-ADR
embryotoxic B-ADR B-ADR
and O-ADR O-ADR
, O-ADR O-ADR
in O-ADR O-ADR
animals O-ADR O-ADR
with O-ADR O-ADR
maternal O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
led O-ADR O-ADR
to O-ADR O-ADR
abortions B-ADR B-ADR
at I-ADR I-ADR
late I-ADR I-ADR
gestational I-ADR I-ADR
stages I-ADR O-ADR
in O-ADR O-ADR
rabbits O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
( O-ADR O-ADR
approximately O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
times O-ADR O-ADR
the O-ADR O-ADR
human O-ADR O-ADR
exposure O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
40 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
greater O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Macular O-ADR O-ADR
Edema O-ADR O-ADR
Fingolimod O-ADR O-ADR
increases O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
. O-ADR O-ADR
Symptoms O-ADR O-ADR
of O-ADR O-ADR
macular B-ADR B-ADR
edema I-ADR I-ADR
included O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
visual I-ADR I-ADR
acuity I-ADR I-ADR
. O-ADR O-ADR
Changes O-ADR O-ADR
in O-ADR O-ADR
Serum O-ADR O-ADR
Creatinine O-ADR O-ADR
Dolutegravir O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
increase B-ADR B-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
due O-ADR O-ADR
to O-ADR O-ADR
inhibition O-ADR O-ADR
of O-ADR O-ADR
tubular O-ADR O-ADR
secretion O-ADR O-ADR
of O-ADR O-ADR
creatinine O-ADR O-ADR
without O-ADR O-ADR
affecting O-ADR B-ADR
renal O-ADR I-ADR
glomerular O-ADR I-ADR
function O-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Studies O-ADR O-ADR
102 O-ADR O-ADR
and O-ADR O-ADR
103 O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
creatinine I-ADR I-ADR
and O-ADR O-ADR
decreases B-ADR B-ADR
in I-ADR I-ADR
estimated I-ADR I-ADR
creatinine I-ADR I-ADR
clearance I-ADR I-ADR
occurred O-ADR O-ADR
early O-ADR O-ADR
in O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
STRIBILD O-ADR O-ADR
, O-ADR O-ADR
after O-ADR O-ADR
which O-ADR O-ADR
they O-ADR O-ADR
stabilized O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
trametinib O-ADR O-ADR
if O-ADR O-ADR
no O-ADR O-ADR
improvement O-ADR O-ADR
after O-ADR O-ADR
3 O-ADR O-ADR
weeks O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
labeling O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Interstitial B-ADR B-ADR
Lung I-ADR I-ADR
Disease O-ADR O-ADR
/ O-ADR O-ADR
Pneumonitis O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
Interval I-ADR I-ADR
Prolongation I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Bradycardia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Severe O-ADR O-ADR
Visual B-ADR B-ADR
Loss I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
vision B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
edema B-ADR B-ADR
, O-ADR O-ADR
elevated B-ADR B-ADR
transaminases I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
dysgeusia B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
discontinuation O-ADR O-ADR
rate O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
was O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ELIQUIS O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
enoxaparin O-ADR O-ADR
/ O-ADR O-ADR
warfarin O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
AMPLIFY O-ADR O-ADR
study O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
JEVTANA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
fetal B-ADR B-ADR
harm I-ADR I-ADR
when O-ADR O-ADR
administered O-ADR O-ADR
to O-ADR O-ADR
a O-ADR O-ADR
pregnant O-ADR O-ADR
woman O-ADR O-ADR
. O-ADR O-ADR
Eye B-ADR B-ADR
disorders I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
severe O-ADR O-ADR
eye B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
chemical B-ADR B-ADR
conjunctivitis I-ADR I-ADR
, O-ADR O-ADR
corneal B-ADR B-ADR
burn I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
eyelid B-ADR B-ADR
ptosis I-ADR I-ADR
, O-ADR O-ADR
periorbital B-ADR B-ADR
edema I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
after O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
postmarketing O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
Gadavist O-ADR O-ADR
. O-ADR O-ADR
Some O-ADR O-ADR
deaths B-ADR B-ADR
due O-ADR O-ADR
to O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
did O-ADR O-ADR
not O-ADR O-ADR
have O-ADR O-ADR
a O-ADR O-ADR
clear O-ADR O-ADR
etiology O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
and O-ADR O-ADR
abatacept O-ADR O-ADR
or O-ADR O-ADR
anakinra O-ADR O-ADR
was O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
serious O-ADR O-ADR
infections O-ADR B-ADR
; O-ADR O-ADR
therefore O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
concomitant O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
and O-ADR O-ADR
these O-ADR O-ADR
biologic O-ADR O-ADR
products O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
recommended O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
these O-ADR O-ADR
reasons O-ADR O-ADR
, O-ADR O-ADR
comparison O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
other O-ADR O-ADR
products O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
misleading O-ADR O-ADR
. O-ADR O-ADR
Possible O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
include O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
existing O-ADR O-ADR
low O-ADR O-ADR
white O-ADR O-ADR
blood O-ADR O-ADR
cell O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
WBC O-ADR O-ADR
) O-ADR O-ADR
/ O-ADR O-ADR
absolute O-ADR O-ADR
neutrophil O-ADR O-ADR
count O-ADR O-ADR
( O-ADR O-ADR
ANC O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
induced O-ADR O-ADR
leukopenia O-ADR O-ADR
/ O-ADR O-ADR
neutropenia O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
brentuximab O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
directed O-ADR O-ADR
against O-ADR O-ADR
the O-ADR O-ADR
antibody O-ADR O-ADR
component O-ADR O-ADR
of O-ADR O-ADR
brentuximab O-ADR O-ADR
vedotin O-ADR O-ADR
in O-ADR O-ADR
all O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
transiently O-ADR O-ADR
or O-ADR O-ADR
persistently O-ADR O-ADR
positive O-ADR O-ADR
antibodies O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
more O-ADR O-ADR
information O-ADR O-ADR
, O-ADR O-ADR
go O-ADR O-ADR
to O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
DUAVEE O-ADR O-ADR
. O-ADR O-ADR
com O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
call O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
438 O-ADR O-ADR
- O-ADR O-ADR
1985 O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
lowering O-ADR O-ADR
sulfonylurea O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
dosage O-ADR O-ADR
when O-ADR O-ADR
starting O-ADR O-ADR
TANZEUM O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reaction O-ADR O-ADR
Rate O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
1581 O-ADR O-ADR
Nausea B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Headache B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Feeling B-ADR B-ADR
hot I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Dizziness B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Back B-ADR B-ADR
pain I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
Vomiting B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Blood B-ADR B-ADR
pressure I-ADR I-ADR
increased I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
reactions I-ADR I-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Dysgeusia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Paresthesia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Flushing B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Parosmia B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Pruritus B-ADR B-ADR
( I-ADR I-ADR
generalized I-ADR I-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Rash B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Respiratory B-ADR O-ADR
disorders I-ADR O-ADR
( O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
respiratory B-ADR B-ADR
distress I-ADR I-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Fatigue B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Chest B-ADR B-ADR
pain I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Vertigo B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Dry B-ADR B-ADR
mouth I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Chills B-ADR B-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Feeling B-ADR B-ADR
abnormal I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
< O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
EOVIST O-ADR O-ADR
include O-ADR O-ADR
: O-ADR O-ADR
tremor B-ADR B-ADR
, O-ADR O-ADR
akathisia B-ADR B-ADR
, O-ADR O-ADR
bundle B-ADR B-ADR
branch I-ADR I-ADR
block I-ADR I-ADR
, O-ADR O-ADR
palpitation B-ADR B-ADR
, O-ADR O-ADR
oral B-ADR B-ADR
discomfort I-ADR I-ADR
, O-ADR O-ADR
salivary B-ADR B-ADR
hypersecretion I-ADR I-ADR
, O-ADR O-ADR
maculopapular B-ADR B-ADR
rash I-ADR I-ADR
, O-ADR O-ADR
hyperhidrosis B-ADR B-ADR
, O-ADR O-ADR
discomfort B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
malaise B-ADR B-ADR
. O-ADR O-ADR
Anti O-ADR O-ADR
- O-ADR O-ADR
tuberculosis O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
also O-ADR O-ADR
be O-ADR O-ADR
considered O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
CIMZIA O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
past O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
latent O-ADR O-ADR
or O-ADR O-ADR
active O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
whom O-ADR O-ADR
an O-ADR O-ADR
adequate O-ADR O-ADR
course O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
negative O-ADR O-ADR
test O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
but O-ADR O-ADR
having O-ADR O-ADR
risk O-ADR O-ADR
factors O-ADR O-ADR
for O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
list O-ADR O-ADR
also O-ADR O-ADR
includes O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
organ O-ADR O-ADR
systems O-ADR O-ADR
from O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
highest O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
NSF O-ADR O-ADR
, O-ADR O-ADR
do O-ADR O-ADR
not O-ADR O-ADR
exceed O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
Gadavist O-ADR O-ADR
dose O-ADR O-ADR
and O-ADR O-ADR
allow O-ADR O-ADR
a O-ADR O-ADR
sufficient O-ADR O-ADR
period O-ADR O-ADR
of O-ADR O-ADR
time O-ADR O-ADR
for O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administration O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypoglycemia B-ADR B-ADR
: O-ADR O-ADR
Can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
insulin O-ADR O-ADR
secretagogues O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
sulfonylureas O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
insulin O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
initiated O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
active O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
clinically O-ADR O-ADR
important O-ADR O-ADR
localized O-ADR O-ADR
infections O-ADR O-ADR
. O-ADR O-ADR
Treatment O-ADR O-ADR
with O-ADR O-ADR
antibacterial O-ADR O-ADR
agents O-ADR O-ADR
can O-ADR O-ADR
alter O-ADR O-ADR
the O-ADR O-ADR
normal O-ADR O-ADR
flora O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
colon O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
permit O-ADR O-ADR
overgrowth O-ADR O-ADR
of O-ADR O-ADR
C O-ADR O-ADR
. O-ADR O-ADR
difficile O-ADR O-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
MTC O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
and O-ADR O-ADR
inform O-ADR O-ADR
them O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
tumors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
mass O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
neck O-ADR O-ADR
, O-ADR O-ADR
dysphagia O-ADR O-ADR
, O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
persistent O-ADR O-ADR
hoarseness O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
leading O-ADR O-ADR
to O-ADR O-ADR
dose O-ADR O-ADR
reduction O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
were O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
PPES B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
chills B-ADR B-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Lymphopenia B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
angioedema B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pruritus B-ADR B-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
This O-ADR O-ADR
information O-ADR O-ADR
was O-ADR O-ADR
abstracted O-ADR O-ADR
and O-ADR O-ADR
categorized O-ADR O-ADR
using O-ADR O-ADR
the O-ADR O-ADR
National O-ADR O-ADR
Cancer O-ADR O-ADR
Institute O-ADR O-ADR
( O-ADR O-ADR
NCI O-ADR O-ADR
) O-ADR O-ADR
` O-ADR O-ADR
` O-ADR O-ADR
Common O-ADR O-ADR
Terminology O-ADR O-ADR
Criteria O-ADR O-ADR
for O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
' O-ADR O-ADR
' O-ADR O-ADR
( O-ADR O-ADR
CTCAE O-ADR O-ADR
) O-ADR O-ADR
version O-ADR O-ADR
3 O-ADR O-ADR
scale O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
pyrexia B-ADR B-ADR
( O-ADR O-ADR
62 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
36 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
febrile B-ADR B-ADR
neutropenia I-ADR I-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
( O-ADR O-ADR
25 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
( O-ADR O-ADR
23 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
constipation B-ADR B-ADR
( O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Across O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
administered O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
RPED B-ADR B-ADR
was O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
/ O-ADR O-ADR
202 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
patients O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
1 O-ADR O-ADR
month O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
or O-ADR O-ADR
preterm O-ADR O-ADR
infants O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
corrected O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
less O-ADR O-ADR
than O-ADR O-ADR
44 O-ADR O-ADR
weeks O-ADR O-ADR
) O-ADR O-ADR
could O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
gasping B-ADR B-ADR
syndrome I-ADR I-ADR
if O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequent O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
injection B-ADR B-ADR
site I-ADR I-ADR
coldness I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
burning B-ADR B-ADR
sensation I-ADR I-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
End O-ADR O-ADR
- O-ADR O-ADR
Stage O-ADR O-ADR
Renal O-ADR O-ADR
Disease O-ADR O-ADR
No O-ADR O-ADR
studies O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
conducted O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
end O-ADR O-ADR
- O-ADR O-ADR
stage O-ADR O-ADR
renal O-ADR O-ADR
disease O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
L O-ADR O-ADR
ong O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
beta O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
adrenergic O-ADR O-ADR
agonists O-ADR O-ADR
, O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
A O-ADR O-ADR
RCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
, O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
asthma O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
death B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
Chronic O-ADR O-ADR
Obstructive O-ADR O-ADR
Pulmonary O-ADR O-ADR
Disease O-ADR O-ADR
The O-ADR O-ADR
clinical O-ADR O-ADR
program O-ADR O-ADR
for O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
included O-ADR O-ADR
7 O-ADR O-ADR
, O-ADR O-ADR
700 O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
lung O-ADR O-ADR
function O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
two O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
exacerbation O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
6 O-ADR O-ADR
other O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
shorter O-ADR O-ADR
duration O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
observed O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
trial O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
HORIZANT O-ADR O-ADR
were O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
headache B-ADR B-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
diagnosis O-ADR O-ADR
of O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
is O-ADR O-ADR
excluded O-ADR O-ADR
, O-ADR O-ADR
Kyprolis O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
restarted O-ADR O-ADR
. O-ADR O-ADR
GILENYA O-ADR O-ADR
may O-ADR O-ADR
therefore O-ADR O-ADR
increase O-ADR O-ADR
the O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
some O-ADR O-ADR
serious O-ADR O-ADR
in O-ADR O-ADR
nature O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
higher O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
malignancies O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
COPD O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
Wegener O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
granulomatosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
concomitant O-ADR O-ADR
cyclophosphamide O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
greater O-ADR O-ADR
portion O-ADR O-ADR
of O-ADR O-ADR
malignancies B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocker O-ADR O-ADR
group O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
controlled O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
Your O-ADR O-ADR
healthcare O-ADR O-ADR
provider O-ADR O-ADR
should O-ADR O-ADR
check O-ADR O-ADR
any O-ADR O-ADR
unusual O-ADR O-ADR
vaginal O-ADR O-ADR
bleeding O-ADR O-ADR
to O-ADR O-ADR
find O-ADR O-ADR
out O-ADR O-ADR
the O-ADR O-ADR
cause O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hypersensitivity B-ADR B-ADR
: O-ADR O-ADR
anaphylactic B-ADR B-ADR
reactions I-ADR I-ADR
with O-ADR O-ADR
cutaneous B-ADR B-ADR
manifestations I-ADR I-ADR
, O-ADR O-ADR
ranging O-ADR O-ADR
from O-ADR O-ADR
mild O-ADR O-ADR
to O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
death B-ADR B-ADR
, O-ADR O-ADR
have O-ADR O-ADR
uncommonly O-ADR O-ADR
occurred O-ADR O-ADR
. O-ADR O-ADR
Seventy O-ADR O-ADR
- O-ADR O-ADR
eight O-ADR O-ADR
percent O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
693 O-ADR O-ADR
of O-ADR O-ADR
893 O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
able O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
all O-ADR O-ADR
planned O-ADR O-ADR
doses O-ADR O-ADR
to O-ADR O-ADR
complete O-ADR O-ADR
their O-ADR O-ADR
prescribed O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypertension O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
adequately O-ADR O-ADR
controlled O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
risk O-ADR O-ADR
- O-ADR O-ADR
benefit O-ADR O-ADR
decision O-ADR O-ADR
on O-ADR O-ADR
continued O-ADR O-ADR
Kyprolis O-ADR O-ADR
therapy O-ADR O-ADR
is O-ADR O-ADR
needed O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
immediately O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
percentage O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
withdrew O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
study O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
was O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
and O-ADR O-ADR
Prolia O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
. O-ADR O-ADR
Male B-ADR B-ADR
genital I-ADR I-ADR
mycotic I-ADR I-ADR
infections I-ADR I-ADR
occurred O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
in O-ADR O-ADR
uncircumcised O-ADR O-ADR
males O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
males O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
balanitis O-ADR O-ADR
or O-ADR O-ADR
balanoposthitis O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
ENTEREG O-ADR O-ADR
was O-ADR O-ADR
administered O-ADR O-ADR
30 O-ADR O-ADR
minutes O-ADR O-ADR
to O-ADR O-ADR
5 O-ADR O-ADR
hours O-ADR O-ADR
before O-ADR O-ADR
the O-ADR O-ADR
scheduled O-ADR O-ADR
start O-ADR O-ADR
of O-ADR O-ADR
surgery O-ADR O-ADR
and O-ADR O-ADR
then O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
hospital O-ADR O-ADR
discharge O-ADR O-ADR
( O-ADR O-ADR
or O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
maximum O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
postoperative O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
potassium I-ADR I-ADR
were O-ADR O-ADR
more O-ADR O-ADR
commonly O-ADR O-ADR
seen O-ADR O-ADR
in O-ADR O-ADR
those O-ADR O-ADR
with O-ADR O-ADR
elevated O-ADR O-ADR
potassium O-ADR O-ADR
at O-ADR O-ADR
baseline O-ADR O-ADR
. O-ADR O-ADR
Permanent O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
treatment O-ADR O-ADR
for O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
1964 O-ADR O-ADR
patients O-ADR O-ADR
participated O-ADR O-ADR
in O-ADR O-ADR
two O-ADR O-ADR
12 O-ADR O-ADR
- O-ADR O-ADR
week O-ADR O-ADR
, O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
efficacy O-ADR O-ADR
and O-ADR O-ADR
safety O-ADR O-ADR
studies O-ADR O-ADR
and O-ADR O-ADR
subsequent O-ADR O-ADR
open O-ADR O-ADR
- O-ADR O-ADR
label O-ADR O-ADR
extension O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
: O-ADR O-ADR
Non O-ADR O-ADR
- O-ADR O-ADR
Hematologic O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
195 O-ADR O-ADR
) O-ADR O-ADR
Ofatumumab O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
191 O-ADR O-ADR
) O-ADR O-ADR
System O-ADR O-ADR
Organ O-ADR O-ADR
Class O-ADR O-ADR
ADR O-ADR O-ADR
Term O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
All O-ADR O-ADR
Grades O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
or O-ADR O-ADR
4 O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Subjects O-ADR O-ADR
with O-ADR O-ADR
multiple O-ADR O-ADR
events O-ADR O-ADR
for O-ADR O-ADR
a O-ADR O-ADR
given O-ADR O-ADR
ADR O-ADR O-ADR
term O-ADR O-ADR
are O-ADR O-ADR
counted O-ADR O-ADR
once O-ADR O-ADR
only O-ADR O-ADR
for O-ADR O-ADR
each O-ADR O-ADR
ADR O-ADR O-ADR
term O-ADR O-ADR
. O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
: O-ADR O-ADR
Pooled O-ADR O-ADR
data O-ADR O-ADR
on O-ADR O-ADR
mean O-ADR O-ADR
changes O-ADR B-ADR
in O-ADR I-ADR
body O-ADR I-ADR
weight O-ADR I-ADR
and O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
meeting O-ADR O-ADR
a O-ADR O-ADR
weight B-ADR B-ADR
gain I-ADR I-ADR
criterion O-ADR O-ADR
of O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
body O-ADR O-ADR
weight O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
, O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
schizophrenia O-ADR O-ADR
and O-ADR O-ADR
bipolar O-ADR O-ADR
mania O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
presented O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
PML O-ADR O-ADR
is O-ADR O-ADR
an O-ADR O-ADR
opportunistic O-ADR O-ADR
viral O-ADR O-ADR
infection O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
brain O-ADR O-ADR
caused O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
JC O-ADR O-ADR
virus O-ADR O-ADR
( O-ADR O-ADR
JCV O-ADR O-ADR
) O-ADR O-ADR
that O-ADR O-ADR
typically O-ADR O-ADR
only O-ADR O-ADR
occurs O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
immunocompromised O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
that O-ADR O-ADR
usually O-ADR O-ADR
leads O-ADR O-ADR
to O-ADR O-ADR
death O-ADR B-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
disability O-ADR B-ADR
. O-ADR O-ADR
Do O-ADR O-ADR
not O-ADR O-ADR
restart O-ADR O-ADR
NESINA O-ADR O-ADR
if O-ADR O-ADR
liver O-ADR O-ADR
injury O-ADR O-ADR
is O-ADR O-ADR
confirmed O-ADR O-ADR
and O-ADR O-ADR
no O-ADR O-ADR
alternative O-ADR O-ADR
etiology O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
found O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
frequently O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
APTIOM O-ADR O-ADR
at O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
800 O-ADR O-ADR
mg O-ADR O-ADR
or O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
dizziness B-ADR B-ADR
, O-ADR O-ADR
somnolence B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
diplopia B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
vertigo B-ADR B-ADR
, O-ADR O-ADR
ataxia B-ADR B-ADR
, O-ADR O-ADR
blurred B-ADR B-ADR
vision I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
tremor B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Cataracts O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
corticosteroids O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
posterior B-ADR B-ADR
subcapsular I-ADR I-ADR
cataract I-ADR I-ADR
formation O-ADR O-ADR
. O-ADR O-ADR
Hydronephrosis B-ADR B-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
one O-ADR O-ADR
of O-ADR O-ADR
whom O-ADR O-ADR
had O-ADR O-ADR
associated O-ADR O-ADR
renal B-ADR B-ADR
function I-ADR I-ADR
impairment I-ADR I-ADR
that O-ADR O-ADR
resolved O-ADR O-ADR
upon O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
POTIGA O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Urinary O-ADR O-ADR
Retention O-ADR O-ADR
POTIGA O-ADR O-ADR
caused O-ADR O-ADR
urinary B-ADR B-ADR
retention I-ADR I-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR I-ADR
abnormal O-ADR I-ADR
coagulation O-ADR I-ADR
: O-ADR O-ADR
Use O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
anticoagulant O-ADR O-ADR
medications O-ADR O-ADR
other O-ADR O-ADR
than O-ADR O-ADR
low O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
aspirin O-ADR O-ADR
within O-ADR O-ADR
7 O-ADR O-ADR
days O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
injection O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
: O-ADR O-ADR
Overall O-ADR O-ADR
Infections B-ADR B-ADR
and O-ADR O-ADR
Select O-ADR O-ADR
Infections B-ADR B-ADR
with O-ADR O-ADR
Identified O-ADR O-ADR
Etiology O-ADR O-ADR
by O-ADR O-ADR
Treatment O-ADR O-ADR
Group O-ADR O-ADR
following O-ADR O-ADR
One O-ADR O-ADR
and O-ADR O-ADR
Three O-ADR O-ADR
Years O-ADR O-ADR
of O-ADR O-ADR
Treatment O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
* O-ADR O-ADR
Up O-ADR O-ADR
to O-ADR O-ADR
Year O-ADR O-ADR
1 O-ADR O-ADR
Up O-ADR O-ADR
to O-ADR O-ADR
Year O-ADR O-ADR
3 O-ADR O-ADR
NULOJIX O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
401 O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Cyclosporine O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
405 O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
NULOJIX O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
401 O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Cyclosporine O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
405 O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
were O-ADR O-ADR
not O-ADR O-ADR
designed O-ADR O-ADR
to O-ADR O-ADR
support O-ADR O-ADR
comparative O-ADR O-ADR
claims O-ADR O-ADR
for O-ADR O-ADR
NULOJIX O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
this O-ADR O-ADR
table O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Neurological B-ADR B-ADR
toxicities I-ADR I-ADR
, O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
severe O-ADR O-ADR
, O-ADR O-ADR
life O-ADR O-ADR
- O-ADR O-ADR
threatening O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
fatal B-ADR B-ADR
, O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
. O-ADR O-ADR
Because O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
conducted O-ADR O-ADR
under O-ADR O-ADR
widely O-ADR O-ADR
varying O-ADR O-ADR
conditions O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
drug O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
directly O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
of O-ADR O-ADR
another O-ADR O-ADR
drug O-ADR O-ADR
and O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
reflect O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
practice O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
summarize O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
reported O-ADR O-ADR
for O-ADR O-ADR
Zydelig O-ADR O-ADR
+ O-ADR O-ADR
rituximab O-ADR O-ADR
and O-ADR O-ADR
placebo O-ADR O-ADR
+ O-ADR O-ADR
rituximab O-ADR O-ADR
arms O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
Reported O-ADR O-ADR
by O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
Treated O-ADR O-ADR
with O-ADR O-ADR
Either O-ADR O-ADR
the O-ADR O-ADR
NULOJIX O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
or O-ADR O-ADR
Control O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
Through O-ADR O-ADR
Three O-ADR O-ADR
Years O-ADR O-ADR
* O-ADR O-ADR
, O-ADR O-ADR
Adverse O-ADR O-ADR
Reaction O-ADR O-ADR
NULOJIX O-ADR O-ADR
Recommended O-ADR O-ADR
Regimen O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
401 O-ADR O-ADR
% O-ADR O-ADR
Cyclosporine O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
405 O-ADR O-ADR
% O-ADR O-ADR
* O-ADR O-ADR
All O-ADR O-ADR
randomized O-ADR O-ADR
and O-ADR O-ADR
transplanted O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
Studies O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Prednisone O-ADR O-ADR
reduction O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
accomplished O-ADR O-ADR
by O-ADR O-ADR
reducing O-ADR O-ADR
the O-ADR O-ADR
daily O-ADR O-ADR
prednisone O-ADR O-ADR
dose O-ADR O-ADR
by O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
mg O-ADR O-ADR
on O-ADR O-ADR
a O-ADR O-ADR
weekly O-ADR O-ADR
basis O-ADR O-ADR
during O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Acorda O-ADR O-ADR
Therapeutics O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
367 O-ADR O-ADR
- O-ADR O-ADR
5109 O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
paradoxical O-ADR O-ADR
bronchospasm O-ADR O-ADR
occurs O-ADR O-ADR
following O-ADR O-ADR
dosing O-ADR O-ADR
with O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
immediately O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
inhaled O-ADR O-ADR
, O-ADR O-ADR
short O-ADR O-ADR
- O-ADR O-ADR
acting O-ADR O-ADR
bronchodilator O-ADR O-ADR
; O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
discontinued O-ADR O-ADR
immediately O-ADR O-ADR
; O-ADR O-ADR
and O-ADR O-ADR
alternative O-ADR O-ADR
therapy O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
4 O-ADR O-ADR
studies O-ADR O-ADR
FARXIGA O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
monotherapy O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
in O-ADR O-ADR
8 O-ADR O-ADR
studies O-ADR O-ADR
FARXIGA O-ADR O-ADR
was O-ADR O-ADR
used O-ADR O-ADR
as O-ADR O-ADR
add O-ADR O-ADR
- O-ADR O-ADR
on O-ADR O-ADR
to O-ADR O-ADR
background O-ADR O-ADR
antidiabetic O-ADR O-ADR
therapy O-ADR O-ADR
or O-ADR O-ADR
as O-ADR O-ADR
combination O-ADR O-ADR
therapy O-ADR O-ADR
with O-ADR O-ADR
metformin O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Clinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Tables O-ADR O-ADR
2 O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
summarize O-ADR O-ADR
the O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
and O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
ZYKADIA O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
during O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
chromaturia B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
alanine B-ADR B-ADR
aminotransferase I-ADR I-ADR
increased I-ADR I-ADR
, O-ADR O-ADR
arthralgia B-ADR B-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
feasible O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
Natazia O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
4 O-ADR O-ADR
weeks O-ADR O-ADR
before O-ADR O-ADR
and O-ADR O-ADR
through O-ADR O-ADR
2 O-ADR O-ADR
weeks O-ADR O-ADR
after O-ADR O-ADR
major O-ADR O-ADR
surgery O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
surgeries O-ADR O-ADR
known O-ADR O-ADR
to O-ADR O-ADR
have O-ADR O-ADR
an O-ADR O-ADR
elevated O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
thromboembolism O-ADR O-ADR
. O-ADR O-ADR
Less O-ADR O-ADR
Common O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
additional O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
< O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
HALAVEN O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Eye O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
increased B-ADR B-ADR
lacrimation I-ADR I-ADR
* O-ADR O-ADR
Gastrointestinal O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
dyspepsia B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
stomatitis B-ADR B-ADR
, O-ADR O-ADR
dry B-ADR B-ADR
mouth I-ADR I-ADR
* O-ADR O-ADR
General O-ADR O-ADR
Disorders O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
Site O-ADR O-ADR
Conditions O-ADR O-ADR
: O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
* O-ADR O-ADR
Infections O-ADR O-ADR
and O-ADR O-ADR
Infestations O-ADR O-ADR
: O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
* O-ADR O-ADR
Metabolism O-ADR O-ADR
and O-ADR O-ADR
Nutrition O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
hypokalemia B-ADR B-ADR
* O-ADR O-ADR
Musculoskeletal O-ADR O-ADR
and O-ADR O-ADR
Connective O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
muscle B-ADR B-ADR
spasms I-ADR I-ADR
, O-ADR O-ADR
muscular B-ADR B-ADR
weakness I-ADR I-ADR
* O-ADR O-ADR
Nervous O-ADR O-ADR
System O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
dysgeusia B-ADR B-ADR
, O-ADR O-ADR
dizziness B-ADR B-ADR
* O-ADR O-ADR
Psychiatric O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
* O-ADR O-ADR
Skin O-ADR O-ADR
and O-ADR O-ADR
Subcutaneous O-ADR O-ADR
Tissue O-ADR O-ADR
Disorders O-ADR O-ADR
: O-ADR O-ADR
rash B-ADR B-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
Neutralizing O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
I O-ADR O-ADR
or O-ADR O-ADR
AUX O-ADR O-ADR
- O-ADR O-ADR
II O-ADR O-ADR
, O-ADR O-ADR
were O-ADR O-ADR
detected O-ADR O-ADR
in O-ADR O-ADR
60 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
51 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
, O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
tested O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Hepatotoxicity B-ADR B-ADR
: O-ADR O-ADR
ZYKADIA O-ADR O-ADR
can O-ADR O-ADR
cause O-ADR O-ADR
hepatotoxicity B-ADR B-ADR
. O-ADR O-ADR
Avoid O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
ADCETRIS O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
moderate O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
B O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
( O-ADR O-ADR
Child O-ADR O-ADR
- O-ADR O-ADR
Pugh O-ADR O-ADR
C O-ADR O-ADR
) O-ADR O-ADR
hepatic O-ADR O-ADR
impairment O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Use O-ADR O-ADR
in O-ADR O-ADR
Specific O-ADR O-ADR
Populations O-ADR O-ADR
( O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
rashes B-ADR B-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
placebo O-ADR O-ADR
subjects O-ADR O-ADR
. O-ADR O-ADR
During O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
proportion O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
was O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
CIMZIA O-ADR O-ADR
and O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
for O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pruritus B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
colitis B-ADR B-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
in O-ADR O-ADR
adults O-ADR O-ADR
was O-ADR O-ADR
diarrhea B-ADR B-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
associated O-ADR O-ADR
with O-ADR O-ADR
Zydelig O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
and O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
other O-ADR O-ADR
sections O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
prescribing O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
some O-ADR O-ADR
cases O-ADR O-ADR
, O-ADR O-ADR
disseminated B-ADR B-ADR
intravascular I-ADR I-ADR
coagulation I-ADR I-ADR
( O-ADR O-ADR
DIC B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
capillary B-ADR B-ADR
leak I-ADR I-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
CLS B-ADR B-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
hemophagocytic B-ADR B-ADR
lymphohistiocytosis O-ADR I-ADR
/ O-ADR O-ADR
macrophage O-ADR O-ADR
activation B-ADR B-ADR
syndrome I-ADR I-ADR
( O-ADR O-ADR
HLH O-ADR O-ADR
/ O-ADR O-ADR
MAS O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
setting O-ADR O-ADR
of O-ADR O-ADR
CRS B-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Postmarketing O-ADR O-ADR
Experience O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
identified O-ADR O-ADR
during O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
approval O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
occurring O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
thrombocytopenia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
fatigue B-ADR B-ADR
, O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
upper B-ADR B-ADR
respiratory I-ADR I-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
bruising B-ADR B-ADR
, O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
and O-ADR O-ADR
decreased B-ADR B-ADR
appetite I-ADR I-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Tables O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Preventive O-ADR O-ADR
measures O-ADR O-ADR
include O-ADR O-ADR
vigorous O-ADR O-ADR
hydration O-ADR O-ADR
and O-ADR O-ADR
close O-ADR O-ADR
monitoring O-ADR O-ADR
of O-ADR O-ADR
blood O-ADR O-ADR
chemistry O-ADR O-ADR
, O-ADR O-ADR
particularly O-ADR O-ADR
potassium O-ADR O-ADR
and O-ADR O-ADR
uric O-ADR O-ADR
acid O-ADR O-ADR
levels O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
reductions O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
XALKORI O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
for O-ADR O-ADR
hepatosplenic O-ADR B-ADR
T O-ADR I-ADR
- O-ADR O-ADR
cell O-ADR O-ADR
lymphoma O-ADR I-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
can O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
excluded O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Reversible B-ADR B-ADR
Posterior I-ADR I-ADR
Leukoencephalopathy I-ADR I-ADR
Syndrome I-ADR I-ADR
( O-ADR O-ADR
RPLS B-ADR B-ADR
) O-ADR O-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
factors O-ADR O-ADR
that O-ADR O-ADR
contribute O-ADR O-ADR
to O-ADR O-ADR
fracture O-ADR O-ADR
risk O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
INVOKANA O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Based O-ADR O-ADR
on O-ADR O-ADR
effective O-ADR O-ADR
donor O-ADR O-ADR
screening O-ADR O-ADR
and O-ADR O-ADR
product O-ADR O-ADR
manufacturing O-ADR O-ADR
processes O-ADR O-ADR
, O-ADR O-ADR
it O-ADR O-ADR
carries O-ADR O-ADR
an O-ADR O-ADR
extremely O-ADR O-ADR
remote O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
transmission B-ADR O-ADR
of I-ADR O-ADR
viral I-ADR B-ADR
diseases I-ADR I-ADR
. O-ADR O-ADR
Seventy O-ADR O-ADR
- O-ADR O-ADR
seven O-ADR O-ADR
subjects O-ADR O-ADR
initiated O-ADR O-ADR
a O-ADR O-ADR
lipid O-ADR O-ADR
- O-ADR O-ADR
lowering O-ADR O-ADR
agent O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
; O-ADR O-ADR
their O-ADR O-ADR
last O-ADR O-ADR
fasted O-ADR O-ADR
on O-ADR O-ADR
- O-ADR O-ADR
treatment O-ADR O-ADR
values O-ADR O-ADR
( O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
starting O-ADR O-ADR
the O-ADR O-ADR
agent O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
used O-ADR O-ADR
regardless O-ADR O-ADR
if O-ADR O-ADR
they O-ADR O-ADR
discontinued O-ADR O-ADR
the O-ADR O-ADR
agent O-ADR O-ADR
( O-ADR O-ADR
SPRING O-ADR O-ADR
- O-ADR O-ADR
2 O-ADR O-ADR
: O-ADR O-ADR
TIVICAY O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
9 O-ADR O-ADR
, O-ADR O-ADR
raltegravir O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
13 O-ADR O-ADR
; O-ADR O-ADR
SINGLE O-ADR O-ADR
: O-ADR O-ADR
TIVICAY O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
25 O-ADR O-ADR
and O-ADR O-ADR
ATRIPLA O-ADR O-ADR
: O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
safety O-ADR O-ADR
profile O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
was O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
that O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
subjects O-ADR O-ADR
without O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
, O-ADR O-ADR
although O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
of O-ADR O-ADR
ALT B-ADR B-ADR
abnormalities I-ADR I-ADR
were O-ADR O-ADR
higher O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
subgroup O-ADR O-ADR
with O-ADR O-ADR
hepatitis O-ADR O-ADR
B O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
C O-ADR O-ADR
virus O-ADR O-ADR
co O-ADR O-ADR
- O-ADR O-ADR
infection O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
treatment O-ADR O-ADR
groups O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Increased O-ADR O-ADR
Risks O-ADR O-ADR
in O-ADR O-ADR
Elderly O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
Dementia O-ADR O-ADR
- O-ADR O-ADR
Related O-ADR O-ADR
Psychosis O-ADR O-ADR
Increased O-ADR O-ADR
Mortality O-ADR O-ADR
Elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
atypical O-ADR O-ADR
antipsychotic O-ADR O-ADR
drugs O-ADR O-ADR
are O-ADR O-ADR
at O-ADR O-ADR
an O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
death B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
Overall O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
mean O-ADR O-ADR
age O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
PHN O-ADR O-ADR
studies O-ADR O-ADR
ranged O-ADR O-ADR
from O-ADR O-ADR
61 O-ADR O-ADR
to O-ADR O-ADR
64 O-ADR O-ADR
years O-ADR O-ADR
of O-ADR O-ADR
age O-ADR O-ADR
across O-ADR O-ADR
dose O-ADR O-ADR
groups O-ADR O-ADR
; O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
male O-ADR O-ADR
( O-ADR O-ADR
45 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
61 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Caucasian O-ADR O-ADR
( O-ADR O-ADR
80 O-ADR O-ADR
% O-ADR O-ADR
to O-ADR O-ADR
98 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
in O-ADR O-ADR
COPD B-ADR O-ADR
or O-ADR O-ADR
loss B-ADR O-ADR
of I-ADR O-ADR
efficacy I-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Leukopenia B-ADR B-ADR
, O-ADR O-ADR
Neutropenia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Agranulocytosis B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
antipsychotics O-ADR O-ADR
. O-ADR O-ADR
GILOTRIF O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
keratitis O-ADR O-ADR
, O-ADR O-ADR
ulcerative O-ADR O-ADR
keratitis O-ADR O-ADR
, O-ADR O-ADR
or O-ADR O-ADR
severe O-ADR O-ADR
dry O-ADR O-ADR
eye O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
resulting O-ADR O-ADR
in O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
treatment O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BENLYSTA O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
infusion B-ADR B-ADR
reactions I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
lupus B-ADR B-ADR
nephritis I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
infections B-ADR B-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
% O-ADR O-ADR
BENLYSTA O-ADR O-ADR
and O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
ULESFIA O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
Lotion O-ADR O-ADR
may O-ADR O-ADR
cause O-ADR O-ADR
eye B-ADR B-ADR
irritation I-ADR I-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
VORAXAZE O-ADR O-ADR
methotrexate O-ADR O-ADR
concentrations O-ADR O-ADR
> O-ADR O-ADR
100 O-ADR O-ADR
mumol O-ADR O-ADR
/ O-ADR O-ADR
L O-ADR O-ADR
were O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
a O-ADR O-ADR
second O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
VORAXAZE O-ADR O-ADR
48 O-ADR O-ADR
hours O-ADR O-ADR
after O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
dose O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
toxicity O-ADR O-ADR
recurs O-ADR O-ADR
at O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
consider O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
Common O-ADR O-ADR
Terminology O-ADR O-ADR
Criteria O-ADR O-ADR
( O-ADR O-ADR
CTC O-ADR O-ADR
) O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
and O-ADR O-ADR
4 O-ADR O-ADR
non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
was O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Stopping O-ADR O-ADR
or O-ADR O-ADR
slowing O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
cessation O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
. O-ADR O-ADR
After O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
, O-ADR O-ADR
observe O-ADR O-ADR
patients O-ADR O-ADR
carefully O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
pancreatitis O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
persistent O-ADR O-ADR
severe O-ADR O-ADR
abdominal O-ADR O-ADR
pain O-ADR O-ADR
, O-ADR O-ADR
sometimes O-ADR O-ADR
radiating O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
back O-ADR O-ADR
and O-ADR O-ADR
which O-ADR O-ADR
may O-ADR O-ADR
or O-ADR O-ADR
may O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
accompanied O-ADR O-ADR
by O-ADR O-ADR
vomiting O-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
closely O-ADR O-ADR
monitored O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
infection O-ADR O-ADR
during O-ADR O-ADR
and O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
CIMZIA O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
possible O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
tuberculosis O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
tested O-ADR O-ADR
negative O-ADR O-ADR
for O-ADR O-ADR
latent O-ADR O-ADR
tuberculosis O-ADR O-ADR
infection O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
initiating O-ADR O-ADR
therapy O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
comparator O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
subject O-ADR O-ADR
with O-ADR O-ADR
normal O-ADR O-ADR
baseline O-ADR O-ADR
transaminases O-ADR O-ADR
had O-ADR O-ADR
post O-ADR O-ADR
- O-ADR O-ADR
baseline O-ADR O-ADR
ALT B-ADR B-ADR
elevation I-ADR I-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
10 O-ADR O-ADR
times O-ADR O-ADR
ULN O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Nephrogenic B-ADR B-ADR
Systemic I-ADR I-ADR
Fibrosis I-ADR I-ADR
has O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
impaired O-ADR O-ADR
elimination O-ADR O-ADR
of O-ADR O-ADR
GBCAs O-ADR O-ADR
. O-ADR O-ADR
SAPHRIS O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
used O-ADR O-ADR
cautiously O-ADR O-ADR
when O-ADR O-ADR
treating O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
receive O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
other O-ADR O-ADR
drugs O-ADR O-ADR
that O-ADR O-ADR
can O-ADR O-ADR
induce O-ADR O-ADR
hypotension O-ADR O-ADR
, O-ADR O-ADR
bradycardia O-ADR O-ADR
, O-ADR O-ADR
respiratory O-ADR O-ADR
or O-ADR O-ADR
central O-ADR O-ADR
nervous O-ADR O-ADR
system O-ADR O-ADR
depression O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Immunogenicity O-ADR O-ADR
As O-ADR O-ADR
with O-ADR O-ADR
all O-ADR O-ADR
therapeutic O-ADR O-ADR
proteins O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
is O-ADR O-ADR
a O-ADR O-ADR
potential O-ADR O-ADR
for O-ADR O-ADR
an O-ADR O-ADR
immune O-ADR O-ADR
response O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
EYLEA O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
reactivation O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
stop O-ADR O-ADR
SIMPONI O-ADR O-ADR
ARIA O-ADR O-ADR
and O-ADR O-ADR
begin O-ADR O-ADR
anti O-ADR O-ADR
- O-ADR O-ADR
viral O-ADR O-ADR
therapy O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Inactive O-ADR O-ADR
Ingredients O-ADR O-ADR
: O-ADR O-ADR
calcium O-ADR O-ADR
phosphate O-ADR O-ADR
tribasic O-ADR O-ADR
, O-ADR O-ADR
hydroxypropyl O-ADR O-ADR
cellulose O-ADR O-ADR
, O-ADR O-ADR
microcrystalline O-ADR O-ADR
cellulose O-ADR O-ADR
, O-ADR O-ADR
powdered O-ADR O-ADR
cellulose O-ADR O-ADR
, O-ADR O-ADR
hypromellose O-ADR O-ADR
, O-ADR O-ADR
lactose O-ADR O-ADR
monohydrate O-ADR O-ADR
, O-ADR O-ADR
magnesium O-ADR O-ADR
stearate O-ADR O-ADR
, O-ADR O-ADR
polyethylene O-ADR O-ADR
glycol O-ADR O-ADR
, O-ADR O-ADR
sucrose O-ADR O-ADR
, O-ADR O-ADR
ascorbic O-ADR O-ADR
acid O-ADR O-ADR
, O-ADR O-ADR
sucrose O-ADR O-ADR
palmitic O-ADR O-ADR
acid O-ADR O-ADR
ester O-ADR O-ADR
, O-ADR O-ADR
hydroxyethylcellulose O-ADR O-ADR
, O-ADR O-ADR
titanium O-ADR O-ADR
dioxide O-ADR O-ADR
, O-ADR O-ADR
red O-ADR O-ADR
iron O-ADR O-ADR
oxide O-ADR O-ADR
, O-ADR O-ADR
yellow O-ADR O-ADR
iron O-ADR O-ADR
oxide O-ADR O-ADR
, O-ADR O-ADR
black O-ADR O-ADR
iron O-ADR O-ADR
oxide O-ADR O-ADR
, O-ADR O-ADR
povidone O-ADR O-ADR
, O-ADR O-ADR
polydextrose O-ADR O-ADR
, O-ADR O-ADR
maltitol O-ADR O-ADR
, O-ADR O-ADR
poloxamer O-ADR O-ADR
188 O-ADR O-ADR
, O-ADR O-ADR
propylene O-ADR O-ADR
glycol O-ADR O-ADR
, O-ADR O-ADR
isopropyl O-ADR O-ADR
alcohol O-ADR O-ADR
. O-ADR O-ADR
Respiratory O-ADR O-ADR
, O-ADR O-ADR
thoracic O-ADR O-ADR
and O-ADR O-ADR
mediastinal O-ADR O-ADR
disorders O-ADR O-ADR
: O-ADR O-ADR
noninfectious B-ADR B-ADR
pulmonary I-ADR I-ADR
toxicity I-ADR I-ADR
including O-ADR O-ADR
pneumonitis B-ADR B-ADR
, O-ADR O-ADR
interstitial B-ADR B-ADR
lung I-ADR I-ADR
disease I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
ARDS B-ADR B-ADR
( O-ADR O-ADR
some O-ADR O-ADR
with O-ADR O-ADR
fatal B-ADR B-ADR
outcomes O-ADR O-ADR
) O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
10 O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Management O-ADR O-ADR
of O-ADR O-ADR
Immunosuppression O-ADR O-ADR
Only O-ADR O-ADR
physicians O-ADR O-ADR
experienced O-ADR O-ADR
in O-ADR O-ADR
management O-ADR O-ADR
of O-ADR O-ADR
systemic O-ADR O-ADR
immunosuppressant O-ADR O-ADR
therapy O-ADR O-ADR
in O-ADR O-ADR
transplantation O-ADR O-ADR
should O-ADR O-ADR
prescribe O-ADR O-ADR
NULOJIX O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
: O-ADR O-ADR
Incidence O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
of O-ADR O-ADR
Patients O-ADR O-ADR
With O-ADR O-ADR
Lipid B-ADR O-ADR
Abnormalities I-ADR O-ADR
of O-ADR O-ADR
Potential O-ADR O-ADR
Clinical O-ADR O-ADR
Significance O-ADR O-ADR
* O-ADR O-ADR
PRISTIQ O-ADR O-ADR
Placebo O-ADR O-ADR
50 O-ADR O-ADR
mg O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
400 O-ADR O-ADR
mg O-ADR O-ADR
Total B-ADR B-ADR
Cholesterol I-ADR I-ADR
* O-ADR I-ADR
( I-ADR O-ADR
Increase I-ADR B-ADR
of I-ADR O-ADR
> I-ADR O-ADR
= I-ADR O-ADR
50 I-ADR O-ADR
mg I-ADR I-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
and I-ADR O-ADR
an I-ADR O-ADR
absolute I-ADR O-ADR
value I-ADR O-ADR
of I-ADR O-ADR
> I-ADR O-ADR
= I-ADR O-ADR
261 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
3 O-ADR O-ADR
4 O-ADR O-ADR
4 O-ADR O-ADR
10 O-ADR O-ADR
LDL B-ADR B-ADR
Cholesterol I-ADR I-ADR
* O-ADR O-ADR
( I-ADR O-ADR
Increase I-ADR B-ADR
> I-ADR I-ADR
= I-ADR I-ADR
50 I-ADR O-ADR
mg I-ADR I-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
and I-ADR O-ADR
an I-ADR O-ADR
absolute I-ADR O-ADR
value I-ADR O-ADR
of I-ADR O-ADR
> I-ADR O-ADR
= I-ADR O-ADR
190 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
Triglycerides B-ADR O-ADR
, I-ADR O-ADR
fasting I-ADR O-ADR
* O-ADR O-ADR
( I-ADR O-ADR
Fasting I-ADR O-ADR
: I-ADR O-ADR
> I-ADR O-ADR
= I-ADR O-ADR
327 I-ADR O-ADR
mg I-ADR O-ADR
/ O-ADR O-ADR
dl O-ADR O-ADR
) O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
4 O-ADR O-ADR
6 O-ADR O-ADR
Proteinuria O-ADR O-ADR
Proteinuria B-ADR B-ADR
, O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
trace O-ADR O-ADR
, O-ADR O-ADR
was O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pre O-ADR O-ADR
- O-ADR O-ADR
marketing O-ADR O-ADR
fixed O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
AFINITOR O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
introduced O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
daily O-ADR O-ADR
dose O-ADR O-ADR
approximately O-ADR O-ADR
50 O-ADR O-ADR
% O-ADR O-ADR
lower O-ADR O-ADR
than O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
previously O-ADR O-ADR
administered O-ADR O-ADR
depending O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
individual O-ADR O-ADR
clinical O-ADR O-ADR
circumstances O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Dosage O-ADR O-ADR
and O-ADR O-ADR
Administration O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
None O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
antibodies O-ADR O-ADR
were O-ADR O-ADR
shown O-ADR O-ADR
to O-ADR O-ADR
neutralize O-ADR O-ADR
the O-ADR O-ADR
activity O-ADR O-ADR
of O-ADR O-ADR
albiglutide O-ADR O-ADR
in O-ADR O-ADR
an O-ADR O-ADR
in O-ADR O-ADR
vitro O-ADR O-ADR
bioassay O-ADR O-ADR
. O-ADR O-ADR
VORAXAZE O-ADR O-ADR
was O-ADR O-ADR
given O-ADR O-ADR
at O-ADR O-ADR
a O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
50 O-ADR O-ADR
Units O-ADR O-ADR
/ O-ADR O-ADR
kg O-ADR O-ADR
as O-ADR O-ADR
an O-ADR O-ADR
intravenous O-ADR O-ADR
injection O-ADR O-ADR
over O-ADR O-ADR
5 O-ADR O-ADR
minutes O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Eye O-ADR O-ADR
Irritation O-ADR O-ADR
Avoid O-ADR O-ADR
eye O-ADR O-ADR
exposure O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
develop O-ADR O-ADR
radiological O-ADR O-ADR
changes O-ADR O-ADR
suggestive O-ADR O-ADR
of O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis O-ADR O-ADR
and O-ADR O-ADR
have O-ADR O-ADR
few O-ADR O-ADR
or O-ADR O-ADR
no O-ADR O-ADR
symptoms O-ADR O-ADR
may O-ADR O-ADR
continue O-ADR O-ADR
AFINITOR O-ADR O-ADR
therapy O-ADR O-ADR
without O-ADR O-ADR
dose O-ADR O-ADR
alteration O-ADR O-ADR
. O-ADR O-ADR
Postherpetic O-ADR O-ADR
Neuralgia O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
HORIZANT O-ADR O-ADR
in O-ADR O-ADR
417 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
PHN O-ADR O-ADR
included O-ADR O-ADR
207 O-ADR O-ADR
patients O-ADR O-ADR
exposed O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
experienced O-ADR O-ADR
anaphylaxis O-ADR O-ADR
or O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
caution O-ADR O-ADR
when O-ADR O-ADR
they O-ADR O-ADR
are O-ADR O-ADR
re O-ADR O-ADR
- O-ADR O-ADR
administered O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
received O-ADR O-ADR
INVOKANA O-ADR O-ADR
100 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
833 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
INVOKANA O-ADR O-ADR
300 O-ADR O-ADR
mg O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
834 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
placebo O-ADR O-ADR
( O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
646 O-ADR O-ADR
) O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
. O-ADR O-ADR
To O-ADR O-ADR
prevent O-ADR O-ADR
ectropion O-ADR O-ADR
, O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
products O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
injected O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
medial O-ADR O-ADR
lower O-ADR O-ADR
eyelid O-ADR O-ADR
area O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Human O-ADR O-ADR
Albumin O-ADR O-ADR
and O-ADR O-ADR
Transmission O-ADR O-ADR
of O-ADR O-ADR
Viral O-ADR O-ADR
Diseases O-ADR O-ADR
This O-ADR O-ADR
product O-ADR O-ADR
contains O-ADR O-ADR
albumin O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
derivative O-ADR O-ADR
of O-ADR O-ADR
human O-ADR O-ADR
blood O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
effect O-ADR O-ADR
of O-ADR O-ADR
FANAPT O-ADR O-ADR
on O-ADR O-ADR
the O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
was O-ADR O-ADR
augmented O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
presence O-ADR O-ADR
of O-ADR O-ADR
CYP450 O-ADR O-ADR
2D6 O-ADR O-ADR
or O-ADR O-ADR
3A4 O-ADR O-ADR
metabolic O-ADR O-ADR
inhibition O-ADR O-ADR
( O-ADR O-ADR
paroxetine O-ADR O-ADR
20 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
and O-ADR O-ADR
ketoconazole O-ADR O-ADR
200 O-ADR O-ADR
mg O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Withhold O-ADR O-ADR
Kyprolis O-ADR O-ADR
and O-ADR O-ADR
evaluate O-ADR O-ADR
promptly O-ADR O-ADR
. O-ADR O-ADR
Melanoma B-ADR B-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blocking O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
the O-ADR O-ADR
subcutaneous O-ADR O-ADR
formulation O-ADR O-ADR
of O-ADR O-ADR
golimumab O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
patients O-ADR O-ADR
at O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
chronically O-ADR O-ADR
reduced O-ADR O-ADR
renal O-ADR O-ADR
function O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Limiting O-ADR O-ADR
the O-ADR O-ADR
dose O-ADR O-ADR
injected O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
sternocleidomastoid O-ADR O-ADR
muscle O-ADR O-ADR
may O-ADR O-ADR
decrease O-ADR O-ADR
the O-ADR O-ADR
occurrence O-ADR O-ADR
of O-ADR O-ADR
dysphagia O-ADR O-ADR
. O-ADR O-ADR
Increases O-ADR O-ADR
in O-ADR O-ADR
Serum O-ADR O-ADR
Phosphate O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
serum I-ADR I-ADR
phosphate I-ADR I-ADR
levels O-ADR I-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
. O-ADR O-ADR
Dose O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
increases B-ADR B-ADR
in I-ADR I-ADR
non I-ADR I-ADR
- O-ADR O-ADR
HDL O-ADR O-ADR
- O-ADR O-ADR
C O-ADR O-ADR
with O-ADR O-ADR
INVOKANA O-ADR O-ADR
were O-ADR O-ADR
observed O-ADR O-ADR
. O-ADR O-ADR
All O-ADR O-ADR
but O-ADR O-ADR
one O-ADR O-ADR
subject O-ADR O-ADR
who O-ADR O-ADR
died B-ADR B-ADR
of O-ADR O-ADR
TB O-ADR O-ADR
had O-ADR O-ADR
not O-ADR O-ADR
converted O-ADR O-ADR
or O-ADR O-ADR
had O-ADR O-ADR
relapsed O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
Experience O-ADR O-ADR
Mantle O-ADR O-ADR
Cell O-ADR O-ADR
Lymphoma O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
IMBRUVICA O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
that O-ADR O-ADR
included O-ADR O-ADR
111 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
MCL O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
560 O-ADR O-ADR
mg O-ADR O-ADR
daily O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
median O-ADR O-ADR
treatment O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
8 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
and O-ADR O-ADR
Uncontrolled O-ADR O-ADR
Studies O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
and O-ADR O-ADR
uncontrolled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
, O-ADR O-ADR
a O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2513 O-ADR O-ADR
patients O-ADR O-ADR
have O-ADR O-ADR
received O-ADR O-ADR
TECFIDERA O-ADR O-ADR
and O-ADR O-ADR
been O-ADR O-ADR
followed O-ADR O-ADR
for O-ADR O-ADR
periods O-ADR O-ADR
up O-ADR O-ADR
to O-ADR O-ADR
4 O-ADR O-ADR
years O-ADR O-ADR
with O-ADR O-ADR
an O-ADR O-ADR
overall O-ADR O-ADR
exposure O-ADR O-ADR
of O-ADR O-ADR
4603 O-ADR O-ADR
person O-ADR O-ADR
- O-ADR O-ADR
years O-ADR O-ADR
. O-ADR O-ADR
Infusion B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reactions I-ADR I-ADR
within O-ADR I-ADR
one O-ADR I-ADR
hour O-ADR I-ADR
of O-ADR I-ADR
infusion O-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
dose O-ADR O-ADR
of O-ADR O-ADR
NULOJIX O-ADR O-ADR
, O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
placebo O-ADR O-ADR
rate O-ADR O-ADR
. O-ADR O-ADR
Fungal B-ADR B-ADR
infections I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
18 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
NULOJIX O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
22 O-ADR O-ADR
% O-ADR O-ADR
receiving O-ADR O-ADR
cyclosporine O-ADR O-ADR
, O-ADR O-ADR
primarily O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
mucocutaneous B-ADR B-ADR
fungal I-ADR I-ADR
infections I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
best O-ADR O-ADR
method O-ADR O-ADR
of O-ADR O-ADR
detection O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
abnormalities O-ADR O-ADR
and O-ADR O-ADR
the O-ADR O-ADR
optimal O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
periodic O-ADR O-ADR
ophthalmologic O-ADR O-ADR
monitoring O-ADR O-ADR
are O-ADR O-ADR
unknown O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
active O-ADR O-ADR
group O-ADR O-ADR
were O-ADR O-ADR
between O-ADR O-ADR
the O-ADR O-ADR
ages O-ADR O-ADR
of O-ADR O-ADR
18 O-ADR O-ADR
and O-ADR O-ADR
64 O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
HIV O-ADR O-ADR
- O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
infected O-ADR O-ADR
subjects O-ADR O-ADR
receiving O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
Phase O-ADR O-ADR
3 O-ADR O-ADR
trials O-ADR O-ADR
due O-ADR O-ADR
to O-ADR O-ADR
rash B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
experienced O-ADR O-ADR
a O-ADR O-ADR
prior O-ADR O-ADR
infusion O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reaction O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
premedicated O-ADR O-ADR
for O-ADR O-ADR
subsequent O-ADR O-ADR
infusions O-ADR O-ADR
. O-ADR O-ADR
Discontinuations O-ADR O-ADR
resulting O-ADR O-ADR
from O-ADR O-ADR
these O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
common O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
group O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Immune O-ADR O-ADR
Reconstitution O-ADR O-ADR
Syndrome O-ADR O-ADR
Immune B-ADR B-ADR
reconstitution I-ADR I-ADR
syndrome I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
combination O-ADR O-ADR
antiretroviral O-ADR O-ADR
therapy O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
INTELENCE O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Leukoencephalopathy O-ADR O-ADR
Cranial O-ADR O-ADR
magnetic O-ADR O-ADR
resonance O-ADR O-ADR
imaging O-ADR O-ADR
( O-ADR O-ADR
MRI O-ADR O-ADR
) O-ADR O-ADR
changes O-ADR O-ADR
showing O-ADR O-ADR
leukoencephalopathy B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
BLINCYTO O-ADR O-ADR
, O-ADR O-ADR
especially O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
prior O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
cranial O-ADR O-ADR
irradiation O-ADR O-ADR
and O-ADR O-ADR
antileukemic O-ADR O-ADR
chemotherapy O-ADR O-ADR
( O-ADR O-ADR
including O-ADR O-ADR
systemic O-ADR O-ADR
high O-ADR O-ADR
- O-ADR O-ADR
dose O-ADR O-ADR
methotrexate O-ADR O-ADR
or O-ADR O-ADR
intrathecal O-ADR O-ADR
cytarabine O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Hydronephrosis B-ADR B-ADR
was O-ADR O-ADR
not O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
placebo O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
Investigator O-ADR O-ADR
Assessment O-ADR O-ADR
of O-ADR O-ADR
Maximal O-ADR O-ADR
Local B-ADR B-ADR
Skin I-ADR I-ADR
Reactions I-ADR I-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Treatment O-ADR O-ADR
Area O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
57 O-ADR O-ADR
Days O-ADR O-ADR
Post O-ADR O-ADR
Treatment O-ADR O-ADR
Period O-ADR O-ADR
( O-ADR O-ADR
trunk O-ADR O-ADR
/ O-ADR O-ADR
extremities O-ADR O-ADR
trials O-ADR O-ADR
) O-ADR O-ADR
Trunk O-ADR O-ADR
and O-ADR O-ADR
Extremities O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
457 O-ADR O-ADR
) O-ADR O-ADR
Picato O-ADR O-ADR
( O-ADR O-ADR
r O-ADR O-ADR
) O-ADR O-ADR
gel O-ADR O-ADR
, O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
05 O-ADR O-ADR
% O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
for O-ADR O-ADR
2 O-ADR O-ADR
days O-ADR O-ADR
Skin B-ADR B-ADR
reactions I-ADR I-ADR
Any I-ADR I-ADR
Gradea I-ADR I-ADR
> I-ADR I-ADR
Baseline I-ADR I-ADR
Grade I-ADR I-ADR
4 I-ADR I-ADR
58 O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
6 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
2 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
0 O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
a O-ADR O-ADR
Mild O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Moderate O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
Severe O-ADR O-ADR
( O-ADR O-ADR
grade O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
single O-ADR O-ADR
event O-ADR O-ADR
of O-ADR O-ADR
serum B-ADR B-ADR
sickness I-ADR I-ADR
was O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
patient O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
. O-ADR O-ADR
Hypoglycemia O-ADR O-ADR
Hypoglycemic B-ADR B-ADR
events I-ADR I-ADR
were O-ADR O-ADR
documented O-ADR O-ADR
based O-ADR O-ADR
upon O-ADR O-ADR
a O-ADR O-ADR
blood O-ADR O-ADR
glucose O-ADR O-ADR
value O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR O-ADR
. O-ADR O-ADR
Consider O-ADR O-ADR
discontinuation O-ADR O-ADR
for O-ADR O-ADR
Grade O-ADR O-ADR
3 O-ADR O-ADR
infusions O-ADR O-ADR
reactions O-ADR O-ADR
as O-ADR O-ADR
clinically O-ADR O-ADR
appropriate O-ADR O-ADR
considering O-ADR O-ADR
individual O-ADR O-ADR
benefits O-ADR O-ADR
, O-ADR O-ADR
risks O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
supportive O-ADR O-ADR
care O-ADR O-ADR
. O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
observed O-ADR O-ADR
in O-ADR O-ADR
these O-ADR O-ADR
studies O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
similar O-ADR O-ADR
to O-ADR O-ADR
those O-ADR O-ADR
observed O-ADR O-ADR
and O-ADR O-ADR
attributed O-ADR O-ADR
to O-ADR O-ADR
drug O-ADR O-ADR
in O-ADR O-ADR
adjunctive O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
studies O-ADR O-ADR
. O-ADR O-ADR
in O-ADR O-ADR
Placebo O-ADR O-ADR
and O-ADR O-ADR
Active O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
when O-ADR O-ADR
NESINA O-ADR O-ADR
Was O-ADR O-ADR
Used O-ADR O-ADR
as O-ADR O-ADR
Add O-ADR O-ADR
- O-ADR O-ADR
On O-ADR O-ADR
Therapy O-ADR O-ADR
to O-ADR O-ADR
Glyburide O-ADR O-ADR
, O-ADR O-ADR
Insulin O-ADR O-ADR
, O-ADR O-ADR
Metformin O-ADR O-ADR
, O-ADR O-ADR
Pioglitazone O-ADR O-ADR
or O-ADR O-ADR
Compared O-ADR O-ADR
to O-ADR O-ADR
Glipizide O-ADR O-ADR
Add O-ADR O-ADR
- O-ADR O-ADR
On O-ADR O-ADR
to O-ADR O-ADR
Glyburide O-ADR O-ADR
( O-ADR O-ADR
26 O-ADR O-ADR
Weeks O-ADR O-ADR
) O-ADR O-ADR
NESINA O-ADR O-ADR
25 O-ADR O-ADR
mg O-ADR O-ADR
+ O-ADR O-ADR
Glyburide O-ADR O-ADR
Placebo O-ADR O-ADR
+ O-ADR O-ADR
Glyburide O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
198 O-ADR O-ADR
N O-ADR O-ADR
= O-ADR O-ADR
99 O-ADR O-ADR
Overall O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
19 O-ADR O-ADR
( O-ADR O-ADR
9 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
11 O-ADR O-ADR
( O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
Severe O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
Severe O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
hypoglycemia B-ADR B-ADR
were O-ADR O-ADR
defined O-ADR O-ADR
as O-ADR O-ADR
those O-ADR O-ADR
events O-ADR O-ADR
requiring O-ADR O-ADR
medical O-ADR O-ADR
assistance O-ADR O-ADR
or O-ADR O-ADR
exhibiting O-ADR O-ADR
depressed O-ADR O-ADR
level O-ADR O-ADR
or O-ADR O-ADR
loss O-ADR O-ADR
of O-ADR O-ADR
consciousness O-ADR O-ADR
or O-ADR O-ADR
seizure O-ADR O-ADR
. O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
and O-ADR O-ADR
musculoskeletal B-ADR B-ADR
pain I-ADR I-ADR
have O-ADR O-ADR
also O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
To O-ADR O-ADR
report O-ADR O-ADR
SUSPECTED O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
, O-ADR O-ADR
contact O-ADR O-ADR
Amgen O-ADR O-ADR
Inc O-ADR O-ADR
. O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
77 O-ADR O-ADR
- O-ADR O-ADR
AMGEN O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
772 O-ADR O-ADR
- O-ADR O-ADR
6436 O-ADR O-ADR
) O-ADR O-ADR
or O-ADR O-ADR
FDA O-ADR O-ADR
at O-ADR O-ADR
1 O-ADR O-ADR
- O-ADR O-ADR
800 O-ADR O-ADR
- O-ADR O-ADR
FDA O-ADR O-ADR
- O-ADR O-ADR
1088 O-ADR O-ADR
or O-ADR O-ADR
www O-ADR O-ADR
. O-ADR O-ADR
fda O-ADR O-ADR
. O-ADR O-ADR
gov O-ADR O-ADR
/ O-ADR O-ADR
medwatch O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
those O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
require O-ADR O-ADR
the O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
opioids O-ADR O-ADR
to O-ADR O-ADR
treat O-ADR O-ADR
pain O-ADR O-ADR
during O-ADR O-ADR
or O-ADR O-ADR
following O-ADR O-ADR
the O-ADR O-ADR
procedure O-ADR O-ADR
, O-ADR O-ADR
their O-ADR O-ADR
ability O-ADR O-ADR
to O-ADR O-ADR
perform O-ADR O-ADR
potentially O-ADR O-ADR
hazardous O-ADR O-ADR
activities O-ADR O-ADR
such O-ADR O-ADR
as O-ADR O-ADR
driving O-ADR O-ADR
or O-ADR O-ADR
operating O-ADR O-ADR
machinery O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
affected O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Fluid B-ADR B-ADR
Retention I-ADR I-ADR
: O-ADR O-ADR
Monitor O-ADR O-ADR
patients O-ADR O-ADR
and O-ADR O-ADR
manage O-ADR O-ADR
using O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
treatment O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Immediate O-ADR O-ADR
medical O-ADR O-ADR
attention O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
required O-ADR O-ADR
in O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
respiratory O-ADR O-ADR
, O-ADR O-ADR
speech O-ADR O-ADR
or O-ADR O-ADR
swallowing O-ADR O-ADR
difficulties O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Acute O-ADR O-ADR
Renal O-ADR O-ADR
Failure O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
acute B-ADR B-ADR
renal I-ADR I-ADR
failure I-ADR I-ADR
have O-ADR O-ADR
occurred O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
Kyprolis O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Lower O-ADR O-ADR
lid O-ADR O-ADR
injections O-ADR O-ADR
should O-ADR O-ADR
not O-ADR O-ADR
be O-ADR O-ADR
repeated O-ADR O-ADR
if O-ADR O-ADR
diplopia O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
previous O-ADR O-ADR
botulinum O-ADR O-ADR
toxin O-ADR O-ADR
injections O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Cardiac B-ADR B-ADR
failure I-ADR I-ADR
has O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
and O-ADR O-ADR
can O-ADR O-ADR
be O-ADR O-ADR
fatal B-ADR B-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
TTP O-ADR O-ADR
/ O-ADR O-ADR
HUS O-ADR O-ADR
. O-ADR O-ADR
Monotherapy O-ADR O-ADR
Historical O-ADR O-ADR
Control O-ADR O-ADR
Trials O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
monotherapy O-ADR O-ADR
epilepsy O-ADR O-ADR
trials O-ADR O-ADR
( O-ADR O-ADR
Study O-ADR O-ADR
1 O-ADR O-ADR
and O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
13 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
randomized O-ADR O-ADR
to O-ADR O-ADR
receive O-ADR O-ADR
APTIOM O-ADR O-ADR
at O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
doses O-ADR O-ADR
of O-ADR O-ADR
1200 O-ADR O-ADR
mg O-ADR O-ADR
and O-ADR O-ADR
1600 O-ADR O-ADR
mg O-ADR O-ADR
once O-ADR O-ADR
daily O-ADR O-ADR
discontinued O-ADR O-ADR
from O-ADR O-ADR
the O-ADR O-ADR
trials O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
result O-ADR O-ADR
of O-ADR O-ADR
an O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
Study O-ADR O-ADR
2 O-ADR O-ADR
all O-ADR O-ADR
adverse O-ADR O-ADR
events O-ADR O-ADR
of O-ADR O-ADR
all O-ADR O-ADR
Grades O-ADR O-ADR
were O-ADR O-ADR
prospectively O-ADR O-ADR
collected O-ADR O-ADR
. O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
* O-ADR O-ADR
Stop O-ADR O-ADR
INLYTA O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
24 O-ADR O-ADR
hours O-ADR O-ADR
prior O-ADR O-ADR
to O-ADR O-ADR
scheduled O-ADR O-ADR
surgery O-ADR O-ADR
. O-ADR O-ADR
Prescribers O-ADR O-ADR
should O-ADR O-ADR
carefully O-ADR O-ADR
evaluate O-ADR O-ADR
the O-ADR O-ADR
risks O-ADR O-ADR
and O-ADR O-ADR
benefits O-ADR O-ADR
of O-ADR O-ADR
continuing O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
OTEZLA O-ADR O-ADR
if O-ADR O-ADR
such O-ADR O-ADR
events O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
FANAPT O-ADR O-ADR
is O-ADR O-ADR
not O-ADR O-ADR
approved O-ADR O-ADR
for O-ADR O-ADR
the O-ADR O-ADR
treatment O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
psychosis O-ADR O-ADR
[ O-ADR O-ADR
s O-ADR O-ADR
ee O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
MRI O-ADR O-ADR
signs O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
apparent O-ADR O-ADR
before O-ADR O-ADR
clinical O-ADR O-ADR
symptoms O-ADR O-ADR
. O-ADR O-ADR
Three O-ADR O-ADR
of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
had O-ADR O-ADR
subsequent O-ADR O-ADR
tests O-ADR O-ADR
which O-ADR O-ADR
were O-ADR O-ADR
negative O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
reduction O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
cure O-ADR O-ADR
rates O-ADR O-ADR
was O-ADR O-ADR
more O-ADR O-ADR
marked O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ZERBAXA O-ADR O-ADR
plus O-ADR O-ADR
metronidazole O-ADR O-ADR
arm O-ADR O-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
meropenem O-ADR O-ADR
arm O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
for O-ADR O-ADR
suicidal O-ADR O-ADR
thoughts O-ADR O-ADR
or O-ADR O-ADR
behaviors O-ADR O-ADR
. O-ADR O-ADR
Thromboprophylaxis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
and O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
an O-ADR O-ADR
assessment O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
' O-ADR O-ADR
s O-ADR O-ADR
underlying O-ADR O-ADR
risks O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
regimen O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
clinical O-ADR O-ADR
status O-ADR O-ADR
. O-ADR O-ADR
Evaluate O-ADR O-ADR
with O-ADR O-ADR
cardiac O-ADR O-ADR
imaging O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
other O-ADR O-ADR
tests O-ADR O-ADR
as O-ADR O-ADR
indicated O-ADR O-ADR
. O-ADR O-ADR
Atrial O-ADR O-ADR
Fibrillation O-ADR O-ADR
/ O-ADR O-ADR
Flutte O-ADR O-ADR
r O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
pool O-ADR O-ADR
of O-ADR O-ADR
7 O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
and O-ADR O-ADR
active O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
atrial B-ADR B-ADR
fibrillation I-ADR I-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
and O-ADR O-ADR
atrial B-ADR B-ADR
flutter I-ADR I-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
more O-ADR O-ADR
frequently O-ADR O-ADR
for O-ADR O-ADR
TANZEUM O-ADR O-ADR
than O-ADR O-ADR
for O-ADR O-ADR
all O-ADR O-ADR
comparators O-ADR O-ADR
( O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
0 O-ADR O-ADR
% O-ADR O-ADR
, O-ADR O-ADR
respectively O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
For O-ADR O-ADR
cases O-ADR O-ADR
of O-ADR O-ADR
Grade O-ADR O-ADR
4 O-ADR O-ADR
non O-ADR O-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
AFINITOR O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
Frequency O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
Reported O-ADR O-ADR
in O-ADR O-ADR
Clinical O-ADR O-ADR
Trials O-ADR O-ADR
( O-ADR O-ADR
n O-ADR O-ADR
= O-ADR O-ADR
978 O-ADR O-ADR
Administrations O-ADR O-ADR
in O-ADR O-ADR
872 O-ADR O-ADR
Subjects O-ADR O-ADR
) O-ADR O-ADR
Adverse O-ADR O-ADR
drug O-ADR O-ADR
reaction O-ADR O-ADR
n O-ADR O-ADR
( O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
application B-ADR B-ADR
site I-ADR I-ADR
erythema I-ADR I-ADR
17 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
) O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
irritation I-ADR I-ADR
12 O-ADR O-ADR
( O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
Injection B-ADR B-ADR
site I-ADR I-ADR
pain I-ADR I-ADR
38 O-ADR O-ADR
( O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
) O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Image O-ADR O-ADR
interpretation O-ADR O-ADR
errors O-ADR O-ADR
( O-ADR O-ADR
especially O-ADR O-ADR
false O-ADR O-ADR
positives O-ADR O-ADR
) O-ADR O-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Delay O-ADR O-ADR
or O-ADR O-ADR
discontinue O-ADR O-ADR
JEVTANA O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
discussed O-ADR O-ADR
in O-ADR O-ADR
greater O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
another O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Non B-ADR B-ADR
- O-ADR O-ADR
infectious O-ADR O-ADR
pneumonitis I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Retinal B-ADR B-ADR
detachments I-ADR I-ADR
resulting O-ADR O-ADR
from O-ADR O-ADR
trametinib O-ADR O-ADR
are O-ADR O-ADR
often O-ADR O-ADR
bilateral O-ADR O-ADR
and O-ADR O-ADR
multifocal O-ADR O-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
macular O-ADR O-ADR
region O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
retina O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
and O-ADR O-ADR
CMV O-ADR O-ADR
seronegative O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
at O-ADR O-ADR
increased O-ADR O-ADR
risk O-ADR O-ADR
for O-ADR O-ADR
PTLD O-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
are O-ADR O-ADR
EBV O-ADR O-ADR
seropositive O-ADR O-ADR
and O-ADR O-ADR
CMV O-ADR O-ADR
seropositive O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Adverse O-ADR O-ADR
Reactions O-ADR O-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
until O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
. O-ADR O-ADR
Women O-ADR O-ADR
of O-ADR O-ADR
childbearing O-ADR O-ADR
potential O-ADR O-ADR
and O-ADR O-ADR
men O-ADR O-ADR
must O-ADR O-ADR
use O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
two O-ADR O-ADR
forms O-ADR O-ADR
of O-ADR O-ADR
effective O-ADR O-ADR
contraception O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
and O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
treatment O-ADR O-ADR
has O-ADR O-ADR
concluded O-ADR O-ADR
. O-ADR O-ADR
Cases O-ADR O-ADR
of O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
observed O-ADR O-ADR
among O-ADR O-ADR
patients O-ADR O-ADR
receiving O-ADR O-ADR
TNF O-ADR O-ADR
- O-ADR O-ADR
blockers O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Diabetic O-ADR O-ADR
Macular O-ADR O-ADR
Edema O-ADR O-ADR
( O-ADR O-ADR
DME O-ADR O-ADR
) O-ADR O-ADR
The O-ADR O-ADR
data O-ADR O-ADR
described O-ADR O-ADR
below O-ADR O-ADR
reflect O-ADR O-ADR
exposure O-ADR O-ADR
to O-ADR O-ADR
EYLEA O-ADR O-ADR
in O-ADR O-ADR
578 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
DME O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
the O-ADR O-ADR
2 O-ADR O-ADR
- O-ADR O-ADR
mg O-ADR O-ADR
dose O-ADR O-ADR
in O-ADR O-ADR
2 O-ADR O-ADR
double O-ADR O-ADR
- O-ADR O-ADR
masked O-ADR O-ADR
, O-ADR O-ADR
controlled O-ADR O-ADR
clinical O-ADR O-ADR
studies O-ADR O-ADR
( O-ADR O-ADR
VIVID O-ADR O-ADR
and O-ADR O-ADR
VISTA O-ADR O-ADR
) O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
week O-ADR O-ADR
52 O-ADR O-ADR
and O-ADR O-ADR
from O-ADR O-ADR
baseline O-ADR O-ADR
to O-ADR O-ADR
week O-ADR O-ADR
100 O-ADR O-ADR
[ O-ADR O-ADR
seeClinical O-ADR O-ADR
Studies O-ADR O-ADR
( O-ADR O-ADR
14 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
Leukopenia O-ADR O-ADR
, O-ADR O-ADR
Neutropenia O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Agranulocytosis O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
and O-ADR O-ADR
postmarketing O-ADR O-ADR
experience O-ADR O-ADR
, O-ADR O-ADR
leukopenia B-ADR B-ADR
and O-ADR O-ADR
neutropenia B-ADR B-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
temporally O-ADR O-ADR
related O-ADR O-ADR
to O-ADR O-ADR
antipsychotic O-ADR O-ADR
agents O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
SAPHRIS O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
the O-ADR O-ADR
abnormalities O-ADR O-ADR
are O-ADR O-ADR
confirmed O-ADR O-ADR
, O-ADR O-ADR
monitor O-ADR O-ADR
serum O-ADR O-ADR
liver O-ADR O-ADR
tests O-ADR O-ADR
weekly O-ADR O-ADR
until O-ADR O-ADR
resolved O-ADR O-ADR
or O-ADR O-ADR
stabilized O-ADR O-ADR
. O-ADR O-ADR
* O-ADR O-ADR
Heart B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
ADVERSE O-ADR O-ADR
REACTIONS O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
NULOJIX O-ADR O-ADR
are O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
PTLD B-ADR B-ADR
, O-ADR O-ADR
predominantly O-ADR O-ADR
CNS B-ADR B-ADR
PTLD I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
malignancies B-ADR B-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Boxed O-ADR O-ADR
Warning O-ADR O-ADR
and O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
* O-ADR O-ADR
Serious O-ADR O-ADR
infections B-ADR B-ADR
, O-ADR O-ADR
including O-ADR O-ADR
JC B-ADR B-ADR
virus O-ADR O-ADR
- O-ADR O-ADR
associated O-ADR O-ADR
PML B-ADR B-ADR
and O-ADR O-ADR
polyoma B-ADR B-ADR
virus I-ADR I-ADR
nephropathy I-ADR I-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
, O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
20 O-ADR O-ADR
% O-ADR O-ADR
on O-ADR O-ADR
NULOJIX O-ADR O-ADR
treatment O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
anemia B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
urinary B-ADR B-ADR
tract I-ADR I-ADR
infection I-ADR I-ADR
, O-ADR O-ADR
peripheral B-ADR B-ADR
edema I-ADR I-ADR
, O-ADR O-ADR
constipation B-ADR B-ADR
, O-ADR O-ADR
hypertension B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
graft B-ADR B-ADR
dysfunction I-ADR I-ADR
, O-ADR O-ADR
cough B-ADR B-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
headache B-ADR B-ADR
, O-ADR O-ADR
hypokalemia B-ADR B-ADR
, O-ADR O-ADR
hyperkalemia B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
leukopenia B-ADR B-ADR
. O-ADR O-ADR
If O-ADR O-ADR
hypersensitivity O-ADR O-ADR
reactions O-ADR O-ADR
occur O-ADR O-ADR
, O-ADR O-ADR
discontinue O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TANZEUM O-ADR O-ADR
; O-ADR O-ADR
treat O-ADR O-ADR
promptly O-ADR O-ADR
per O-ADR O-ADR
standard O-ADR O-ADR
of O-ADR O-ADR
care O-ADR O-ADR
and O-ADR O-ADR
monitor O-ADR O-ADR
until O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
resolve O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Contraindications O-ADR O-ADR
( O-ADR O-ADR
4 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
CMV O-ADR O-ADR
prophylaxis O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
3 O-ADR O-ADR
months O-ADR O-ADR
after O-ADR O-ADR
transplantation O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Serious O-ADR O-ADR
Febrile O-ADR O-ADR
Reactions O-ADR O-ADR
Serious O-ADR O-ADR
febrile B-ADR B-ADR
reactions I-ADR I-ADR
and O-ADR O-ADR
fever B-ADR B-ADR
of O-ADR O-ADR
any O-ADR O-ADR
severity O-ADR O-ADR
complicated O-ADR O-ADR
by O-ADR O-ADR
hypotension B-ADR B-ADR
, O-ADR O-ADR
rigors B-ADR B-ADR
or O-ADR O-ADR
chills B-ADR B-ADR
, O-ADR O-ADR
dehydration B-ADR B-ADR
, O-ADR O-ADR
or O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
, O-ADR O-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
when O-ADR O-ADR
TAFINLAR O-ADR O-ADR
is O-ADR O-ADR
administered O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
or O-ADR O-ADR
when O-ADR O-ADR
used O-ADR O-ADR
in O-ADR O-ADR
combination O-ADR O-ADR
with O-ADR O-ADR
trametinib O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
and O-ADR O-ADR
treat O-ADR O-ADR
as O-ADR O-ADR
appropriate O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
should O-ADR O-ADR
receive O-ADR O-ADR
premedication O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
Hypersensitivity O-ADR O-ADR
Reactions O-ADR O-ADR
Acute B-ADR B-ADR
hypersensitivity I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
dyspnea B-ADR B-ADR
, O-ADR O-ADR
rash B-ADR B-ADR
pruritus B-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
angioedema B-ADR B-ADR
of I-ADR I-ADR
the I-ADR I-ADR
mouth I-ADR I-ADR
have O-ADR O-ADR
been O-ADR O-ADR
reported O-ADR O-ADR
with O-ADR O-ADR
fidaxomicin O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
both O-ADR O-ADR
groups O-ADR O-ADR
, O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
events O-ADR O-ADR
were O-ADR O-ADR
generally O-ADR O-ADR
male O-ADR O-ADR
, O-ADR O-ADR
older O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
had O-ADR O-ADR
underlying O-ADR O-ADR
renal O-ADR O-ADR
impairment O-ADR O-ADR
or O-ADR O-ADR
cardiac O-ADR O-ADR
disease O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
history O-ADR O-ADR
of O-ADR O-ADR
arrhythmia O-ADR O-ADR
, O-ADR O-ADR
palpitations O-ADR O-ADR
, O-ADR O-ADR
congestive O-ADR B-ADR
heart O-ADR I-ADR
failure O-ADR I-ADR
, O-ADR O-ADR
cardiomyopathy O-ADR B-ADR
, O-ADR O-ADR
etc O-ADR O-ADR
. O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
Most O-ADR O-ADR
common O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
10 O-ADR O-ADR
% O-ADR O-ADR
and O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
2 O-ADR O-ADR
% O-ADR O-ADR
placebo O-ADR O-ADR
) O-ADR O-ADR
were O-ADR O-ADR
flushing B-ADR B-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
nausea B-ADR B-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
( O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
subjects O-ADR O-ADR
) O-ADR O-ADR
during O-ADR O-ADR
Neuraceq O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
are O-ADR O-ADR
shown O-ADR O-ADR
in O-ADR O-ADR
Table O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
Use O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
sensitive O-ADR O-ADR
real O-ADR O-ADR
- O-ADR O-ADR
time O-ADR O-ADR
reverse O-ADR O-ADR
- O-ADR O-ADR
transcription O-ADR O-ADR
polymerase O-ADR O-ADR
chain O-ADR O-ADR
reaction O-ADR O-ADR
( O-ADR O-ADR
RT O-ADR O-ADR
- O-ADR O-ADR
PCR O-ADR O-ADR
) O-ADR O-ADR
assay O-ADR O-ADR
for O-ADR O-ADR
monitoring O-ADR O-ADR
HCV O-ADR O-ADR
- O-ADR O-ADR
RNA O-ADR O-ADR
levels O-ADR O-ADR
during O-ADR O-ADR
treatment O-ADR O-ADR
is O-ADR O-ADR
recommended O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
in O-ADR O-ADR
infantile O-ADR O-ADR
- O-ADR O-ADR
onset O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
majority O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
( O-ADR O-ADR
34 O-ADR O-ADR
of O-ADR O-ADR
38 O-ADR O-ADR
; O-ADR O-ADR
89 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
tested O-ADR O-ADR
positive O-ADR O-ADR
for O-ADR O-ADR
IgG O-ADR O-ADR
antibodies O-ADR O-ADR
to O-ADR O-ADR
alglucosidase O-ADR O-ADR
alfa O-ADR O-ADR
. O-ADR O-ADR
Of O-ADR O-ADR
these O-ADR O-ADR
patients O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
were O-ADR O-ADR
2 O-ADR O-ADR
respiratory O-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
deaths B-ADR B-ADR
in O-ADR O-ADR
the O-ADR O-ADR
ARCAPTA O-ADR O-ADR
NEOHALER O-ADR O-ADR
300 O-ADR O-ADR
mcg O-ADR O-ADR
dose O-ADR O-ADR
group O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
Development O-ADR O-ADR
of O-ADR O-ADR
Drug O-ADR O-ADR
- O-ADR O-ADR
Resistant O-ADR O-ADR
Bacteria O-ADR O-ADR
Prescribing O-ADR O-ADR
ZERBAXA O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
absence O-ADR O-ADR
of O-ADR O-ADR
a O-ADR O-ADR
proven O-ADR O-ADR
or O-ADR O-ADR
strongly O-ADR O-ADR
suspected O-ADR O-ADR
bacterial O-ADR O-ADR
infection O-ADR O-ADR
is O-ADR O-ADR
unlikely O-ADR O-ADR
to O-ADR O-ADR
provide O-ADR O-ADR
benefit O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
patient O-ADR O-ADR
and O-ADR O-ADR
risks O-ADR O-ADR
the O-ADR O-ADR
development O-ADR O-ADR
of O-ADR O-ADR
drug O-ADR O-ADR
- O-ADR O-ADR
resistant O-ADR O-ADR
bacteria O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
commonly O-ADR O-ADR
- O-ADR O-ADR
reported O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
, O-ADR O-ADR
occurring O-ADR O-ADR
in O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
5 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
in O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
were O-ADR O-ADR
nausea B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
, O-ADR O-ADR
pyrexia B-ADR B-ADR
, O-ADR O-ADR
nasopharyngitis B-ADR B-ADR
, O-ADR O-ADR
bronchitis B-ADR B-ADR
, O-ADR O-ADR
insomnia B-ADR B-ADR
, O-ADR O-ADR
pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
, O-ADR O-ADR
depression B-ADR B-ADR
, O-ADR O-ADR
migraine B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
pharyngitis B-ADR B-ADR
. O-ADR O-ADR
Since O-ADR O-ADR
ENTEREG O-ADR O-ADR
acts O-ADR O-ADR
peripherally O-ADR O-ADR
, O-ADR O-ADR
clinical O-ADR O-ADR
signs O-ADR O-ADR
and O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
increased B-ADR O-ADR
sensitivity I-ADR O-ADR
would I-ADR O-ADR
be I-ADR O-ADR
related I-ADR O-ADR
to I-ADR O-ADR
the I-ADR O-ADR
gastrointestinal I-ADR I-ADR
tract I-ADR I-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
abdominal B-ADR B-ADR
pain I-ADR I-ADR
, O-ADR O-ADR
nausea B-ADR B-ADR
and O-ADR O-ADR
vomiting B-ADR B-ADR
, O-ADR O-ADR
diarrhea B-ADR B-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Cerebrovascular O-ADR O-ADR
Adverse O-ADR O-ADR
Events O-ADR O-ADR
, O-ADR O-ADR
Including O-ADR O-ADR
Stroke O-ADR O-ADR
In O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
with O-ADR O-ADR
risperidone O-ADR O-ADR
, O-ADR O-ADR
aripiprazole O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
olanzapine O-ADR O-ADR
in O-ADR O-ADR
elderly O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
dementia O-ADR O-ADR
, O-ADR O-ADR
there O-ADR O-ADR
was O-ADR O-ADR
a O-ADR O-ADR
higher O-ADR O-ADR
incidence O-ADR O-ADR
of O-ADR O-ADR
cerebrovascular B-ADR B-ADR
adverse I-ADR I-ADR
events I-ADR I-ADR
( O-ADR O-ADR
cerebrovascular B-ADR B-ADR
accidents I-ADR I-ADR
and O-ADR O-ADR
transient B-ADR B-ADR
ischemic I-ADR I-ADR
attacks I-ADR I-ADR
) O-ADR O-ADR
including O-ADR O-ADR
fatalities B-ADR B-ADR
compared O-ADR O-ADR
to O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
treated O-ADR O-ADR
patients O-ADR O-ADR
. O-ADR O-ADR
Monitor O-ADR O-ADR
thyroid O-ADR O-ADR
function O-ADR O-ADR
before O-ADR O-ADR
initiation O-ADR O-ADR
of O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
periodically O-ADR O-ADR
throughout O-ADR O-ADR
, O-ADR O-ADR
treatment O-ADR O-ADR
with O-ADR O-ADR
INLYTA O-ADR O-ADR
. O-ADR O-ADR
In O-ADR O-ADR
the O-ADR O-ADR
EMTP O-ADR O-ADR
trial O-ADR O-ADR
, O-ADR O-ADR
safety O-ADR O-ADR
data O-ADR O-ADR
were O-ADR O-ADR
derived O-ADR O-ADR
from O-ADR O-ADR
case O-ADR O-ADR
report O-ADR O-ADR
forms O-ADR O-ADR
that O-ADR O-ADR
collected O-ADR O-ADR
adverse O-ADR O-ADR
event O-ADR O-ADR
information O-ADR O-ADR
. O-ADR O-ADR
Discontinue O-ADR O-ADR
Kyprolis O-ADR O-ADR
if O-ADR O-ADR
suspected O-ADR O-ADR
. O-ADR O-ADR
There O-ADR O-ADR
is O-ADR O-ADR
no O-ADR O-ADR
clinical O-ADR O-ADR
trial O-ADR O-ADR
experience O-ADR O-ADR
with O-ADR O-ADR
XTANDI O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
have O-ADR O-ADR
had O-ADR O-ADR
a O-ADR O-ADR
seizure O-ADR O-ADR
. O-ADR O-ADR
Blepharospasm O-ADR B-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
) O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
Corneal B-ADR B-ADR
exposure I-ADR I-ADR
* O-ADR O-ADR
Injection O-ADR O-ADR
of O-ADR O-ADR
XEOMIN O-ADR O-ADR
into O-ADR O-ADR
the O-ADR O-ADR
orbicularis O-ADR O-ADR
oculi O-ADR O-ADR
muscle O-ADR O-ADR
may O-ADR O-ADR
lead O-ADR O-ADR
to O-ADR O-ADR
reduced B-ADR B-ADR
blinking I-ADR I-ADR
and O-ADR O-ADR
corneal B-ADR B-ADR
exposure I-ADR I-ADR
. O-ADR O-ADR
NSF B-ADR B-ADR
may O-ADR O-ADR
result O-ADR O-ADR
in O-ADR O-ADR
fatal B-ADR B-ADR
or O-ADR O-ADR
debilitating O-ADR O-ADR
fibrosis B-ADR B-ADR
affecting O-ADR O-ADR
the O-ADR O-ADR
skin O-ADR O-ADR
, O-ADR O-ADR
muscle O-ADR O-ADR
and O-ADR O-ADR
internal O-ADR O-ADR
organs O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
majority O-ADR O-ADR
were O-ADR O-ADR
in O-ADR O-ADR
adolescent O-ADR O-ADR
and O-ADR O-ADR
young O-ADR O-ADR
adult O-ADR O-ADR
males O-ADR O-ADR
. O-ADR O-ADR
TABLE O-ADR O-ADR
1 O-ADR O-ADR
: O-ADR O-ADR
Changes O-ADR O-ADR
in O-ADR O-ADR
Fasting O-ADR O-ADR
Glucose O-ADR O-ADR
in O-ADR O-ADR
Adult O-ADR O-ADR
Patients O-ADR O-ADR
N O-ADR O-ADR
* O-ADR O-ADR
= O-ADR O-ADR
Number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
who O-ADR O-ADR
had O-ADR O-ADR
assessments O-ADR O-ADR
at O-ADR O-ADR
both O-ADR O-ADR
Baseline O-ADR O-ADR
and O-ADR O-ADR
Endpoint O-ADR O-ADR
. O-ADR O-ADR
A O-ADR O-ADR
total O-ADR O-ADR
of O-ADR O-ADR
56 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
female O-ADR O-ADR
and O-ADR O-ADR
45 O-ADR O-ADR
% O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
were O-ADR O-ADR
Asian O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
WARNINGS O-ADR O-ADR
AND O-ADR O-ADR
PRECAUTIONS O-ADR O-ADR
EXCERPT O-ADR O-ADR
: O-ADR O-ADR
* O-ADR O-ADR
QT B-ADR B-ADR
prolongation I-ADR I-ADR
can O-ADR O-ADR
occur O-ADR O-ADR
with O-ADR O-ADR
SIRTURO O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
with O-ADR O-ADR
uncontrolled O-ADR O-ADR
or O-ADR O-ADR
significant O-ADR O-ADR
cardiovascular O-ADR O-ADR
disease O-ADR O-ADR
including O-ADR O-ADR
QT O-ADR O-ADR
interval O-ADR O-ADR
prolongation O-ADR O-ADR
were O-ADR O-ADR
excluded O-ADR O-ADR
by O-ADR O-ADR
protocol O-ADR O-ADR
. O-ADR O-ADR
BRAF O-ADR O-ADR
V600E O-ADR O-ADR
Unresectable O-ADR O-ADR
or O-ADR O-ADR
Metastatic O-ADR O-ADR
Melanoma O-ADR O-ADR
: O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
of O-ADR O-ADR
TAFINLAR O-ADR O-ADR
as O-ADR O-ADR
a O-ADR O-ADR
single O-ADR O-ADR
agent O-ADR O-ADR
was O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
586 O-ADR O-ADR
patients O-ADR O-ADR
with O-ADR O-ADR
BRAF O-ADR O-ADR
V600 O-ADR O-ADR
mutation O-ADR O-ADR
- O-ADR O-ADR
positive O-ADR O-ADR
unresectable O-ADR O-ADR
or O-ADR O-ADR
metastatic O-ADR O-ADR
melanoma O-ADR O-ADR
, O-ADR O-ADR
previously O-ADR O-ADR
treated O-ADR O-ADR
or O-ADR O-ADR
untreated O-ADR O-ADR
, O-ADR O-ADR
who O-ADR O-ADR
received O-ADR O-ADR
TAFINLAR O-ADR O-ADR
150 O-ADR O-ADR
mg O-ADR O-ADR
orally O-ADR O-ADR
twice O-ADR O-ADR
daily O-ADR O-ADR
until O-ADR O-ADR
disease O-ADR O-ADR
progression O-ADR O-ADR
or O-ADR O-ADR
unacceptable O-ADR O-ADR
toxicity O-ADR O-ADR
, O-ADR O-ADR
including O-ADR O-ADR
181 O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
at O-ADR O-ADR
least O-ADR O-ADR
6 O-ADR O-ADR
months O-ADR O-ADR
and O-ADR O-ADR
86 O-ADR O-ADR
additional O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
for O-ADR O-ADR
more O-ADR O-ADR
than O-ADR O-ADR
12 O-ADR O-ADR
months O-ADR O-ADR
. O-ADR O-ADR
Myelosuppression O-ADR B-ADR
may O-ADR O-ADR
require O-ADR O-ADR
dose O-ADR O-ADR
delays O-ADR O-ADR
and O-ADR O-ADR
/ O-ADR O-ADR
or O-ADR O-ADR
subsequent O-ADR O-ADR
dose O-ADR O-ADR
reductions O-ADR O-ADR
if O-ADR O-ADR
recovery O-ADR O-ADR
to O-ADR O-ADR
the O-ADR O-ADR
recommended O-ADR O-ADR
values O-ADR O-ADR
has O-ADR O-ADR
not O-ADR O-ADR
occurred O-ADR O-ADR
by O-ADR O-ADR
the O-ADR O-ADR
first O-ADR O-ADR
day O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
next O-ADR O-ADR
scheduled O-ADR O-ADR
cycle O-ADR O-ADR
. O-ADR O-ADR
No O-ADR O-ADR
new O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
11 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
GILOTRIF O-ADR O-ADR
and O-ADR O-ADR
3 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
for O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
pemetrexed O-ADR O-ADR
/ O-ADR O-ADR
cisplatin O-ADR O-ADR
. O-ADR O-ADR
Conditions O-ADR O-ADR
that O-ADR O-ADR
lower O-ADR O-ADR
the O-ADR O-ADR
seizure O-ADR O-ADR
threshold O-ADR O-ADR
may O-ADR O-ADR
be O-ADR O-ADR
more O-ADR O-ADR
prevalent O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
population O-ADR O-ADR
of O-ADR O-ADR
65 O-ADR O-ADR
years O-ADR O-ADR
or O-ADR O-ADR
older O-ADR O-ADR
. O-ADR O-ADR
Renal B-ADR B-ADR
- O-ADR O-ADR
related O-ADR O-ADR
adverse I-ADR I-ADR
reactions I-ADR I-ADR
, O-ADR O-ADR
including O-ADR O-ADR
renal B-ADR B-ADR
failure I-ADR I-ADR
and O-ADR O-ADR
blood B-ADR B-ADR
creatinine I-ADR I-ADR
increase I-ADR I-ADR
, O-ADR O-ADR
were O-ADR O-ADR
more O-ADR O-ADR
frequent O-ADR O-ADR
in O-ADR O-ADR
patients O-ADR O-ADR
treated O-ADR O-ADR
with O-ADR O-ADR
FARXIGA O-ADR O-ADR
( O-ADR O-ADR
see O-ADR O-ADR
Table O-ADR O-ADR
4 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Counsel O-ADR O-ADR
patients O-ADR O-ADR
regarding O-ADR O-ADR
the O-ADR O-ADR
potential O-ADR O-ADR
risk O-ADR O-ADR
of O-ADR O-ADR
MTC O-ADR O-ADR
with O-ADR O-ADR
use O-ADR O-ADR
of O-ADR O-ADR
TRULICITY O-ADR O-ADR
and O-ADR O-ADR
inform O-ADR O-ADR
them O-ADR O-ADR
of O-ADR O-ADR
symptoms O-ADR O-ADR
of O-ADR O-ADR
thyroid O-ADR O-ADR
tumors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
mass O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
neck O-ADR O-ADR
, O-ADR O-ADR
dysphagia O-ADR O-ADR
, O-ADR O-ADR
dyspnea O-ADR O-ADR
, O-ADR O-ADR
persistent O-ADR O-ADR
hoarseness O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
Bacterial O-ADR O-ADR
, O-ADR O-ADR
Mycobacterial O-ADR O-ADR
, O-ADR O-ADR
Viral O-ADR O-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Fungal O-ADR O-ADR
Infections O-ADR O-ADR
Adverse O-ADR O-ADR
reactions O-ADR O-ADR
of O-ADR O-ADR
infectious B-ADR B-ADR
etiology I-ADR I-ADR
were O-ADR O-ADR
reported O-ADR O-ADR
based O-ADR O-ADR
on O-ADR O-ADR
clinical O-ADR O-ADR
assessment O-ADR O-ADR
by O-ADR O-ADR
physicians O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
laboratory O-ADR O-ADR
abnormalities O-ADR O-ADR
( O-ADR O-ADR
incidence O-ADR O-ADR
> O-ADR O-ADR
= O-ADR O-ADR
30 O-ADR O-ADR
% O-ADR O-ADR
) O-ADR O-ADR
are O-ADR O-ADR
neutropenia B-ADR B-ADR
, O-ADR O-ADR
hypertriglyceridemia B-ADR B-ADR
, O-ADR O-ADR
hyperglycemia B-ADR B-ADR
, O-ADR O-ADR
ALT B-ADR B-ADR
elevations I-ADR I-ADR
, O-ADR O-ADR
and O-ADR O-ADR
AST B-ADR B-ADR
elevations I-ADR I-ADR
( O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Nausea B-ADR B-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
8 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Influenza B-ADR B-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
Dyslipidemia B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
Constipation B-ADR B-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
2 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Discomfort B-ADR B-ADR
with I-ADR I-ADR
urination I-ADR I-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
6 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
Pain B-ADR B-ADR
in I-ADR I-ADR
extremity I-ADR I-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
2 O-ADR O-ADR
. O-ADR O-ADR
0 O-ADR O-ADR
1 O-ADR O-ADR
. O-ADR O-ADR
7 O-ADR O-ADR
Pool O-ADR O-ADR
of O-ADR O-ADR
13 O-ADR O-ADR
Placebo O-ADR O-ADR
- O-ADR O-ADR
Controlled O-ADR O-ADR
Studies O-ADR O-ADR
for O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
The O-ADR O-ADR
safety O-ADR O-ADR
and O-ADR O-ADR
tolerability O-ADR O-ADR
of O-ADR O-ADR
FARXIGA O-ADR O-ADR
10 O-ADR O-ADR
mg O-ADR O-ADR
was O-ADR O-ADR
also O-ADR O-ADR
evaluated O-ADR O-ADR
in O-ADR O-ADR
a O-ADR O-ADR
larger O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
study O-ADR O-ADR
pool O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
following O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
are O-ADR O-ADR
described O-ADR O-ADR
in O-ADR O-ADR
more O-ADR O-ADR
detail O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
Warnings O-ADR O-ADR
and O-ADR O-ADR
Precautions O-ADR O-ADR
section O-ADR O-ADR
of O-ADR O-ADR
the O-ADR O-ADR
label O-ADR O-ADR
: O-ADR O-ADR
Seizures B-ADR B-ADR
, O-ADR O-ADR
Anaphylaxis B-ADR B-ADR
, O-ADR O-ADR
and O-ADR O-ADR
Urinary B-ADR B-ADR
Tract I-ADR I-ADR
Infections I-ADR I-ADR
. O-ADR O-ADR
The O-ADR O-ADR
risk O-ADR O-ADR
did O-ADR O-ADR
not O-ADR O-ADR
vary O-ADR O-ADR
substantially O-ADR O-ADR
by O-ADR O-ADR
age O-ADR O-ADR
( O-ADR O-ADR
5 O-ADR O-ADR
- O-ADR O-ADR
100 O-ADR O-ADR
years O-ADR O-ADR
) O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
analyzed O-ADR O-ADR
. O-ADR O-ADR
5 O-ADR O-ADR
. O-ADR O-ADR
9 O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
with O-ADR O-ADR
Strong O-ADR O-ADR
Cytochrome O-ADR O-ADR
P450 O-ADR O-ADR
3A4 O-ADR O-ADR
Inhibitors O-ADR O-ADR
Caution O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
exercised O-ADR O-ADR
when O-ADR O-ADR
considering O-ADR O-ADR
the O-ADR O-ADR
coadministration O-ADR O-ADR
of O-ADR O-ADR
BREO O-ADR O-ADR
ELLIPTA O-ADR O-ADR
with O-ADR O-ADR
long O-ADR O-ADR
- O-ADR O-ADR
term O-ADR O-ADR
ketoconazole O-ADR O-ADR
and O-ADR O-ADR
other O-ADR O-ADR
known O-ADR O-ADR
strong O-ADR O-ADR
CYP3A4 O-ADR O-ADR
inhibitors O-ADR O-ADR
( O-ADR O-ADR
e O-ADR O-ADR
. O-ADR O-ADR
g O-ADR O-ADR
. O-ADR O-ADR
, O-ADR O-ADR
ritonavir O-ADR O-ADR
, O-ADR O-ADR
clarithromycin O-ADR O-ADR
, O-ADR O-ADR
conivaptan O-ADR O-ADR
, O-ADR O-ADR
indinavir O-ADR O-ADR
, O-ADR O-ADR
itraconazole O-ADR O-ADR
, O-ADR O-ADR
lopinavir O-ADR O-ADR
, O-ADR O-ADR
nefazodone O-ADR O-ADR
, O-ADR O-ADR
nelfinavir O-ADR O-ADR
, O-ADR O-ADR
saquinavir O-ADR O-ADR
, O-ADR O-ADR
telithromycin O-ADR O-ADR
, O-ADR O-ADR
troleandomycin O-ADR O-ADR
, O-ADR O-ADR
voriconazole O-ADR O-ADR
) O-ADR O-ADR
because O-ADR O-ADR
increased O-ADR O-ADR
systemic O-ADR O-ADR
corticosteroid O-ADR O-ADR
and O-ADR O-ADR
increased O-ADR B-ADR
cardiovascular O-ADR I-ADR
adverse O-ADR I-ADR
effects O-ADR I-ADR
may O-ADR O-ADR
occur O-ADR O-ADR
[ O-ADR O-ADR
see O-ADR O-ADR
Drug O-ADR O-ADR
Interactions O-ADR O-ADR
( O-ADR O-ADR
7 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
) O-ADR O-ADR
, O-ADR O-ADR
Clinical O-ADR O-ADR
Pharmacology O-ADR O-ADR
( O-ADR O-ADR
12 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
) O-ADR O-ADR
] O-ADR O-ADR
. O-ADR O-ADR
Patients O-ADR O-ADR
receiving O-ADR O-ADR
the O-ADR O-ADR
drug O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
managed O-ADR O-ADR
in O-ADR O-ADR
facilities O-ADR O-ADR
equipped O-ADR O-ADR
and O-ADR O-ADR
staffed O-ADR O-ADR
with O-ADR O-ADR
adequate O-ADR O-ADR
laboratory O-ADR O-ADR
and O-ADR O-ADR
supportive O-ADR O-ADR
medical O-ADR O-ADR
resources O-ADR O-ADR
. O-ADR O-ADR
If O-ADR O-ADR
an O-ADR O-ADR
infusion O-ADR O-ADR
- O-ADR O-ADR
related O-ADR O-ADR
reaction O-ADR O-ADR
occurs O-ADR O-ADR
, O-ADR O-ADR
the O-ADR O-ADR
infusion O-ADR O-ADR
should O-ADR O-ADR
be O-ADR O-ADR
interrupted O-ADR O-ADR
and O-ADR O-ADR
appropriate O-ADR O-ADR
medical O-ADR O-ADR
management O-ADR O-ADR
instituted O-ADR O-ADR
. O-ADR O-ADR
Chronic O-ADR O-ADR
Immune O-ADR O-ADR
( O-ADR O-ADR
Idiopathic O-ADR O-ADR
) O-ADR O-ADR
Thrombocytopenia O-ADR O-ADR
: O-ADR O-ADR
Adults O-ADR O-ADR
: O-ADR O-ADR
In O-ADR O-ADR
clinical O-ADR O-ADR
trials O-ADR O-ADR
, O-ADR O-ADR
hemorrhage B-ADR B-ADR
was O-ADR O-ADR
the O-ADR O-ADR
most O-ADR O-ADR
common O-ADR O-ADR
serious O-ADR O-ADR
adverse O-ADR O-ADR
reaction O-ADR O-ADR
and O-ADR O-ADR
most O-ADR O-ADR
hemorrhagic B-ADR B-ADR
reactions I-ADR I-ADR
followed O-ADR O-ADR
discontinuation O-ADR O-ADR
of O-ADR O-ADR
PROMACTA O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
3 O-ADR O-ADR
shows O-ADR O-ADR
the O-ADR O-ADR
number O-ADR O-ADR
of O-ADR O-ADR
patients O-ADR O-ADR
experiencing O-ADR O-ADR
bleeding B-ADR B-ADR
events O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
pooled O-ADR O-ADR
analysis O-ADR O-ADR
of O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
and O-ADR O-ADR
RE O-ADR O-ADR
- O-ADR O-ADR
COVER O-ADR O-ADR
II O-ADR O-ADR
studies O-ADR O-ADR
during O-ADR O-ADR
the O-ADR O-ADR
full O-ADR O-ADR
treatment O-ADR O-ADR
including O-ADR O-ADR
parenteral O-ADR O-ADR
and O-ADR O-ADR
oral O-ADR O-ADR
only O-ADR O-ADR
treatment O-ADR O-ADR
periods O-ADR O-ADR
after O-ADR O-ADR
randomization O-ADR O-ADR
. O-ADR O-ADR
Table O-ADR O-ADR
1shows O-ADR O-ADR
all O-ADR O-ADR
adverse O-ADR O-ADR
reactions O-ADR O-ADR
that O-ADR O-ADR
occurred O-ADR O-ADR
with O-ADR O-ADR
a O-ADR O-ADR
frequency O-ADR O-ADR
of O-ADR O-ADR
greater O-ADR O-ADR
than O-ADR O-ADR
or O-ADR O-ADR
equal O-ADR O-ADR
to O-ADR O-ADR
1 O-ADR O-ADR
% O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
group O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
two O-ADR O-ADR
3 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
and O-ADR O-ADR
one O-ADR O-ADR
6 O-ADR O-ADR
- O-ADR O-ADR
month O-ADR O-ADR
placebo O-ADR O-ADR
- O-ADR O-ADR
controlled O-ADR O-ADR
trials O-ADR O-ADR
where O-ADR O-ADR
the O-ADR O-ADR
rates O-ADR O-ADR
in O-ADR O-ADR
the O-ADR O-ADR
TUDORZA O-ADR O-ADR
PRESSAIR O-ADR O-ADR
group O-ADR O-ADR
exceeded O-ADR O-ADR
placebo O-ADR O-ADR
. O-ADR O-ADR
The O-ADR O-ADR
median O-ADR O-ADR
duration O-ADR O-ADR
of O-ADR O-ADR
exposure O-ADR O-ADR
was O-ADR O-ADR
6 O-ADR O-ADR
. O-ADR O-ADR
1 O-ADR O-ADR
months O-ADR O-ADR
( O-ADR O-ADR
range O-ADR O-ADR
0 O-ADR O-ADR
. O-ADR O-ADR
3 O-ADR O-ADR
to O-ADR O-ADR
26 O-ADR O-ADR
. O-ADR O-ADR
4 O-ADR O-ADR
months O-ADR O-ADR
) O-ADR O-ADR
. O-ADR O-ADR
